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CHAPTER I 
Mitochondrial DNA mutations in neuromuscular disorders 
Part of this chapter will be published in Clinical Neurology and 
Neurosurgery as an invited review. 

MITOCHONDRIAL DNA MUTATIONS IN 
NEUROMUSCULAR DISORDERS. 
INTRODUCTION 
Since the first patient with a mitochondrial disorder was described (1,2), an increasing 
number of patients with neuromuscular diseases associated with mitochondrial dysfunction 
and/or abnormal morphology have been identified. The group of mitochondrial disorders 
is clinically very heterogenous in several aspects (3). Muscle weakness is often present 
but it can be mild or severe, static or progressive, congenital or of late onset, and 
generalised or localised. Besides pure myopathies, multisystem disorders are observed, 
with e.g. seizures, myoclonus, psychomotor retardation, dementia, deafness, blindness, 
growth retardation, stroke-like episodes and/or difficulties with respiration or feeding. 
Mitochondrial diseases can result in death within days after birth or may become apparent 
only at advanced age. 
Initially, attempts were made to subclassify mitochondrial disorders by 
concentrating on morphological criteria of the mitochondria, but this approach appeared 
not to be satisfactory (4). For instance, ragged red fibers, containing peripheral accumula-
tions of abnormal mitochondria and visualized with the modified Gomori trichrome 
staining, are a morphological hallmark of several different disorders (4). Moreover, 
alterations in mitochondrial size and number are non-specific features of several clinical 
types of mitochondrial neuromuscular disorders (4). 
Since mitochondrial disorders are often associated with defects of the respiratory 
chain in muscle and other tissues (5), classification on the basis of biochemistry has also 
been attempted. However, there is little correlation between these biochemical defects and 
the clinical features (3,5,6). Clinically well-defined mitochondrial diseases can be associa-
ted with a variety of biochemical defects (3,5,6). On the other hand, the same 
biochemical defect has been found to be associated with different clinical syndromes 
(3,5,6). So, biochemically, the picture is also confusing. 
Only recently the investigations of the mitochondrial DNA (mtDNA) have begun 
to contribute to the diagnosis of neuromuscular diseases with mitochondrial involvement. 
Six years ago, the first associations between human mitochondrial disorders and mutations 
in the mitochondrial genome were established (7,8,9). As shown by Holt et al. (7) and 
Lestienne and Ponsot (8) certain patients with mitochondrial myopathies had two 
populations of mtDNA in muscle, in which one of the mtDNA species was deleted by up 
to 7 kilobasepairs (kb). Wallace and coworkers demonstrated an association between a 
mitochondrial missense mutation and maternally transmitted Leber's hereditary optic 
neuropathy (9). Shortly after these first seminal papers appeared our group started in 1990 
the molecular genetic approach towards the study on mitochondrial diseases. To 
contribute to the diagnosis of mitochondrial diseases and to get a better insight in the 
pathogenetic mechanism of neuromuscular disorders we decided to study the mtDNA 
from patients with a morphological and functional defect in muscle mitochondria. During 
the course of the study we included also patients from families with a likely maternal 
inheritance of the neuromuscular disorder involved. The present thesis deals with 
mutations in the mitochondrial DNA from patients with a mitochondrial disorder, either 
or not associated with a respiratory chain defect. 
13 
MITOCHONDRIA 
The theory that mitochondria are living fossil parasites within the eukaryotic cells is now 
generally accepted (10,11). The concept is that primitive cells lacking respiratory 
organelles were parasitised by oxygen-using bacteria that conferred a selective 
evolutionary advantage (11). Host and bacterium subsequently became interdependent and 
obligatorily symbiotic (11). During this process most of the bacterial DNA was 
transferred to the host genome while some remained in the bacteria and led to the 
development of mitochondria (11). 
The primary role of mitochondria within eukaryotic cells is oxidative 
phosphorylation that is the production of energy by the oxidation of carbon substrates to 
C02 and the reduction of oxygen to water (12). This process is linked to the production of 
high-energy compounds such as ATP. Mitochondrial function is closely related to the 
maintenance of cellular integrity. 
Mitochondria are oval-shaped organelles and surrounded by a double membrane 
(12). The folded inner membrane forms deep invaginations into the mitochondrial matrix 
(cristae) (Fig 1). The word mitochondrion is derived from the Greek word mitos (threads) 
and chondrion (granule) (13). Within a mitochondrion, four compartments can be 
distinguished: the matrix, the inner membrane, the intermembrane space and the outer 
membrane (12). 
intermembrane space 
ribo some 
granule 
outer membrane 
inner membrane 
cnstae 
0 1-0 5 MIT» 
1 - 2 , i m 
Figure 1. The structure of the mitochondrion. 
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Functioning of the respiratory chain 
rhe oxidative substrate degradation takes place in the matrix space (12). The intracellular 
concentration of ATP is maintained by oxidation of pyruvate, fatty acids and amino acids 
in the mitochondria. In the cytoplasm, glucose is degraded to pyruvate and lactate by 
glycolytic activity (Fig 2). After entering the mitochondrion pyruvate and acylcamitine-
eslers are oxidized. The oxidation of both pyruvate and fatty acids results in the formation 
Df acetyl-CoA. This compound enters the citric acid cycle by coupling with oxaloacetate. 
The citric acid thus formed undergoes subsequent oxidations during which C0 2 is 
liberated and free NAD* and enzyme bound FAD are reduced. The reducing equivalents, 
NADH and FADH2, enter the respiratory chain via the NADH dehydrogenase complex 
(complex I) and coenzyme Q (ubiquinone, Q), respectively, and become oxidized again. 
The reducing equivalents are transferred towards oxygen via the components of the 
respiratory chain and the major part of the energy liberated is used for formation of ATP. 
LACTATE 
Figure 2. The mitochondrial respiratory chain in relation to part of the intermediary metabolism. 
All functional components of the respiratory chain are located in the mitochondrial 
inner membrane (Fig 3). The non-protein lipid compound coenzyme Q forms the link 
between the NADH dehydrogenase and succinate dehydrogenase (complex II) on one 
hand and the cytochromes on the other. The distal part of the respiratory chain consists of 
three functional units: cytochrome с reductase (complex III), cytochrome с and 
cytochrome с oxidase (complex IV), respectively. Complexes I, II and III contain specific 
proteins for the interaction with coenzyme Q. 
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Figure 3. The four respiratory chain complexes and complex V within the mitochondrial membrane. Above 
is the cytosol and below is the mitochondrial matrix. The subunit composition of each complex is presented 
m the table below. Adapted from Wallace (26). 
Electrons are transferred from NADH to 0 2 through complex I, III and IV, which 
results in the pumping of protons across the inner mitochondrial membrane into the 
intermembrane space. Cytochrome с functions as electron carrier between complex III 
and complex IV. The reduction of oxygen takes place at complex IV (11). 
Another complex, the F^-ATPase complex (complex V), is also located in the 
mitochondrial inner membrane, in direct connection with the functional parts of the 
respiratory chain (12). The F„ portion is the regulatory component of the complex and 
functions as a transmembrane proton pore through the inner membrane. The F[ portion 
possesses ATP synthase activity. The decrease in thermodynamic potential of the extruded 
protons which return to the mitochondrial matrix through the F0 gate, are converted into 
the formation of ATP from ADP and P, (12,14-16). 
Mitochondrial genetics: replication and transcription 
The mitochondrial genome 
Two types of DNA exist in the eukaryotic cell, nuclear DNA (nDNA) and mitochondrial 
DNA (mtDNA). The vast majority of mitochondrial proteins are encoded by nDNA and 
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have to be imported from the cytoplasm into mitochondria through a complicated 
translocation machinery, which is under the control of the nuclear genome (17). In 
addition, nDNA encodes several factors that control mtDNA replication, transcription, 
and translation (18-20). The control of replication of the mtDNA is not directly linked to 
cell cycle phase. Mitochondrial DNA has a different genetic code and structure compared 
to nuclear DNA (21). Table I shows the differences between the mitochondrial genetic 
code of mammals and the nuclear code. The mtDNA sequence of humans was completely 
elucidated in 1981 (10). Human mtDNA is a double stranded circular polymer of 16,569 
base pairs in length, which encodes messenger RNA (mRNA) for 13 subunits of four 
enzyme complexes of the oxidative phosphorylation system, 22 transfer RNAs (tRNA) 
required for translation of mRNA, and two ribosomal RNAs (rRNA) (Fig 4) (10). The 
five complexes of the mitochondrial oxidative phosphorylation, complex I, complex II, 
complex III, complex IV, and complex V, consist of at least 41 (or more), 4, 10, 13, and 
12 dissimilar subunits, respectively (Fig 3) (5,22). The mtDNA codes for 7 subunits of 
complex I, 1 (cytochrome b) of complex III, the 3 catalytic subunits of complex IV, and 
2 of complex V (Fig 4). These subunits are synthesized in mitochondria (5,22,23). The 
mitochondrial genome has no introns: the so-called D-loop (displacement-loop), or control 
region, is one of the few non-coding parts of the mtDNA (20). This 1123-bp stretch of 
mtDNA contains the genetic information for the regulation of replication and transcription 
(5,10,18-20). The D-loop maintains a short piece of the so-called nascent DNA strand (7S 
DNA), which is the leading-strand origin of replication (see below) (10,18,20). The 
guanines and cytosines are asymmetrically distibuted between the two strands. The 
leading strand has been termed the heavy (H) strand, because this strand is guanine-rich. 
Correspondingly, the opposite strand is cytosine-rich, and has been termed the light (L) 
strand (18). 
Table I. Differences between the mitochondrial genetic code of mammals and the nuclear code. 
Codon Mitochondrial code of mammals Nuclear code 
UGA Tryptophane STOP 
AUA Methionine Isoleucine 
AGA Terminalion Arginine 
AGG Termination Arginine 
Mitochondrial DNA replication. 
In the D-loop, the Η-strand is partially unwinded, allowing a 7S DNA replication 
initiation sequence to be synthesized on the L-strand (Figs 4 and 5) (18). Replication 
priming and transcription initiation begin at exactly the same site, which results from the 
fact that replication priming of the heavy strand (at 0„) is dependent upon a transcrip­
tional promoter function (20). The participation of RNA as a primer in the DNA 
replication process is suggested, because at the origin of Η-strand replication (Он) are 
several sites where transition from RNA synthesis to DNA synthesis takes place (20). 
This transition from RNA synthesis to DNA synthesis occurs over a region of three short 
conserved sequence elements, termed conserved sequence blocks (CSB) I, II and III (Fig 
4). This region has a regulatory role in mtDNA replication and expression and is 
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recognized by a protein with RNase activity, which cleaves the mtRNA transcripts that 
are complementary to the D-loop region between the most highly conserved CSB II and 
CSB III, possibly to initiate extension by mtDNA polymerase (Fig 4). 
Figure 4. The mitochondrial genome. 
The mitochondrial DNA is represented by the inner (L-strand) and outer (Η-strand) circles. Black regions 
are protein coding genes and ribosomal RNA genes. ND1-NDS are the genes coding for subunit 1-5 of 
complex I, respectively. Cytb is the gene coding for the cytochrome b subunit of complex III. COI-1II are 
the genes coding for subunit 1-3 of complex IV, respectively. ATPase 6 and 8 are the genes coding for 
subunits of complex V. 12S rRNA and 16S rRNA are coding for the ribosomal RNAs. The transfer RNA 
genes are the light blocks indicated by the single amino acid letter code. The origins of H- and L-strand 
replication, О
н
 and 0 L , the H- and L-strand promoters, PH and PL, the conserved sequence blocks (CSB) I-
III, and the transcription factor (TF1) binding sites "s are depicted. The arrow between CSB II and CSB III 
indicates the site at which transition from RNA synthesis to DNA synthesis occurs. The shaded inner and 
outer arcs are the stable, processed, L-strand and Η-strand transcripts, respectively. Adapted from Wallace 
et al. (37). 
The human mitochondrial DNA replication occurs in an unidirectional manner 
with an increasing displacement of the parental Η-strand with the L-strand serving as 
matrix (Fig 5) (18,20). Synthesis of the daughter Η-strand continues until the new H 
strand has elongated to two-thirds of its total length. Then, the origin of L-strand 
replication (OJ is exposed on the displaced parental H strand and initiation of the 
daughter L-strand synthesis takes place. The 0 L forms a hairpin-loop secondary structure 
located within a cluster of five tRNAs (Fig 4) (5). Human mitochondria contain a mtDNA 
primase, being an enzyme that recognizes 0 L and initiates RNA priming and DNA 
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synthesis. The mtDNA primase is imported into the mitochondrion from the cytosol (20). 
Daughter L-strand synthesis is primed by RNA, which is complementary to a T-rich loop 
structure in 0 L . The transition site from RNA to DNA synthesis is a short pentanucleotide 
sequence, at the base of the OL stem and is part of the gene coding for the tRNA for 
cysteine (20). Furthermore, a distinct mtDNA polymerase is involved in the elongation of 
the progeny strands (20). 
7S DNA 
single stranded 
parent H-strand 
daughter 
H-strand 
daughter 
L-strand 
parent 
L-strand 
daughter 
H-strand 
parent 
H-strand 
daughter 
L-strand 
Figure 5. Mitochondrial DNA replication. 
A. Mitochondrial DNA replication begins at 0 H with D-loop displacement of the 7S DNA. В. The parent 
H-strand becomes single stranded as daughter H-strand synthesis proceeds. С Once daughter H-strand 
synthesis reaches 0 L , daughter L-strand synthesis begins in opposite direction. D. Daughter H-strand 
synthesis ends first and L-strand synthesis is subsequently completed. Adapted from Shofmer and Wallace 
(5). 
Mitochondrial DNA transcription 
The human mitochondrial transcription starts from two major promoters, the heavy strand 
promoter PH and the light strand promoter PL in the D-loop (Fig 4), and proceeds 
symmetrically in opposite directions around the mtDNA (5). The PH and PL are composed 
of approximately SO base pair sequences and are separated by 150 base pairs from each 
other. Transcription factor mtTFl, in addition to a mitochondrial RNA polymerase, is 
involved in promoter-mediated transcription (20). The transcription factor binds to 
mtTFl-responsive elements within the PH and PL and functions bidirectionally. Its affinity 
is higher for the PL, which provides an explanation for the observation that this is the 
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most active one (20). 
Primary transcripts are prokaryote-like in that they are polycistronic (Fig 6A). The 
polycistronic messengers of the mtDNA contain multiple mRNAs that are cleaved into 
individual mRNAs posttranscriptionally (10,19). The tRNAs, which are strategically 
placed between most of the individual mRNA segments of the primary transcript, are 
excised as free tRNAs, thereby also releasing the intervening mRNAs (Fig 6B). The 
tRNAs are probably removed by a RNase-like activity that recognizes the tRNA seconda-
ry structure (20). The presence of other RNA processing enzymes has not been ruled out 
yet. Most of the reading frames of the mtDNA lack termination codons. After the tRNAs 
have been precisely cleaved out of the primary transcript, mRNAs from those reading 
frames with no termination codon would be left with either a U or UA at their 3'ends in 
phase with the reading frame (Fig 6A). By posttranscriptional polyadenylation of the 
mRNAs a UAA termination codon would be created in-phase (Fig 6B). Finally, translati-
on of these mRNAs on mitochondrial ribosomes will take place (Fig 6C) (9,19,20). The 
only genes not separated by tRNAs are the COIII + ATPase 6 genes, the ATPase 6 + 8 
genes, and the ND4 + ND4L genes. The overlapping coding sequences between the 
ATPase 6 + 8 and ND4L + ND4 transcripts may modulate translation of the proteins 
(5). In the case of the COIII + ATPase 6 genes, the mRNA is cleaved in the absence of 
an intervening tRNA (5). 
Figure 6. Mitochondrial RNA processing. 
A. Primary mitochondrial transcripts are cleaved into individual mRNAs by excision of the intervening 
tRNAs. B. The released mRNAs are completed by posttranscriptional polyadenylation. C. The mature 
mRNAs are translated on mitochondrial ribosomes. Adapted from Clayton (19). 
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The H-strand can be transcribed either completely from the tRNA^-gene 5'-end to 
the tRNA11" gene З'-end or transcription can be terminated after the 16S rRNA 3'end (Fig 
4) (5). The difference in rRNA transcription may be determined by a promoter-
independent bidirectional termination site at the 16S rRNA-tRNA^"1 gene boundary (24). 
As few as 13 base pairs are sufficient to direct termination. The tridecamer sequence, 5'-
TGGCAGAGCCCGG-3', is located entirely within the gene for tRNA^^™1" and 
functions bidirectionally. The same termination site corresponds to L-strand transcripts 
which are frequently terminated in this region. A nucleus-encoded termination factor, of 
the apparent size of 34 kD protein, binds to the tridecamer site and acts as a barrier to the 
transcription process (25). 
The sequence of the Η-strand is the main coding region (10). The RNAs for 
twelve of the subunit genes, the 12S and 16S rRNA and 14 tRNA genes are transcribed 
from the H strand (Fig 4). The genes for subunit ND6 of complex I and eight tRNA 
genes are located on the L-strand (Fig 4). 
Still many aspects concerning the exact mechanisms involved in the regulation of 
replication and transcription have to be clarified. 
DISTINCTIVE FEATURES OF MITOCHONDRIAL DNA RELEVANT 
TO TIIE UNDERSTANDING OF MITOCHONDRIAL DNA-RELATED 
DISEASES 
The genetics of the mtDNA differs from that of the nuclear DNA in five important 
aspects (3,5,10,26). 
1. First, the mitochondria are polyploid. Each human cell has hundreds of 
mitochondria each containg 6 (range 2-10) mtDNA molecules (27,28). Cells can 
harbor mixtures of mutant and wild type mtDNA molecules, a phenomenon which 
is called heteroplasmy (3,5,26). During cell division, mitochondria are randomly 
distributed to the daughter cells (Fig 7) (5). This means that the proportion of 
progenitor cell 
daughter cells 
threshold for phenotypic expression 
Figure 7. Random segregation of mitochondria and threshold expression of mtDNA. Because mitochondria 
are randomly distributed to the daughter cells during cell division, the proportion of mutant and wild-
type mtDNAs that are distributed to daughter cells can fluctuate. Accumulation of mutated mtDNA 
over a certain threshold level yields a disease phenotype. Adapted from Shoffner and Wallace (5). 
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mutant and wild-type mtDNA that are distributed to daughter cells can fluctuate. 
Consequently, after repeated cell divisions, the mtDNA genotype can progressively 
drift towards either pure mutant or wild-type mtDNAs (homoplasmy) (5,26). 
To explain the rapid segregation observed in vertebrate mitochondrial DNA 
despite its high copy number, the following model has been proposed for 
mitochondrial genome transmission to the progeny (29). No more than 5 mtDNA 
molecules from one generation serve to define the cytoplasmic genotype of the 
next generation, also defined as the "bottleneck" (29). Mitochondrial DNA 
selection occurring each generation takes place as a result of at least three factors. 
First, as a result of an enormous amplification in the number of mitochondria and 
to a lesser extent in the number of mtDNA molecules during follicular 
development. In cows a decrease of the mtDNA/mitochondria ratio to near 1 was 
found. Second, these mitochondria of low genome copy number will subsequently 
segregate into the dividing cells of the early embryo. Third, later developmental 
stages in mammalian embryogenesis may also contribute to the mtDNA selection. 
The phenotypic result of this mtDNA segregation is threshold expression 
(3,5,26). Unlike chromosomal genes, there are hundreds to thousands copies of 
mtDNA genes per cell. Therefore, a single mutated gene copy is unlikely to cause 
cellular dysfunction leading to a disease, but accumulation of mutated gene copies 
over a certain threshold would be expressed phenotypically as a disease (Fig 7). It 
has been assumed that in patients with mtDNA mutations, the phenotype is a 
product of the nature of the mutation, the percentage of mutant mtDNA in each 
cell type and the relative reliance of each organ system on mitochondrial energy 
production (5,26). A certain percentage mutant mtDNA can cause the mitochondri-
al ATP production to decline, so as to fall below the minimum energetic levels 
necessary for each organ to function adequately (energetic threshold). This will 
result in a progressive increase in the number and severity of clinical symptoms. 
In order of vulnerability, the retinas and the optic nerves, the central nervous 
system, muscle, heart, pancreatic islets, kidney, and liver will be primarily 
affected (5,26). 
The third unique genetic characteristic of the mtDNA is the maternal inheritance 
(30). The mother transmits her oocyte mtDNA to all of her offspring and her 
daughters transmit their mtDNA to the next generation. This is the direct 
consequence of the fact that the oocyte harbors several hundred thousand mtDNA 
copies, while the human sperm has only a few hundred mtDNA molecules, which 
are concentrated in the mid-piece of the spermatids which do not enter the egg 
upon fertilization (26). So the mtDNA contribution of the sperm is negligible. 
Moreover, since the sperm mitochondrion is a potent source of free radicals due to 
its extremely high metabolic activity, oxidative damage to the unprotected 
mitochondrial genome may be extensive in mature, active sperm (31). This could 
result in inefficient/abnormal zygote mitochondria if the replication of these 
damaged organelles was allowed to occur after fertilization. Evidence has been 
obtained for a mechanism of active destruction of sperm mitochondria mediated by 
the egg in mammals (30). 
The fourth feature of mtDNA is that it is semi-autonomous, consistent with its 
endosymbiotic origin. Because of this autonomy, mitochondria and mtDNAs can 
be physically transferred from one cultured cell to another by cytoplast fusion or 
microinjection (32). Moreover, the mtDNAs within the cell readily interact, 
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presumably through repeated mitochondrial fusion and fission (33). In some cells, 
mitochondrial fusion progresses to the extreme of forming one interconnected 
mitochondrial network. However, mtDNA recombination is not common in human 
cells, presumably due to the lack of the required enzymes. Mitochondria are at 
most semi-autonomous, since the nucleus contains the genes for 80% of the 
proteins involved in the oxidative phosphorylation (Fig 3) (5). 
5. The last unique aspect of mtDNA genetics is its high rate of sequence evolution 
(5,26). The rate of mutation in mtDNA is about 10 to 20 times higher than that of 
nuclear DNA. This is likely due to a combination of factors, such as absence of 
DNA-binding proteins like histones, absence of simple DNA repair mechanism, 
and because of constant exposure to free radicals (34,35). This explains why a 
wide variety of presumably non-pathological mtDNA mutations have been fixed in 
various human populations, and why highly deleterious mutations may arise 
frequently (3,5,26). 
OUTLINE OF THIS STUDY 
Insight in the significance of mtDNA mutations in human pathology has been deepening 
very rapidly during the last five years, and studies on mtDNA have revealed various types 
of mutations that are associated with mitochondrial myopathy and related diseases. In a 
nation-wide collaboration between Dutch departments of Neurology, Pediatrics, 
Biochemistry and Human Genetics, tissues from patients with neuromuscular diseases 
with possible mitochondrial involvement were collected, processed for histochemical and 
biochemical investigations and tested for mutations in the mtDNA. The biochemical 
investigations of the respiratory chain as described in the following chapters of this thesis, 
are depicted in Figure 8 (36). 
One of our aims was to improve the diagnosis of mitochondrial disorders by 
studying the mtDNA from a large group of patients with neuromuscular disorders with 
possible mitochondrial involvement for large deletions and point mutations in the tRNA 
coding genes and the protein coding genes (chapters II-VI). The studies on human 
mtDNA molecular genetics are presented in the following chapters of this thesis. The 
chapters are divided on the basis of the mtDNA defects. The clinical and biochemical 
characteristics of the patients suffering from a disorder with mitochondrial involvement 
will be discussed in more detail in relation to the different defects of the mtDNA. 
Another goal of this study was to relate respiratory chain defects to genetic errors 
encoded by the mtDNA. To this end, the results of mutation analyses were correlated 
with biochemical findings (chapters II, ΙΠ-2, III-3, V, VI-1). Moreover, a group of 
patients was selected on the basis of a decreased respiratory chain activity of a single 
enzyme complex and the corresponding mitochondrial genes, coding for subunits of this 
complex, were studied in detail (chapter VI-2). In addition, the relation between the 
presence of a particular mtDNA mutation and the clinical phenotype of the patient was 
studied (chapters II-V). 
Different techniques to detect mutations have been used in these studies. Southern 
blot analysis was applied for the detection of gross rearrangements in the mtDNA (chapter 
II). Restriction enzyme digestion was applied to visualize point mutations that give rise to 
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NADH 
NAD* 
Η,Ο 
Figure 8. The biochemical investigations of the respiratory chain. Indicated are the enzyme complexes, 
which are involved in the various enzyme assays. 
1. NADH.'Q, dehydrogenase 
2. Succinate dehydrogenase 
3. Succinatexytochrome с oxidoreductase 
4. Cytochrome с oxidase 
5. NADH.Oj oxidoreductase 
= complex I = NADH dehydrogenase 
= complex II 
= complex II + CoQ + complex III 
= complex IV 
= complex I + CoQ + complex III + complex IV 
the loss or the gain of a restriction site (chapters III and IV-1). Restriction digestion-based 
tests were also used to monitor the presence and to quantify a particular point mutation in 
various tissues in different family members (chapters III and IV). For point mutations that 
do not give rise to the loss or gain of a restriction enzyme site, a method was developed 
to detect and quantify point mutations through fluorescent DNA cycle sequencing (chapter 
IV-2). Finally, the polymerase chain reaction (PCR) followed by direct sequencing was 
used for the detection of new mutations in the mtDNA (chapters IV-VI). 
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CHAPTER Π 
Deletions in the mitochondrial DNA 
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Abstract—A patient with the Pearson marrow and pancreas syndrome is presented She showed 
an anaemia with neutropenia and thrombopenia, failure to thrive, diarrhoea, disturbed glucose 
homeostasis and lactic acidosis An exocrine pancreatic insufficiency was lacking The disease 
followed a fatal course Biochemical investigations of skeletal muscle revealed a disturbed 
mitochondrial energy metabolism, while many ultrastructural abnormal features were observed 
in the muscle tissue Molecular genetic studies showed a tie no\o deletion in the mitochondrial 
DNA (mtDNA), different in size from the already published deletions and flanked by two 4 bp 
direct repeats, interspaced by 4-5 non-repeated nucleotides mtDNA from 12 other tissues 
showed the same deletion in different percentages No obvious relation between these 
percentages and tissue dysfunction was found In spite of an open reading frame of 74 codons, 
only little transcription product of the genomic region resulting from the deletion was found 
Key words Pearson syndrome, anaemia, lactic acidosis, mitochondrial myopathy, 
mitochondrial energy metabolism, mtDNA deletion 
INTRODUCTION 
Pearson syndrome (Mc Kusick 26056) is charac­
terized by refractory sideroblastic anaemia with 
vacuolization of bone marrow precursors and 
exocrine pancreatic insufficiency [1,2] Onset is in 
early infancy and most patients die before the age 
of 3 yr [2] Recently, cases of Pearson syndrome 
with large deletions in part of their mitochondrial 
D N A genome were described [3-9] The de­
letions were similar to those seen in Kearns-
Sayre syndrome [10-15] In the present paper the 
clinical course, the muscular abnormalities and 
the molecular genetic features of a girl with the 
Pearson syndrome are described 
PATIENT AND METHODS 
Case history 
The patient, a girl, was born after an un­
eventful term pregnancy to healthy unrelated 
parents Three older siblings were healthy 
X Author to whom correspondente should be addressed at 
DNA-diagnoslic Laboratory Department of Human Genetics, 
University Hospital Nijmegen PO Box 9101, 6Í00 HB 
Nijmegen The Netherlands 
Immediately after birth she showed an aspiration 
syndrome Laboratory examination revealed severe 
anaemia, metabolic acidosis and hyperglycemia 
The necessary treatment was given These problems 
seemed to be temporary and she was discharged 
at the age of 4 weeks, but re-admitted at the age 
of 2 months, because of a severe anaemia and a 
moderate lactic acidemia Moreover, lactate 
excretion in urine was extremely elevated A 
generalized amino aciduria was found as well as 
an increased concentration of alanine in serum 
Normal levels of serum iron, serum ferritin, 
vitamin B,2, folic acid and H b F were found, there 
was no evidence of haemolysis A bone marrow 
aspirate revealed normal numbers of mega-
karyocytes, the number of red cell precursors was 
markedly reduced and the granulocytes showed a 
marked cytoplasmic vacuolization No ringed 
sideroblasts were seen She appeared to need 
transfusions every 2-3 weeks After a year she 
showed a decrease in leucocyte and thrombocyte 
number 
A quadriceps muscle biopsy was performed 
under general anaesthesia and tissue was pro-
cessed for histochemistry, electron microscopy 
and biochemistry 
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At the age of 3 months her glucose homeo­
stasis showed a tendency to hypoglycemia There 
was no evidence for a glycogenosis, a disorder in 
the gluconeogenesis or a hormonal disorder 
When she became older she had an unexplicable 
strong tendency to hyperglycemia, especially 
during infections 
At the age of 7 months she was admitted to the 
hospital because of vomiting, diarrhoea and 
weight loss There appeared to be a transitory 
atrophy of the intestinal villi An exocrine pan­
creatic dysfunction was never found A few 
months before death the liver function tests were 
disturbed, possibly due to hepatitis С infection 
Growth was severely stunted, at the age of 1 yr 
her height, weight and head circumference were 
all below the third percentile 
She died at the age of 16 months due to an 
infection with Aspergillus fumigatus which 
spread from the ethmoidal sinus to the lungs At 
autopsy the liver was enlarged, the thymus was 
small, the spleen and pancreas were of normal 
weight and macroscopic and morphologic aspect 
Muscle biochemistry 
The oxidation rates for pyruvate and malate 
and the production of ATP plus creatine phos­
phate of the intact mitochondria in a 600 g 
supernatant of the fresh muscle specimen were 
determined in the presence of specific inhibitors 
as described previously [16] The activity of the 
pyruvate dehydrogenase complex [17] and the 
carnitine content [18] were determined in the 
total homogenate 
The activity of cytochrome с oxidase, the 
rotenonc-sensitive NADH Q, and NADH 0 2 
oxidoreductase, the antimycine Α-sensitive suc­
cinate cytochrome с oxidoreductase and the 
activity of the mitochondrial reference enzyme 
citrate synthase were measured according to 
Fischer et al [16] 
DNA methods 
Blood DNA was prepared according to 
standard procedures [19] Total DNA was ex­
tracted from fresh muscle and autopsy material 
as described for liver tissue by de Vries et al [20] 
Two micrograms of digested DNA were re­
solved by agarose gel electrophoresis, immo­
bilized on Gene Screen Plus, and hybridized with 
a labelled mlDNA probe (see below) [21, 22] 
Densitometrie scanning was performed on an 
Ultroscan XL laser densitometer (Pharmacia, 
Woerden, The Netherlands) The amount of 
deleted mtDNA was measured vs the amount of 
intact mtDNA per tissue 
Preparation of mtDNA probe 
Total mtDNA was extracted from blood 
platelets obtained from 500 ml whole blood from 
controls Platelet-nch plasma was obtained by 
spinning for 20 mm at 2000 g at room tempera­
ture and the platelets were subsequently pelleted 
by spinning for 20 mm at 2000 g The platelet 
pellet was washed twice with lOmMNaCland 10 
mM EDTA To 0 5 g wet weight of the pellet 2 25 
ml 75 mM NaCl, 24 mM EDTA and 113 μ\ 10% 
SDS were added and incubated for 10 min at 
room temperature Subsequently 125 μΐ 
proteinase К (10 mg ml" 1) were added and 
further incubated overnight at 55°C The clear 
solution was extracted with phenol chloroform 
[21] and the mtDNA was precipitated with 
ethanol for 3-5 days at -20°C The DNA was 
purified by gel electrophoresis in low-melting 
agarose The DNA containing band was cut out 
of the agar, diluted with three volumes of H 20, 
and used as a template for the preparation of a 
radioactive hybridization probe by random prime 
labelling with [12P] dCTP [22] 
PCR. APCR and direct sequencing 
Oligonucleotides used for priming the poly­
merase chain reaction (PCR), the asymmetric 
PCR (APCR) and sequencing were synthesized 
by automated DNA synthesis using the β-
cyanoethyl amidite chemistry on a Cyclone 
DNA synthesizer (Biosearch-Milhgen Co ) One 
microgram of total DNA from blood cells was 
submitted to PCR amplification with oligo­
nucleotide primers A and В (see Table 1, mtDNA 
nucleotide numbering according to Anderson et 
al [23]) PCR amplification was carried out for 
20 cycles with the use of a thermal cycler (Perkin 
Elmer Cetus) as described previously [20] The 
Table I Nucleotide position and sequences of the primers used in the PCR APCR and direct sequencing 
Primer Position Sequence Gene 
A 
В 
С 
D 
E 
F 
7425-7446 
14 257-14 278 
7586-7607 
14 127-14 148 
9207-9228 
9969-9990 
COC GTA TAC ATA AAA TCT AGA С COI 
AGG GTT CAT TCG GGA GGA TCC Τ ND6 
ATG GCA CAT GCA GCG CA A GTA G C02 
ATA ACC ATG CAC ACT ACT ATA A ND5 
ATG ACC CAC CAA TCA CAT GCC Τ СОЗ 
AAG ACC CTC АТС AAT AGA TGG A COJ 
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cycle conditions were as follows denaturation 60 
s at 92°C, annealing 90 s at 55°C, primer 
extension 90 s at 72°C APCR was performed 
according to the method described by Gibbs et al 
[24] The APCR products were prepared for 
sequencing by phenol chloroform extraction 
[21] The resulting 1 ml volume was reduced to 50 
μΐ following centnfugation in a Centneon 30 
microconcentrator (Amicon) according to the 
manufacturer's instructions Direct sequencing 
was performed according to the Sanger dideoxy 
method for sequencing with the Pharmacia T7 
polymerase sequence kit (Pharmacia, Woerden, 
The Netherlands) following the manufacturer's 
recommendations The primers used for the PCR 
were also used in the sequencing reaction, but 
only after purification by gel electrophoresis The 
sequencing reaction products were loaded 
directly on a 6 6%/7 M denaturing Polyacryl­
amide gel which was pre-run for 30 min at 60 W 
The gel was electrophoresed at 60 W for 6 5 h 
Lymphoblastom" cell line 
Mononuclear leukocytes were isolated from 
10 ml hepannized blood of the patient after 
separation on Ficoll-Paque (Pharmacia, Woerden, 
The Netherlands) [25] A lymphoblastoid cell line 
from B-lymphocytes of the patient was estab­
lished using the procedure described by Neitzet 
[26] The supernatant of 10* cells from the 
lymphoblastoid marmoset cell line B95 8 in 1 ml 
was diluted with 1 ml RPMI 1640 The separated 
mononuclear leukocytes were resuspended in the 
B95 8 supernatant at a cell concentration of 2 x 
IO6 cells ml ' Cyclosporin A was added to the 
culture 24 h after transformation to prevent 
regression of the transformed B-cells 
mRNA isolation 
Total cellular RNA was isolated from 
lymphoblastoid cells of the patient, using the 
lithium-urea procedure described by Auffray 
and Rougeon [27] cDNA synthesis was essen­
tially as described by Bussemakers et al [28] One 
and a half micrograms of ohgo (dT)1 2,8 were 
annealed to 1 //g of mRNA, purified by ohgo 
(dT)-cellulose affinity chromatography, by in­
cubation for 5 min at 68°C and quenching on ice 
First strand synthesis was performed for 60 min 
at 37°C using Super Reverse Transcriptase (Life 
Technologies, Breda, The Netherlands) The first 
strand product was then separated from the free 
nucleotides using a Sephadex G50 spin column 
This purified first strand cDNA was used as a 
template in the PCR as described before 
RESULTS 
Muscle morphology 
Histological examination of the quadriceps 
muscle obtained at the age of 3 months revealed a 
slightly increased variability in fibre diameter 
The myosin ATPase reaction showed a normal 
distribution of fibre types, the type I comprising 
61 % Modified Gomon tnchrome staining, PAS 
staining.'Sudan black staining and the staining of 
oxidative enzymes, including cytochrome с oxi­
dase and succinate dehydrogenase, were all 
normal The connective tissue content was 
somewhat increased 
Electron microscopic studies showed a paucity 
of enstae and an almost complete absence of 
matrix electron density [Figs 1(a) and (b)] Those 
enstae present showed a fragmented and often 
distinctly curved appearance In almost all 
mitochondria vesicle-like structures could be 
detected [Fig 1(b), arrowheads], with occasion­
ally profiles suggestive for a process of extrusions 
of these vesicles from the mitochondnal inner 
compartment (not illustrated) Identical mito­
chondnal fine structural abnormalities were seen 
in the endothelial cells and in the fibroblast-hke 
cells between the muscle fibres (see below) 
Mitochondrial giant deformation or crystalline 
inclusions were not observed, nor was there 
subsarcolemmal aggregation of mitochondria 
Glycogen granules were numerous both in the 
subsarcolemmal regions and in the muscle fibre 
I-zones [Figs 1(a) and (b)] Minute membrane 
bound structures with glycogen granules were 
frequently seen Lipid droplets were also regu­
larly encountered between the myofibrils [Fig 
1(a)] Apart from focal spots of Z-line streaming 
no abnormalities were seen in the contractile 
elements The intrafascicular collagen content 
was distinctly increased and highly active fibro-
blast-like cells were numerous between the 
muscle fibres The capillaries were either 
completely normal or showed a strongly swollen 
endothelial lining 
Muscle biochemistry 
Decreased rates for pyruvate and malate 
oxidation were found in all substrate/inhibitor 
combinations tested (Table 2) The control ranges 
applied were suitable for the age of the patient at 
which the muscle biopsy has been performed [29] 
The pyruvate oxidation rate remained decreased 
in the presence of the uncoupling agent car-
bonylcyanid-m-chlorphenyl-hydrazon (СССР) 
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Fig. 1. Electron micrographs of the patient's quadriceps muscle: (a) showing mitochondrial abnormalities (M) and lipid 
droplets (L); and (b) showing accumulation of glycogen (G) and vesicle-like structures (arrowheads) 
(a) magnification: 6650x: (b) magnification: ¡7500χ 
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Table 2. Metabolie rates in 600 £ supernaíants from muscle 
Substrates/inhibitors Patient Control range* 
( я - 1 4 ) 
Oxidation rates 
(I - u C]pyruvate + malate 
[I - ,4Clpyruvate + carnitine 
¡I - ,4C)pyruvate + malate +CCCP 
(U - ,4C]malale + pyruvate + malonale 
[U- l4C]malate +acetylcarnitine + malonate 
ATP + creatine phosphate production from 
Pyruvate + malate 
Succinate + acetylcarnitine 
1 66 
20O 
1 53 
1 65 
1 65 
3.6-7.5 
2.8-82 
2.7-8.3 
4.7-96 
3.4-7.3 
132 
29 
42.1-81 2 
7.2-18.4 
•Values are expressed m /«-moles product h ' mU ' citrate synthase. 
Table 3 Enzyme activities* and carnitine contentt in muscle 
Enzymes Patient Control range 
Citrate synthase 
Cytochrome с oxidase 
Succinate: cytochrome с oxidoreductase 
NADH : Q oxidoreductase 
Pyruvate dehydrogenase complex 
Carnitine, total 
Carnitine, non-esterified 
68 
62 
23 
18 
2 5 
2 3 
1 9 
48-162 
68-437 
22-88 
4.4-25.9 
3 0-11.8 
2.7-4.6 
2.2-Í.2 
32 
54 
15 
2K 
25 
21 
21 
•Values are expressed in mU (mg protein)"1. 
fValues are expressed in umoles (g muscle)" 
η • number of control specimens. 
(Boehringer Mannheim GmbH, Mannheim, 
F.R.G.). Despite these findings a well-defined 
defect could not be demonstrated in the res­
piratory chain (Table 3). Cytochrome с oxidase 
and pyruvate dehydrogenase complex had rela­
tively the lowest activity. The carnitine 
concentration was slightly diminished. 
mtDNA 
Southern blotting of blood DNA digested with 
the restriction enzyme PvuII (cleavage at bp 
position 2650) and hybridization using a total 
mtDNA probe showed that the patient had two 
populations of mtDNA, one normal (16.5 kb) 
and one partly deleted species (10 kb) (Fig. 2). 
Her parents and three siblings only had the 
normal sized mtDNA (data not shown). Com­
parison of the ratio mtDN A/nuclear DNA in the 
patient and controls revealed that the amount of 
intact mtDNA in the blood from the patient was 
reduced by a half. Digestion with other restriction 
enzymes showed that the deletion spanned the 
genes coding for cytochrome с oxidase subunit 3, 
both ATPase genes, NADH dehydrogenase 
subunit 3, 4L, 4 and the tRNA genes for Lys, 
Gly, Arg, His, Ser and Leu. 
The boundaries of the deletion were further 
explored by the PCR. PCR primers were chosen 
in order to flank the maximal deletion as judged 
from restriction enzyme site mapping. A 900 bp 
fragment was obtained from the patient's 
mtDNA with primer A and primer В (see Table 1 ) 
after 20 cycles of the PCR. No PCR fragment 
23.1 kb 
11.5 kb 
9.4 kb 
6.6 kb 
Fig. 2. Southern blot analysis of a PvuII digest of total blood 
D N A , hybridized with a m t D N A probe isolated from blood 
platelets. (1) л D N A digested with H i n d l l l PstI; (2) Pearson 
patient; and (3) control . 
was obtained in control mtDNA, including the 
other family members. As a control a second 
PCR was performed on the patient and control 
mtDNA with the primers E and F, to amplify the 
gene coding for cytochrome с oxidase subunit 3 
(СОЗ) derived from the intact mtDNA (Table 1 ). 
All samples showed a PCR product (data not 
shown). 
APCR and direct sequencing revealed that the 
deletion spanned 6017 bp from nt 7778 to nt 
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G А Τ С 
. . . 
• 
*·*%*· 
deletion 6017bp 
Fig. 3. Characterization of the nucleotide structure at the endpoints of the deletion. Sequence analysis of the deleted region. 
The two four base pair direct repeats flanking the deletion are marked with vertical lines. 
13,794 (Fig. 3) between the gene coding for 
cytochrome с oxidase subunit 2 (C02) and the 
gene coding for NADH dehydrogenase subunit 5 
(ND5). Two four base pair direct repeats were 
detected at the boundaries of the deletion in the 
patient (Fig. 3). 
Upon investigation of fresh muscle, fibro­
blasts, and the autopsy material we found the 
deletion in all tissues examined. The same size of 
deletion was found in all tissues but the 
percentage deleted mtDNA vs intact mtDNA 
varied. Results from densitometric scannings are 
shown in Table 4. In blood, kidney and liver 
more than 90% of the mtDNA was deleted. 
Transcription of the fusion gene resulting from the 
deletion 
To investigate whether the mtDNA deletion 
gave rise to an abnormal mRNA we isolated 
mRNA from the lymphoblastoid cells of the 
patient. The ratio of the percentage deleted vs 
normal mtDNA in the lymphoblastoid cells was 
4 : 1 . We generated cDNA from the patient's 
mRNA and performed a specific PCR on the 
cDNA to amplify the C02-ND5 cDNA, fused as 
a result of the deletion. As a control, a second 
PCR on the cDNA was performed to amplify the 
СОЗ cDNA derived from the intact mtDNA. 
Only a small amount of amplification product of 
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bp1353 ^ 
bp 603 -
1 2 3 4 5 6 7 8 9 
Fig. 4. Amplification products of the patient's mRNA and DNA originating from lymphoblastoid cells. Lanes 2-5: 30 cycles of 
the PCR; Lanes 6-9: 40 cycles of the PCR. Lane \:Ri φΧ DNA digested with Hae III; Lanes 2 and 6: PCR on DNA with 
primers flanking the deletion, within the coding sequences for the mRNA of the C02 (primer C. Table 1 ) and the ND5 (primer 
D, Table I) genes; Lanes 3 and 7: PCR on cDNA of the mRNA with primers С and D; Lanes 4 and 8: PCR on DNA with 
primers generating the СОЗ gene (primerset E and F, Table 1), positioned within the coding sequence for the mRNA of the 
СОЗ gene; Lanes 5 and 9: PCR on cDN A of the mRNA with primers E and F. 
the C02-ND5 cDNA resulting from the 
deletion, is seen (Fig. 4: lanes 3 and 7) compared 
with the amplification product of the СОЗ 
cDNA from the intact mtDNA (Fig. 4: lanes 
5 and 9). As a control for the amplification 
reactions on cDNA, the same PCR reactions 
were performed on total cellular DNA isolated 
from the lymphoblastoid cells (Fig. 4: lanes 2,4,6 
and 8). 
DISCUSSION 
Pearson syndrome is a very rare disorder. Only 
13 patients have been described, 7 of them only 
recently [3, 9]. The clinical picture of our patient 
is dominated by hypoplastic anaemia accom­
panied by a tendency to neutropenia and 
thrombopenia. Besides disordered glucose 
homeostasis and lactic acidosis, failure to thrive 
and diarrhoea were observed. 
The aplastic anaemia was associated with a 
marked vacuolization in the granulocyte pre­
cursors in the bone marrow aspirate. This is in 
agreement with data of other patients with 
Pearson's syndrome, although our patient did 
not have sideroblastic anaemia [1, 2, 3, 9, 30]. 
Development of thrombopenia and neutropenia 
was also seen in the majority of other patients [ 1, 
2, 3, 30]. 
The periods with hyperglycemia interchanged 
with periods of severe hypoglycemia. It is not 
unlikely that these disturbances were caused by 
an endocrine pancreatic dysfunction although 
we could not prove this. A disturbed glucose 
homeostasis was seen previously although in a 
less severe form [1, 9]. Like the present child, all 
seven children described by Cormier et al. [3] and 
McShane et al. [9] had a lactic acidosis. 
Three patients [3] had an atrophy of the 
intestinal villi, similar to our patient. Most 
persons had periods of diarrhoea, which, unlike 
in the present child, could be ascribed to 
dysfunctioning of the exocrine pancreas [2, 3, 9, 
29]. Hepatocellular dysfunction was seen in the 
majority of the described cases [2, 3, 9]. 
The failure to thrive, as our patient showed, is 
a non-specific but frequent symptom of the 
disease: 10 of the 13 patients described also 
showed this symptom [1, 2, 3, 9]. Eight of the 
reported persons have died [1-3], one developed 
the Kearns-Sayre syndrome [9], the other four 
were at the moment of publication still alive with 
a variable extent of disease [3]. 
Electron microscopic studies of the muscle 
biopsy revealed a widespread affection of mito­
chondrial ultrastructure. These mitochondrial 
alterations in the muscle tissue have not been 
reported previously in Pearson syndrome. 
Comparable alterations can be seen in patients 
with mitochondrial myopathies. 
Since our patient was suffering from a lactic 
acidosis we investigated the energy metabolism 
of her muscle mitochondria. Biochemical exam­
ination revealed a disordered energy metabolism. 
However, a clear defect of a single enzyme could 
not be demonstrated, although the activity of the 
cytochrome с oxidase and pyruvate dehydro­
genase complex was slightly decreased (Table 3). 
Cormier et al. [3] showed abnormal oxygen 
consumption and low enzyme activities in intact 
and fragmented lymphocytes but their bio­
chemical studies of muscle gave normal results. 
Majander et al. [31] studied a patient with a 
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variant of the Pearson syndrome with deleted 
mitochondrial DNA in muscle, leucocytes, 
fibroblasts and kidney and they demonstrated 
decreased activities of respiratory chain enzymes 
in muscle mitochondria 
Deletion mapping with restriction enzymes 
showed that the mitochondria of this patient 
suffering from the Pearson syndrome contained 
both normal and deleted mtDNA The bound-
aries of the mtDNA deletion were identified 
exactly by PCR and direct sequencing with 
pnmers flanking the maximal possible deletion 
As the pnmers chosen for the PCR were 6811 bp 
distance from each other on the normal mtDNA, 
no PCR product was generated under our 
conditions, which do not allow amplification of 
DNA stretches larger than 3 kbp A 900 bp PCR 
fragment was obtained from the patient's 
mtDNA, consistent with the restriction enzyme 
mapping Sequencing of the 900 bp deletion 
fragment revealed that the size of the deletion 
was 6017 bp, spanning the region from bp 7778 to 
bp 13794 
The same size of the deletion was found in 
several tissues However, the percentage of de-
leted mtDNA vs normal mtDNA differed from 
one tissue to the other The measured 
percentages of deleted mtDNA per tissue were in 
agreement with the percentages published by 
Rouget al [6, Table4] 
A lymphoblastoid cell line of the Pearson 
patient containing the deletion, enabled us to 
perform mRNA studies The mtDNA deletion 
fusing the C02 with the ND5 gene, caused a 
frameshift at the breakpoint of the ND5 gene 
resulting in a gene with an open reading frame 
:oding for 74 amino acids Only a low level of 
transcription of the fusion gene was seen This 
may be ascribed to impaired transcription of the 
fusion gene or to rapid degradation of the 
transcription product In contrast with our re-
sults, Nakase et al [32] showed that the deleted 
genomes of two patients with Kearns-Sayre 
>yndrome were transcriptionally active in muscle 
and fibroblast cells They described that the 
deleted mtDNAs were unable to translate any of 
the transcribed mtRNAs, whether derived from 
the deleted or undeleted regions of the genome 
In fact both findings resulted'in an impaired 
»ynthesis of the fusion protein, making it a less 
ikely component of the pathogenetic mech-
inism 
The deletion of our Pearson patient was 
distinct from the deletions in the Pearson patients 
reported by Rotig, Blaw and Larsson et al [5, 6, 
8, 33] Moreover, this particular deletion did not 
have its counterpart in any other mtDNA dele-
tion described in other mitochondrial myo-
pathies [34] Only two four base pair direct 
repeats were present at the boundaries of the 
deletion These two short sequences are repeated 
very often throughout the rest of the 
mitochondrial genome, consequently making the 
assignment of the causative role of direct repeats 
m the mtDNA deletion mechanism of the 
Pearson syndrome less straightforward [13, 35, 
36] It is possible that the two four base pair 
direct repeats formed one repeat of eight base 
pairs by looping out the intervening base pairs, m 
such a way generating the slip replication mech-
anism [36] 
Considering the presence of the same classes of 
deletions [35] in Kearns-Sayre syndrome and, as 
our data indicate, in Pearson syndrome, it is df 
interest that patients with Pearson syndrome 
may develop Kearns-Sayre syndrome [33, 37] 
This suggests that these clinically very different 
syndromes are related and might have a similar 
pathophysiological basis Ragged red fibres are a 
common feature in mitochondrial disorders with 
mutated mtDNA [38-40] The observation that 
there were no ragged red fibres in this patient 
provides supporting evidence to the suggestion 
that ragged red fibres represent the response to 
deleted mitochondrial DNA and its con-
sequences, rather than being of primary patho-
logical significance [38] 
Mitochondria of the parents and siblings of 
the patient contained only normal DNA sug-
gesting that the deletion found in the patient was 
derived from a de novo mutation All tissues 
investigated contained the deletion, comprising 
entodermal, ectodermal, and mesodermal tis-
sues So the de novo mutation must have taken 
place before the stage of mtDNA segregation in 
the oocyte [13] Hauswirth et al have suggested 
that there must be a "bottleneck" at which one to 
five of the many thousands of mtDNAs in every 
oocyte are selected to populate the organism [41, 
42] It is likely that the deleted mtDNA was 
already present before the "bottleneck", and was 
subsequently distributed over all the tissues of 
the patient 
Rotig et al described that rearranged mtDNA 
was predominant in the most severely affected 
organs, whereas a relatively high level of normal 
mtDNA was found in the less affected tissues in 
their patients [5] Moraes et al showed that 
depletion of mtDNA in liver tissue of a patient 
was correlated with a fatal hepatic failure with 
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Table 4 Percentages of deleted mtDNA of the total amount of mtDNA per tissue 
V. deleted mtDNA 
Present 
patient* 
Lit J 
Tissue affected 
Present 
patientt 
Ut§ 
Lung 
Pancreas 
Liver 
Small intestine 
Large intestine 
Spleen 
Musculus psoas 
Musculus intercostal» 
Musculus quadriceps 
Musculus diaphragm 
Kidney 
Blood 
Heart muscle 
76 
88 
>99 
81 
64 
89 
67 
56 
82 
66 
94 
91 
38 
90 
90 
90 
90 
40-60 
90 
90 
40-60 
'The percentage of deleted mlDNA and tlhe involvement of the various tissues of our Pearson 
patient were compared with tthc values and §biochemical and clinical data reported by Cormier 
« al [7] 
abnormal mitochondrial morphology and pro­
liferation in the liver [43]. However, in our 
patient it was impossible to correlate the level of 
rearranged mtDNA with the severity of tissue 
involvement. In many tissues in our patient we 
found a discrepancy between the clinical and 
molecular genetic data: in pancreas, kidney and 
heart muscle the total amount of mtDNA con­
sisted of approximately 90% deleted mtDNA vs 
10% normal mtDNA, whereas these tissues 
showed no clinical failure. And in spite 
of a more or less depletion of normal mtDNA in 
the liver of our patient [20], the liver function was 
normal up to the last 3 months of her life. When 
the liver function became disturbed it was 
postulated that it was caused by a hepatitis С 
infection. 
In summary, the patient studied is the first 
example in which an exocrine pancreatic insuffi­
ciency is not an obligate characteristic of 
the Pearson syndrome. Mitochondrial morph­
ology and mitochondrial energy metabolism 
in muscle was disturbed and a de novo dele­
tion in the mtDNA was identified. The same 
mtDNA sequence rearrangement was found in 
all tissues, but the percentage of deleted mtDNA 
molecules vs normal mlDNA differed and did not 
correlate with tissue involvement. The exact 
deleted region was different in size from the 
already published deletions in Pearson patients 
and an imperfect direct repeat was found at the 
boundaries of the deletion. mRNA studies 
showed hardly any transcription from the fused 
DNA region, resulting from the deletion. In 
conclusion we would recommend classification 
of the Pearson syndrome as a mitochondrial 
cytopathy. 
The lymphoblastoid cell line carrying deleted 
mtDNA will be useful for further studies on the 
origin and maintenance of deleted mtDNA. 
Manipulation of the nuclear and mtDNA in 
these cells in culture will lead to a better under­
standing of the primary defect and its con­
sequences in mitochondrial disorders. 
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Short Communication 
Detection of Extremely Low Levels of 
Wild-Type Mitochondrial DNA in the Liver 
of a Patient with Pearson Syndrome by a 
Sensitive PCR Assay 
D. D. DE VRIES 1 , W . RUITENBEEK 2 and В. A. VAN O O S T 1 
Departments of l Human Genetics and 2Paediatrics, University Hospital Nijmegen, 
P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 
Pearson's marrow and pancreas syndrome is characterized by refractory sideroblastic 
anaemia with vacuolization of bone marrow precursors and exocrine pancreatic 
insufficiency (Pearson et al 1979). Onset is in early infancy and many patients die 
before the age of 3 years. Recently it has become apparent that patients with Pearson 
syndrome have large deletions in part of their mitochondrial DNA (mtDNA) (Rötig 
et al 1989, 1990, 1991; Cormier et al 1990; McShane et al 1991). Similar molecular 
defects are found in a number of patients with a mitochondrial myopathy, especially 
in the Kearns-Sayre syndrome (Holt et al 1988, 1989; Lestienne and Ponsot 1988; 
Moraes et al 1989). 
We present a mtDNA study in tissues of a girl suffering from sideroblastic 
transfusion-dependent anaemia, disordered glucose homeostasis, stunted growth and 
transient malabsorption. Besides the absence of pancreatic dysfunction, the pavent 
fulfills the diagnostic criteria for Pearson syndrome. We have identified a 6-kb 
deletion in the mtDNA from blood of this patient in the presence of a normal amount 
of intact mtDNA (de Vries et al, manuscript in preparation). The patient died at the 
age of 16 months and investigation of obduction material revealed the deletion in 14 
different tissues. The same size of deletion was found in all tissues, but the percentage 
of deleted mtDNA molecules differed (de Vries et al, manuscript in preparation). In 
particular, in liver tissue we were unable to detect normal mtDNA with Southern 
blot analysis of restricted total DNA. 
By using a sensitive and specific PCR assay we studied the normal and deleted 
mtDNA in the liver tissue of our patient. 
MATERIALS AND METHODS 
Liver tissue of the patient was obtained by obduction 5 h after death and immediately 
frozen in liquid nitrogen. Total genomic DNA was extracted by overnight incubation 
of lOOmg liver tissue in 1ml 75mmol/L NaCl, 24mmol/L EDTA (pH 8.0), 1% 
sodium dodecyl sulphate and 10% proteinase K. Subsequently 460 pi 6mol/L NaCl 
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was added, vortexed and spun for 15 min at 3000 rpm. The supernatant was extracted 
with an equal volume of 0.1 mol/L Tris- (pH 8.0) saturated phenol, subsequently with 
an equal volume of phenol-chloroform-isoamylalcohol (1:1:0.02 v/v/v) and finally 
with an equal volume of chloroform-isoamylalcohol (1:0.04 v/v). The DNA was 
concentrated on a Centricon-30 microconcentrator (Amicon). 
Primer set ATG ACC CAC CAA TCA CAT GCC Τ (bp9207-9229) and AAG 
ACC CTC АТС AAT AGA TGG A (bp9969-9990) was used to amplify the gene 
coding for cytochrome с oxidase subunit (СОЗ gene) and primer set CCT ATT CCC 
CCG AGC AAT CTC A (bpl4149-14170) and ATG ATG TAT GCT TTG 
TTT CTG Τ (bpl4652-14673) was used to amplify the gene coding for NADH 
dehydrogenase subunit 6 (ND6 gene), nucleotide numbering according to Anderson 
et al (1981). Primers were synthesized on a DNA synthesizer (Cyclone, Biosearch 
Inc.) with phosphoamidite chemistry. 
Fragments of mtDNA were amplified from 1 μ% of total DNA in 100μ1 of reaction 
mixture containing 8.3mmol/L of each dNTP, 16.6mmol/L (NH4)2S04, 67mmol/L 
Tris-HCL(pH 8.8),6.7mmol/L MgCl2,10mmol/L/}-mercaptoethanol, 10% dimethyl-
sulphoxide, 0.2 /ig of each primer and 8% bovine serum albumin. The reaction was 
carried out for 16, 18, 20 and 22 cycles with the use of a thermal cycler (Perkin Elmer 
Cctus). The cycle times were as follows: denaturation 60s at 92CC; annealing 90s at 
58Χ; primer extension 3 min at 72°C. The amplified fragments were separated by 
electrophoresis on 1% agarose gels and detected fluorographically after staining with 
ethidium bromide. 
RESULTS 
Varying cycles of the PCR on liver and blood DNA from the patient and blood 
DNA from a control were tested with the primer sets for the СОЗ gene and the ND6 
gene. The СОЗ gene is present on wild-type mtDNA but absent on deleted mtDNA, 
whereas the ND6 gene is present on both wild-type and deleted mtDNA. Figure 1 
shows a СОЗ-amplification product from DNA of both patient blood and control 
blood after 18 cycles of the PCR reaching a high yield after 22 cycles of the PCR. 
From the patient's liver DNA no СОЗ-amplification product was observed up to 20 
cycles of the PCR, whereas a very small yield was seen after 22 cycles of the PCR. 
In contrast, the ND6-amplification products from DNA from liver and blood tissue 
of the patient and from blood of the control are indistinguishable in size and intensity 
for all three cycles. 
DISCUSSION 
PCR has proved to be a very useful technique for detecting quantities of DNA that 
are below the limits of detection by Southern blot analysis. Liver tissue of our Pearson 
patient contains hardly any wild-type mtDNA as shown by the low yield of the СОЗ-
amplification product from DNA of this tissue compared to the normal yield of the 
amplification product of the non-deleted ND6 gene. Despite the extremely low 
percentage of wild-type mtDNA in liver mitochondria, no functional defect of the 
liver was demonstrated during the patient's life. At obduction the liver was enlarged 
(610g, normal = 260 g), but had a normal appearance. 
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Figure 1 Amplification of the СОЗ and ND6 gene in patient's liver (LI), patient's blood (Bl) 
and control blood (B2) after 16, 18, 20 and 22 cycles. The open circles represent the СОЗ-
amplification products, the closed circles represent the ND6-amplification products 
Deletions of the mtDNA are consistent features of Pearson syndrome. In Pearson 
syndrome an increasing number of tissues become affected in the course of the disease 
(Rötig et al 1990). It was noted that rearranged mtDNA species were predominant 
in the most severely affected organs, whereas a relatively high level of normal mtDNA 
molecules was found in the clinically, biochemically, and morphologically less affected 
tissues (Rötig et al 1990). However, the presence of virtually only deleted mtDNA in 
the liver is difficult to correlate with the absence of any liver failure in our patient. 
Selfishness of deleted mtDNA might be an explanation for the phenomenon found 
in the liver mtDNA, as suggested by Poulton et al (1991), who studied a familial 
form of Kearns-Sayre syndrome in which the patient shows a dramatic increase of 
the amount of deleted mtDNA compared to his asymptomatic relatives. The 
fluctuation of the proportion of deleted mtDNA in different tissues might also account 
for the recovery seen in another patient with Pearson syndrome, who subsequently 
developed Kearns-Sayre syndrome (Larsson et al 1990). More biochemical and 
molecular studies are required to elucidate the pathogenetic mechanism behind 
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míDNA deletions in Pearson syndrome, Kearns-Sayre syndrome and other mito-
chondrial myopathies. 
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CHAPTER ΙΠ 
Point mutations in tRNA coding regions of the mitochondrial DNA 
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Abst rac t . A family wilh myoclonus epilepsy has been de-
scribed previously as suffering from an X-linked disorder, 
because at least four males were affected, and only mild 
and variable symptoms were seen in some female carriers. 
In this family, we have now identified a mitochondrial 
A - » G (8344) hctcroplasmic point mutation. This point 
mutation has been described in families with maternally 
inherited myoclonus epilepsy and ragged red fibers. The 
degree of seventy of the disorder in the different family 
members was reflected in the relative quantity of mutated 
mitochondrial DNA. It is concluded that the mode of in-
heritance in this family is not X-linked but maternal 
ternal inheritance with variable expression, we rcstudied 
3 affected and 2 unaffected family members for the 
presence of the crucial A—»G mlDNA transition in the 
tRIMA1»". 
Patients and methods 
Case report 
The pedigree of Ihe family described by Wicnkcr e( al (1979) is 
presented in Fig I A brief summary of the clinical description, com-
plete with new clinical and biochemical dala, is given here In this 
family, IV-1, V-3. V-5. VI-1. VI-2. Vl-4 and VI-5 were affected 
Milder symptoms were observed in the females IV-1 and V-3, in 
which symptoms developed at 60 and 45 years of age, respectively 
V-3 died at age 63, IV-1 at age 83. and Vl-4 al age 31 
Introduction 
Progressive myoclonic epilepsy is a class of generalized 
epilepsies associated with myoclonic and tomc-clonic 
seizures, and progressive neurological dysfunction. Myo-
clonic epilepsy and ragged red fiber disease (MERRF) is a 
subgroup of these disorders (Tsairis et al. 1973; Fukuhara 
et al. 1980). In the past decade, MERRF has been shown 
to be a maternally transmitted disorder of oxidative phos-
phorylation (OXPHOS) (Wallace et al 1988), and recent-
ly a mutation in the mitochondrial tRNA gene for lysine 
has been identified in a number of non-related MERRF 
patients (Shoffner el al. 1990; Shoffner and Wallace 1991 ; 
Yoneda et al. 1990; Noer et al. 1991; Zeviam et al. 1991; 
Se ibe ie ta l . 1990). 
Previously, we described a family with progressive 
myoclonus epilepsy, ataxia and mental deterioration in 
2 brothers and a maternal cousin (Wienker et al. 1979; 
McKusickNo. 310370) Similar but less severe symptoms 
were seen in the maternal grandmother. Therefore, an X-
linked mode of inheritance was suggested. However, be-
cause the pedigree structure was also compatible with ma-
oW 
ОтО 
III 
IV X Aw • Ú ' 
(W tip'M 
Blood 20% 
VI 
. . 
704 50% n.a. 70% Blood 
40% n.a. 2% 40% Fibroblasts 
n.a. n.a. 60% n.a. Musei· 
Fig. 1. Pedigree of the MERRF family Ü. male; O. female. • . · , af-
fected persons, 0. 0. deceased The percentages mentioned in the 
ionerpart of the pedigree are the percentages of mutated mtDNA in 
the different tissues, n.a.. Samples not available for study 
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VI 2 The clinical cour« of this patient up to 23 years of age was de 
scribed previously (Wtenkeret al 1979) In comparison v. Uh the find 
ings in 1977 no changes were seen in the electroencephalogram 
(EEG) bul elecuoneurographic studies led to the diagnosis of axonal 
polyneuropathy at the age of 31 The lactate level in liquor was 2 I 
2 2mmol/l (maximum control le\el I 9mmol/l) and no aciduria was 
found The patient received anti-epileptic medication from the age of 
31 (timonil 600mg/day nvotnl I mg/day) To ameliorate his indiffer 
enee the patient was subjected lo ergothcrapy A muscle biopsy was 
performed when the patient was 26 years of age Histochemical and 
electron microscopy of the muscle specimen revealed characteristics 
of a mitochondrial disorder (ragged red fibers abnormal mitochondn 
al ullrastructure) 
VI 4 The clinical course ol this patient up to his 20th year of age was 
described before (Vv lenker et al 1979) The patient died at the age of 
31 Histochemical and electron microscopic studies of the muscle re 
vcalcd that the patient suffered from a mitochondnopathy with ragged 
red fibers Moreover analysis of the nervus surahs revealed axonal 
neuropathy affecting both the central and peripheral nervous systems 
VI 5 The clinical course of patient VI 5 was uneventful up to 13 years 
of age At the age of 19 a first epileptic seizure dysrythmic EEG 
and focal signs were seen At age 24 the patient suffered from myo 
clonic seizures ataxia proximal muscle weakness muscular atrophy 
and reduced visus Histochemical ¿nd electron microscopic studies of 
the muscle biopsy taken at the age of 24 revealed a mitochondnopa 
thy with ragged red fibers Up to now no progression has been seen 
under medication [valproate 2 χ 500 mg/day coenzyme Q 120 mg/day 
(Decorenone)] 
DNA methods 
Isolation of genomic DNA The fibroblast cultures of patient VI 2 VI 
4 and VI 5 were started m 1975 The cells from VI 2 had undergone 
10 passages The cells from VI 4 and VI 5 had both undergone 17 
passages Fibroblasts and blood DNA was prepared according to stan 
dard procedures (Miller et al 1988) Total DNA was extracted from 
muscle as described for liver tissue by de Vries et al (1992) 
Polymerase chain reaction The polymerase chain reaction (PCR) to 
detect the MERRI mutation was performed according to Zeviani et 
al (1991) in which one primer modifies the PCR product to create a 
Bgl\ restriction site in mutant but not wild type mtDNA Modifica 
tmns to the PCR protocol were the lollowing lOmin at 96°C then 30 
cycles of 48s at 92°C 48sat55°C and 2mm at 72°C with l-10Ong 
total DNA 66 6 nmoles of each dNTP I unit Taq DNA polymerase 
(Ampli Taq Celus) in 67mA/ TRIS HCl pH8 8 6 7mAÍMgCl 16 6 
mW (NHj) SO., lOmA/ β mercapto ethanol 8mg bovine serum al 
bumin and 200 ng of oligonucleotide primers in a total volume of 
100μ1 
To increase the sensitivity of the detection method for this muta 
tion the PCR was performed with 1 2P labeled oligonucleotide 
primers Labeling was performed by linking 1 pmol γ 3 Τ ATP (Amers 
ham UK) to lOOng of both oligonucleotide pnmers with T4 polynu 
cleotide kinase (Pharmacia The Netherlands) in 50mMTRIS HCl pH 
7 6 lOmM MgCI 5mM DTT 0 I mW spermidine HCl and 0 1 mM 
EDTA Subsequently the PCR products were digested with Bgll and 
run on a non denaturing 6% Polyacrylamide gel Autoradiography 
was performed by a 2 h exposure of the gel to X ray film with two in 
tensifying screens 
Results and discussion 
Thirteen years ago, the disease in the family under study-
was described as a sex linked inherited metabolic neu 
ropathy probably a variant of myoclonus epilepsy (Wien 
k e r e t a l 1979) Later the clinical course, and histochemi 
cal and electron microscopic studies of muscle biopsies in 
the affected males revealed that they were indeed suffer 
ing from the M E R R F syndrome 
В F M 
^ c s i c ï i n ru *- in ^ 
per > > > > > > > > 
m -133bp 
Fig 2 Autoradiograph of Я^/1-digested J 1P labeled PCR samples of 
different members of the MERRF pedigree separated on a polyacryl 
amide gel When the heteroplasmic A—>G mutation on np 8144 was 
present the 175 bp PCR fragment was cut into a 133 bp fragment and 
a smaller (not visible) 42 bp fragment The percentage of mutated 
mtDNA was estimated from the autoradiograph as the ratio of twice 
the amount of digested PCR product versus the amount of undigested 
product on the aery I amide gel (note that the wild type PCR product 
contained two labeled primers) The tissues studied were blood (B) 
fibroblast (F) and muscle (M) The pedigree numbers on top of 
the lanes refer directly to the pedigree shown in Hg 1 per on top of 
lane I represents the undigested PCR product 
PCR and restriction enzyme analysis of the mtDNA re­
vealed an A—>G mutation on nucleotide position (np) 
8344 in the t R N A ^ i n the mtDNA in this family (Fig 2) 
All individuals studied were heteroplasmic for the A—*G 
mutation on np 8344, consistent with the maternal inhen 
tance of mtDNA However the percentage of mutated 
mtDNA varied widely between family members The 
A—>G mutation on np 8344 was apparently specific tor 
the M E R R F phenotype as the mutation was absent in 85 
patients with other mitochondrial (encephalo )myopathies 
that were tested in our laboratory 
The patients were also screened for other mutations in 
their mtDNA Restriction enzyme analysis and Southern 
blotting of mtDNA from blood and fibroblasts did not re­
veal any deletions or rearrangements Moreover, the diag­
nostic tests described for the np 3243 (Goto et al 1990) 
and np 4317 (Tanaka et al 1990) mtDNA mutations found 
in patients with mitochondrial encephalomyopathy lactic 
acidosis and stroke like episodes (MELAS) were nega 
ti ve 
In Fig 1, the percentage of mutated mtDNA in different 
tissues of the family members are given The relative 
amounts of mutated mtDNA varied between different tis 
sues of the same patient In patients VI 2 and VI 5, the 
percentage of mutated mtDNA found in blood (70%) was 
higher than the percentage of mtDNA in fibroblasts 
(40%) In patient VI-4, the percentage of mutated mtDNA 
in muscle was much higher (80%) than that found in fi­
broblasts (2%) The finding of a variable percentage of 
mutated mtDNA in different tissues of the same patient 
is a common finding in mtDNA pathology Seibel et al 
(1991) have reported different percentages of mutated 
tRNA l y s mtDNA in blood muscle fibroblasts, and hair 
The relative amount of mutated mtDNA for a particular 
tissue was also different between patients In blood 
mtDNA 7 0 % mutated mtDNA was found in patients VI-2 
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and patient VI-5 Mutated mtDNA was also found in 
blood from the non affected persons V-l and VI 3, al­
though to a lower extent ( 5 0 % and 20%, respectively) A 
threshold level of mutated mtDNA molecules seems nec­
essary for the disorder to become manifest Seibel et al 
(1991) found 7 7 % and 8 2 % mutated mtDNA in blood 
from 3 severely affected persons, and 5 3 % mutated 
mtDNA in blood from a mildly affected person In skeletal 
muscle from a severely affected patient (VI 4, Fig I), we 
found a high percentage of mutated mtDNA Unfortu­
nately, no muscle tissue specimen from his mildly affected 
mother was available, but supportive evidence comes 
from studies from other groups who have also measured 
high percentages of mutated mtDNA in muscle from af­
fected persons For instance, Shoffner et al (1990), and 
Shoffner and Wallace (1992) have shown that 7 8 % - 9 8 % 
of the total muscle mtDNA is mutated in affected patients, 
whereas unaffected persons have 100% wild type 
mtDNA, Seibel et al (1991) have found that 8 3 % and 
8 4 % of the total mtDNA content is mutated in persons 
with severe symptoms Therefore, the percentage of mu­
tated mtDNA in blood and muscle seems to be correlated 
with the seventy of the manifestation of the disease How­
ever, the relationship between the disease manifestation 
and the amount of mutated mtDNA in fibroblasts is less 
clear Fibroblasts from patients VI-2 and VI 5 showed 
4 0 % mutated mtDNA, whereas fibroblasts from patient 
VI 4 showed hardly any mutated mtDNA In spite of the 
severity of the disease in VI-4, only 2 % of mutated 
mtDNA was found in his fibroblasts Seibel et al (1991) 
also measured low percentages of mutated mtDNA in fi­
broblasts from affected persons, v iz, 4 8 % mutated 
mtDNA in fibroblasts from a severely affected patient and 
3 1 % in fibroblasts from a more mildly affected patient 
The maternal inheritance of the disorder, the biochemi­
cal defect in OXPHOS, and the point mutation in the mi 
tochondnal iRNA'1" have confirmed that, in most cases, 
MERRF is a mtDNA related disorder, caused by an A-»G 
mutation on np 8344 (Rosing et al 1985, Wallace et al 
1988, Shoffner et al 1990, Lauber et al 1991, Noer et al 
1991, Seibel et al 1991, Shoffner and Wallace 1991, 
Yonedaetal 1990, Zeviani et al 1991) The finding of a 
suggestive correlation between the relative amount of mu­
tated mtDNA in blood and muscle and the seventy of the 
disease manifestation in the family presented here argue 
strongly for a mitochondrial disorder that was earlier sup­
posed to be an X linked disease 
The phenotype in this family seems to have a male pref­
erence All fully affected sibs in generation V and VI are 
males showing an almost identical clinical picture and dy­
ing very early in adulthood, whereas female sibs are, at 
most, mildly affected with manifestations appearing much 
later in life with a very vanable clinical picture The ob­
served male bias suggests that a nuclear gene trait, prob­
ably X linked, is involved in or even superimposed on this 
mtDNA disorder This phenomenon can also be noticed in 
Leber hereditary neuropathy (LHON), a maternally inher­
ited disease transmitted by mutations in mtDNA In 1987, 
Wallace ( 1987) proposed that LHON could be the result of 
an interaction between a mitochondrial gene defect and an 
X-linked gene coding for an optic nerve protein Later, 
Vilkki et al (1991) found genetic linkage to a locus on the 
X chromosome in 6 pedigrees with LHON Moreover, Bu 
and Rotter (1991) demonstrated a role of X chromosome 
inactivation in the transmission pattern observed in 
LHON Thus, even if the primary cause of MERRF is ma 
temally inhentcd, the disease might be influenced by 
some X-linked gene(s) However, none of the recently 
published MERRF pedigrees showed an X-linked mode of 
inheritance as all families consisted of male and female 
patients with the MhRRF phenotype (Shoffner et al 1990, 
Shoffner and Wallace 1991, Noer et al 1991, Zeviani et 
al 1991, Seibel et al 1990,1991) In these studies the age 
of onset of the disease, and the occurrence and percentage 
of the heteroplasmic point mutation did not differ between 
the two sexes 
In conclusion, we have provided evidence that, in a 
family with an apparently X linked myoclonus epilepsy a 
point mutation in the mtDNA is the major determinant of 
the disease Indeed as there are no other reports of clearly 
X linked myoclonus epilepsy, this entity may not exist 
Additional evidence could come from mtDNA studies in 
each family that has myoclonus epilepsy for which an X 
linked mode of inheritance has been considered 
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Abstract 
In a family with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes with extremely varying 
clinical expression, we have identified the A3243G hctcropljsmic point mutation in mitochondrial DNA The degree of severity 
of the clinical symptoms in the various family members was reflected in the relative quantity of mutated mitochondrial DNA in 
different tissues The biochemical activity of complex I of the respiratory chain in muscle was decreased in some members of this 
family 
Key words Mitochondrial myopathy, MELAS, Complex I deficiency, A3241G mutation 
1. Introduction 
Mitochondrial encephalomyopathy, lactic acidosis, 
and stroke-like episodes (MELAS) is one of the clini­
cally defined multisystemic mitochondrial syndromes 
(Pavlakis et al 1984), which is often associated with 
biochemical and morphological abnormalities in mus­
cle, and with mutations in the mitochondrial DNA 
(mtDNA) (Kobayashi et al 1987, Goto et al 1990, 
1991, Ino et al 1991, Tulintus et al 1991, Hirano et al 
1992) Measurements of the respiratory chain enzyme 
activities in muscle revealed that more than 50% of the 
MELAS patients have complex I or I + IV deficiency 
(Hirano et al 1992, Goto et al 1992) In about 75-87% 
of MELAS patients, analysis of mtDNA has uncovered 
two possible transitions in the tRNA for leucine (Goto 
et al 1992, Hirano et al 1992) The most frequent 
point mutation is found at nucleotide position (np) 
3243 and in some MELAS patients a point mutation is 
found at np 3271 (Goto et al 1990, 1991, Ino et al 
1991) Moraes et al (1992) reported correlation among 
* Corresponding author Tel ( + 3180)613616 Fax ( + 31 80) 
542151 
the percentage mutated mtDNA, complex IV defi­
ciency, and muscle morphology Although many 
MELAS patients have been described recently, a clear 
relationship between the clinical seventy, the respira 
tory chain enzyme activities and the proportion of 
mutant mtDNA in muscle has not been demonstrated 
as yet 
A family with a complicated neurological disorder in 
some members is presented Since mitochondrial inher­
itance of the disorder was considered in this family, the 
activities of the enzymes of the respiratory chain and 
the mtDNA of the affected as well as the unaffected 
family members were studied and related to the clini­
cal severity of the symptoms in the family members 
2. Patients and methods 
2 I Case histories 
The pedigree of the family is presented in Fig 1 
The unrelated parents of Indonesian descent and two 
of their children (II 2 and 11-4) did not have any 
symptoms Patients II 1, II 3 and II-5 showed several 
abnormalities, which arc summarized below 
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Fig 1 Pedigree of the MELAS family D male О female О 
affected person · severely affected person # died The percentages 
given below the symbols are the percentages mutated miDNA in the 
three different tissues N D samples not determined 
Patu ηί Π I 
Patient II 1 the first born child in this family was born after an 
uneventful pregnancy and delivery From her 15th year of age she 
Marted to suffer from increasing sensorineural hearing loss 
Patient II 3 
This paiii.nl a girl was born after an uneventful term pregnancy 
and delivery At the age of 18 years she suffered from severe 
convulsions Treatment with clonazepam brought relief after 3 S h, 
but was followed by coma After 4 days she slowly recovered with 
residual neurological signs She was lacking good memory and re­
acted slow and her gait was unsteady One month later she suddenly 
became dizzy had visual disturbances and was unconscious fur S 
mm She also suffered again from convulsions which occurred with 
regular intervals during a few days Treatment with high doses of 
clonazepam brought short relief but she was again in coma for 2 
days And epileptic medication was given but this did not prevent 
the convulsive attacks On examination she was dull and 
bradyphrenic her speech was slow and slightly dysarthnc and her 
eye movements were jerky An ataxic gait persisted Tendon reflexes 
were brisk LXG did not show any abnormalities Magnetic reso 
nance images of the cerebrum showed minimal enlargement of the 
ventricular system The frontal and temporal regions showed small 
areas with a lowered signal intensity There was no sign of cardiac 
involvement Lactate and pvruvate concentrations were elevated in 
cerebrospinal fluid (CSF) and in blood (Table 1) Lactate excretion 
in urine was increased (Table 1) At the age of 19 the quadriceps 
muscle was biopsied 
Panent И 5 
This patient the fifth child was also born after an uneventful 
pregnancy and delivery She had a normal psychomotor develop· 
Table 1 
Pyruvate lauate and alanine concentrations of two family members 
Metabolite (mmol/l) Patient 
II 3 
Patient 
115 
Control range 
Pvruvate in blood 0 13 Ü20 0 0 4 - 0 08 
Lactate in blood 24 57 0 6 - 1 8 
Alanine in blood 0 68 0 79 0 15 -0 50 
Pyruvate in CSF 0 22 0 18 01 -0 14 
Lactate in CSF 4 4 4 6 1 4 - 1 9 
láclate in urine 15 50 < 0 6 
Alanine in urine 0 95 M l 0 016-0 068 
(mmol/mmol creatinine) 
ment At 7 years of age an epileptic seizure of the righi hand was 
observed Physical and neurological examination as well as EEG and 
CT did not reveal any abnormalities apart from an enlarged cisterna 
magna Six months later she was admitted to hospital because of 
vomiting, convulsions and visual disturbances On physical examina 
lion hypotonia and areflexia was noticed Her EEG now showed 
severe general disturbances The girl was dystrophic with thin ex 
tremities. lying in a fetal position Her height weight and head 
circumference were below the 3rd percentile She neither spoke, nor 
seemed to give good contact She was very hypotonic and had no 
head balance and disliked her legs being touched No tendon re 
flexes could be elicited She could not stand or walk and when she 
was put in a silting position she showed no supportive reaction of the 
upper extremities A marked hepatomegaly (5 cm below ihe right 
costal margin) was noticed Feeding by nasogastric drip was started 
and after a few days oral feeding became possible again One week 
later she spoke a few words again and became more cooperative 
Neurological examination at that time showed clear sensory distur 
bances regarding pain and touch especially in the distal pans of the 
extremities Her extremities were paretic and hypotonic with drop 
ping hands A mild distal and truncal ataxia was present which could 
not be explained by the paresis EMG examination of the arms and 
legs showed as well signs of active denervation in different muscles 
as decreased nerve conduction velocity A CT scan showe.d patchy 
hypodensities of white and grey matter throughout the entire brain 
Visual evoked responses were severely disturbed 
Laboratory examination revealed slightK elevated creatine kinase 
(CK) levels (82 U / l control range 0-50 U/ l ) Lactate dthydroge 
nase activity was slightly increased in liver Moreover alanine lac 
tate and pyruvate concentrations were elevated (Table 1) The in 
creased concentrations of pyruvate, láclale and alanine pointed to a 
mitochondrial enzyme defect and therefore metabolic studies wen, 
performed During and after these studies a ketogenie diet was 
applied Vitamin Bl was supplied (dose 3x500 mg/day) The mas-
sive lactate excretion in urine decreased after introduction of the 
kelogenic diet in combination with vitamin B, therapy (from 40-50 
mmol/ l to 1-2 mmol/ l , normal 0 6 mmol/l) An oral glucose 
tolerance lest (2 g/kg) showed a clear rise in blood lactate The 
paiienl died al the age of 14 years from severe cardiomyopathy 
2 2 Morphology and biochemistry 
Quadriceps muscle was obtained from patient 11-3 
by surgical biopsy at the age of 19 years, and the fresh 
tissue was processed for histochemistry, electron mi-
croscopy and biochemistry The oxidation rates for 
pyruvate and malate, the ATP + creatine phosphate 
production rates, and activities of enzyme complexes of 
the respiratory chain and the pyruvate dehydrogenase 
complex were measured in 600 xg supernatant of \Q% 
(w/v) muscle homogenate, as described previously 
(Fischer et al 1986, Speri et al 1990) From patient 
11-5 musculus quadriceps was obtained within 1 h after 
death From two other siblings (II-l and II-4) and from 
both the father and mother (l-l and 1-2) musculus 
quadriceps was obtained at the age of 14, 21, 59 and 55 
years, respectively, by means of a needle biopsy The 
latter 5 muscle specimens were stored at -70°C En-
zyme activities were measured in total homogenate 
prepared from the frozen muscle (Fischer et al 1986) 
The mitochondrial enriched fractions from cultured 
fibroblasts were made by homogcnization and subse-
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quent differentia] centrifugation The complex I activ­
ity of each family member was measured in a mito­
chondrial enriched fraction of fibroblasts and ex­
pressed per ml) cytochrome с oxidase or citrate syn­
thase to correct for mitochondrial recovery 
2 3 DNA methods 
Isolation of genomic DNA 
Fibroblasts and blood DNA were prepared accord­
ing to standard procedures (Miller et al 1988) Total 
DNA was extracted from muscle as described by De 
Vries et al (1992), with the modification that DNA was 
concentrated by ethanol precipitation 
Polymerase chain reaction 
The polymerase chain reaction (PCR) to detect the 
A3243G mutation was performed according to Goto et 
al (1990), using the restriction enzyme Apa\ to cleave 
mutant but not wild-type mtDNA The set of oligonu­
cleotide primers used to generate the PCR fragment 
were as follows np 3189-3210 (forward) 5'-CAA CTT 
AGT ATT ATA CCC АСА C-3' and np 3329-3350 
(reverse) 5'-ATT AGA ATG GGT ATG AGG A-3' 
(nucleotide numbering according to Anderson et al 
(1981)) To increase the sensitivity of the detection 
method the PCR was performed with y-32P-labeled 
primer B, as described (de Vries et al 1993) The 
products were separated on a 6% Polyacrylamide/bis-
acrylamide gel with 10% glycerol The percentage mu­
tated mtDNA was estimated from the autoradiograph 
as the ratio of the amount of digested PCR product 
versus the amount of undigested product on Polyacryl­
amide gel The proportion of mutant mtDNA obtained 
by the method described above compared favorable to 
the proportion derived under conditions when only 
during the last extension reaction the radiolabeled 
reverse primer was present (Moraes et al 1992) 
3. Results 
Muscle morphology 
Histological examination of the quadriceps muscle 
obtained from patient 11-3 revealed a slightly increased 
variability in fibre diameter, the type IIB fibers being 
very small (range 23-77 μπι, normal range 40-80 μιτι) 
In the succinate dehydrogenase stain and in the modi­
fied Gomori tnchrome stain only one type I ragged red 
fiber was seen in 1500 fibers The myosin ATPase 
reaction showed a normal distribution of fibre types, 
with only 29% type I fibers (normal range 35-50Γ-£·) 
Many type I fibers contained lipid droplets Electron-
microscopic studies revealed little abnormalities of the 
mitochondria Some mitochondria showed a paucity of 
cristae 
Biochemistry 
The biochemical study on fresh muscle mitochon­
dria of patient II-3 revealed diminished rates for pyru­
vate and malate oxidation and for ATP plus creatine 
phosphate production The oxidation rate of [1-
NC]pyruvate in the presence of malate was 0 80 nmol 
M C 0 2 per min per mil citrate synthase (control range 
3 61-7 48), while in parallel incubations 6 1 nmol ATP 
plus creatine phosphate were produced per mm per 
mU citrate synthase (control range 42 1-81 2) Using 
succinate as substrate a normal production rate of the 
high-energy compounds was found 10 9 vs 7 2-18 4 for 
controls These data are best explained by a defect in 
the complex I activity of the respiratory chain The 
NADH Q, oxidoreductase values of muscle specimens 
of all 5 family members examined are given in Table 2, 
together with the activities of other mitochondrial en­
zymes In patients II-3 and II-5 the complex 1 activity is 
clearly subnormal, and 11-1 and II-4 showed normal 
enzyme activities, when the activities are referred to 
total protein However, when the complex 1 activities 
Table 2 
Mitochondrial enzyme activities in frozen skeletal muscle homogenates of five family members 
Enzyme Patient Control 
NADH Ql oxidoreductase 
Succinate cytochrome с oxidoreductase 
Cytochrome с oxidase 
Pyruvate dehydrogenase complex 
Citrate synthase 
1 1 
3 7 
-
48 
-
53 
1 2 
17 
-
39 
-
51 
II 1 
13 
21 
153 
7 7 
98 
11 3 
2 7 
22* 
127* 
5 5 
46 
114 
4 4 
-
95 
-
104 
115 
10 
13 
80 
2 9 
110 
range 
4 7- 29 
4 2- 29 
52 -186 
2 7- 8 2 
48 -162 
Enzyme activities are given in mU/mg protein 
* Measured in 600x g supernatant prepared from fresh muscle which control ranges are different from those which are found in homogenstes 
prepared from frozen muscle namely 22-89 for succinate cytochrome r oxidoreductase and 68-437 for cytochrome с oxidase 
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Fig 2 Autoradiograph of Apal digested 'Г Ubelcd PCR fragments of different members of the MELAS pedigree When the heteroplastic 
A ~*G mutation on bp 32-11 was present the 162 bp PCR fragment was cut in a 104 bp fragment and a not visible 58 bp fragment The tissues 
studied were blood fibroblasts and muscle The pedigree numbers on lop of the lanes refer to the pedigree shown in Fig 1 Lane С represents 
the undigested PCR product 
are referred to citrate synthase the healthy sib H-4 has 
a lower activity than the severely affected sib 11-3 Both 
parents showed low complex I activities, but the other 
mitochondrial enzymes, including the reference en­
zyme citrate synthase, were low or low normal, too 
No complex I deficiency could be found in the 
fibroblasts of any of the family members 
mlDNA 
The percentages mutated mtDNA in various tissues 
of the family members are given in Fig 1 The clini­
cally unaffected mother 1-2, had 35% mutated mlDNA 
in her muscle (Fig 2, lane 15), but no mutated mlDNA 
in blood (Fig 2, lane 3), nor in fibroblasts (Fig 2, lane 
8) The deaf patient II-I had 50% mutated mtDNA in 
muscle (Fig 2, lane 16), 20% in blood (Fig 2, lane 4), 
and 40% in fibroblasts (Fig 2, lane 9) The clinically 
unaffected sib II-2 had 5% mutated mtDNA in blood 
(F-ig 2, lane 5), and 1% in fibroblasts (Fig 2, lane 10) 
Muscle from sib II-2 was not available The severely 
affected patient II-3 had 90% mutated mtDNA in 
muscle (Fig 2, lane 17), 25% in blood (Fig 2, lane 6) 
and 60% in fibroblasts (Fig 2, lane 11) The other 
severely affected deceased sib II-5 had 60% mutated 
mtDNA in muscle (Fig 2, lane 19) and 40% in fibro­
blasts (Fig 2, lane 13) Blood from patient II-5 was not 
available 
In the other family members no mutated mtDNA 
was found After exposing the gel 6 times longer than 
the gel shown in Fig 2, a very faint band of mutated 
mtDNA could be detected on the autoradiogram in 
blood from the mother, indicating that less than 1% of 
the mtDNA in blood was mutated However, even 
after longer exposure only the wild type mtDNA could 
be detected in fibroblasts from the mother, and in 
blood, fibroblast and muscle from sib 11-4 
The patients were also screened for other mutations 
in the mtDNA Restriction enzyme analysis and South­
ern blotting of mtDNA from blood and fibroblasts did 
not reveal any deletions or rearrangements Moreover, 
the diagnostic tests described for the bp 4317 (Tanaka 
et al 1990) mtDNA mutation also found in patients 
with MELAS and the bp 8344 (Zcviani et al 1991) 
mtDNA mutation found in patients with myoclonus 
epilepsy and ragged red fiber disease revealed no ab­
normalities in our family 
4. Discussion 
The A-» G transition in the mitochondrial tRNA 
gene for leucine (UUR) at nucleotide position 3243 
detected in the present family, has been identified in a 
number of patients with the MELAS syndrome (Goto 
et al 1990, Kobayashi et al 1990, Johns and Hurko 
1991, Tanaka et al 1991, Sato el al 1992) The symp­
toms m patients II-3 and 11-5, such as mitochondrial 
encephalomyopathy, short stature, episodic vomiting, 
seizures, and recurrent strokes and lactic acidosis, 
match the clinical criteria for MELAS (Pavlakis et al 
1984, Goto et al 1992, Hirano et al 1992) Although it 
has been reported that an increased percentage of 
ragged red fibers is present in muscle biopsies in the 
majority of MELAS patients (Goto et al 1992), the 
proportion of ragged red fibers in the muscle biopsy of 
patient II-3 was normal ( < 0 1%) 
The complex I deficiency in muscle found in the 
severely affected patients 11-3 and 11-5, was in accor­
dance with the described relationship between MELAS 
and complex I deficiency in muscle (Kobayashi et al 
1987, Tulinius et al 1991, Ciafaloni el al 1992, Goto et 
al 1992, Hirano et al 1992, Moraes et al 1992) 
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However, the healthy sib II-4 also showed a very low 
complex I activity when referred to citrate synthase 
Unfortunately, only a needle biopsy could be exam­
ined, and consequently the ratios between complex I 
and the other mitochondrial enzyme activities could 
not be established No indications for mitochondrial 
dysfunction were found in vivo Both parents showed 
low complex I activities as well, but the other two 
measured mitochondrial enzymes were also not very 
active These low normal activities might be an age-re­
lated phenomenon (Trounce et al 1989) 
The proportion of the mutant mtDNA in muscle 
was significantly higher in the severely affected mem­
bers of the pedigree, II-3 and II-5, than in the less 
affected relative II-l and in those who were asymp­
tomatic (case 1-1, 1-2 and II-4) The speculation that 
the onset of MELAS is caused by exceeding the quan­
titative threshold of about 60% mutated genome in 
muscle (Miyabayashi et al 1992) is in accordance with 
our findings in muscle Similar to our findings in the 
present MELAS family, other groups also reported 
that the percentage of mutation was always lower in 
blood than in muscle (Ciafaloni et al 1992, Inui et al 
1992) Nevertheless, the amount of mutated mtDNA in 
blood seems to be a reliable indicator for disease 
manifestation in this family The percentage mutated 
mtDNA in blood (25%) and fibroblasts (60%) from the 
affected sib II-3 was higher than the percentage mea­
sured in blood (20%) and fibroblasts (40%) from the 
less affected sib II-l, which in turn were higher than in 
the unaffected family members 1-1,1-2 and II-4 Unfor­
tunately no blood was available of the deceased patient 
11-5 The percentage mutated mtDNA in fibroblasts of 
the severely affected patient 11-5 (40%) was equal to 
the percentage mutated mtDNA in fibroblasts of the 
less affected sib 11-1 Perhaps fibroblasts are a less 
good indicator for disease manifestation This phe­
nomenon was noticed previously in fibroblasts from 
MERRF patients (De Vries et al 1993) Bourgeron et 
al (1993) noted that the percentage mutated mtDNA 
is not always constant in different passages of the 
fibroblasts 
We found an extreme variation in the amount of 
mutated mtDNA in the different family members 
Other groups reported of appreciable amounts of mu­
tant mtDNA in blood from the family members of 
MELAS patients, including all asymptomatic family 
members (Enter et al 1991, Kobayashi et al 1992, Sato 
et al 1992) Only two groups (Ciafaloni et al 1992, 
Martinuzzi et al 1992) reported of cases like 1-2 in our 
family, in which less than 1% mutated mtDNA could 
be detected in blood and fibroblasts (Fig 2, lanes 3 and 
8) One of her daughters Π-3 has as much as 25% and 
60% mutated mtDNA in blood and fibroblasts, respec­
tively (Fig 2, lanes 6 and 11), which indicates that the 
proportion of mutated mtDNA can segregate very 
rapidly from one generation to the other This phe­
nomenon underlines the difficulty of genetic counsel­
ing of MELAS families 
The clinical expression of the disease in the present 
family varied from a slight sensorineural deafness in 
patient II-l to severe neuromuscular symptoms in pa­
tients 11-3 and II-5 The hearing loss, as seen in patient 
II-l, is a frequent manifestation in MELAS syndrome 
(Hirano et al 1992) The correlation of the proportion 
mutant mtDNA with the clinical phenotype of the 
family members, strongly suggests that in patient II 1 
the syndrome is probably expressed incompletely In­
complete MELAS syndrome has also been described 
by Remes et al (1993) The same A3243G mutation 
has been described in (chronic) progressive external 
ophthalmoplegia (CPEO), Kearns-Sayre syndrome 
(KSS), diabetes mellitus and encephalomyopathies in 
combinations with PEO, ataxia, dementia, seizures, 
deafness and weakness (Hammans et al 1991, Zeviani 
et al 1992) Since diabetes mellitus is also a frequent 
manifestation of MELAS syndrome, it is not unlikely 
that the above mentioned diseases are all manifesta­
tions of one and the same syndrome 
In conclusion, we found variable percentages of 
mutated mtDNA in different tissues of the family 
members There is no obvious correlation between the 
activities of the respiratory enzymes in muscle and 
fibroblasts either with the disease manifestations or 
with the amount of mutated mtDNA The percentage 
of mutated mtDNA in muscle and blood is clearly 
correlated with the severeness of the clinical manifes­
tations in the pedigree However, the relationship be­
tween the amount of mutated mtDNA in cultured 
fibroblasts and the disease manifestations is less clear 
More detailed studies on fibroblasts and chorionic villi 
are required before mtDNA analysis can be applied for 
prenatal diagnostic purposes in the future 
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ABSTRACT 
Different clinical presentations of mitochondrial encephalomyopathy may coexist within a 
family. We report of a family in which the clinical picture ranged from sensorineural 
deafness, retinitis pigmentosa, diabetes mellitus and mild exercise intolerance in some 
family members to MELAS syndrome in others. Two deceased patients in this family 
suffered from MELAS syndrome. Six other family members showed more or less severe 
clinical symptoms usually associated with mitochondrial encephalomyopathies. Elevated 
lactate levels were found in the family members with MELAS and in the more severely 
affected oligosymptomatic members in this family. We sought for the explanation of this 
clinical variability by analysis of mitochondrial DNA. In muscle and blood from three of 
the family members tested, the A3243G tRNA^1""™' mutation in the mitochondrial DNA 
was present. We conclude that the variability in clinical symptoms in this family is the 
maternally inherited intrafamilial clinical variability of MELAS syndrome, associated with 
the A3243G tRNALEU(UUI" mutation in the mitochondrial DNA. Different percentages of 
this mutation were found in various family members. 
INTRODUCTION 
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 
(MELAS) is one of the mitochondrial encephalopathies which is often associated with 
biochemical and morphological abnormalities in muscle, as well as with mutations in the 
mitochondrial DNA (mtDNA) (1,2,3,4). The MELAS syndrome is characterized by short 
stature, episodic vomiting, seizures, and recurrent strokes causing hemiparesis, 
hemianopia or cortical blindness and is always associated with lactic acidosis (2,3,5). 
Additional features include neurosensory hearing loss, cardiomyopathy, and basal ganglia 
calcifications (2,3). Measurement of the respiratory chain enzyme activities in muscle has 
revealed a predominance of complex I and a combined complex I and IV deficiency in 
MELAS patients (2,3,6). Analysis of mtDNA has uncovered two possible heteroplasmic 
transitions in the tRNA for leucine. The most frequent point mutation is found at 
nucleotide position (np) 3243 and in some MELAS patients a point mutation is found at 
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np 3271 (7,8,9). In about 80% of the clinical MELAS patients one of these two point 
mutations are found (2,3). Tanaka et al. also reported of a point mutation at np 4317 in 
the tRNA for isoleucine in a patient with MELAS and fatal infantile cardiomyopathy (10). 
Recently another point mutation has been reported at np 8356 in the tRNA for lysine in 
two families (11,12), one of which had the clinical characteristics of myoclonus epilepsy 
and ragged red fiber disease (MERRF) and MELAS syndrome (12). We report here on a 
family with an extreme variation in clinical phenotype associated with the presence of the 
A3243G mutation in the tRNALB,(UUR). 
PATIENTS AND METHODS 
Patients 
The pedigree of the family is presented in Fig. 1. The clinical characteristics of the 
family members are summarized in Table I and a discrimination can be made between 
MELAS- (patient III-4 and III-6), oligosymptomatic- (patients 1-2, II-1, II-2, III-1, III-2 
and ΙΠ-3) and asymptomatic family members (sib III-5). 
The results from biochemical studies and from neurophysiological, radiological and 
pathological studies of nerve and muscle are summarized in Table II. 
Ill 
60% In muscle 
y¿5>* 
10% , 25% and 15% In blood 
Fig. 1 The pedigree of Ihe family. (^_J \ | 
patients, ^ Р Ц are MELAS patients and, 
symbols are the percentages mutated mtDNA 
available from the family member II-1 
are asymptomatic persons 
i ts, В a r e  ti t  and, Ç^)'V_\ bave died. The percentages mentioned below the 
к m blood о 
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are oligosymptomatic 
i  l  t  
or muscle. Tissue for DNA analysis was not 
Table I: CLINICAL CHARACTERISTICS OF THE FAMILY MEMBERS 
Ш-4 III-6 II-2 III-l 1-2 II-I ΠΙ-2 Ш-3 Ш-5 
Phenotype 
Onset of disease (yrs) 
Age of death (yrs) 
Sex 
MELAS 
5 
16 
M 
CLINICAL SYMPTOMS OF MELAS: 
stroke-like episodes 
episodic headache 
vomiting 
unconsciousness 
convulsions 
cerebral blindness 
transient hemiplegia 
hemianopsia 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
ADDITIONAL SYMPTOMS 
muscle weakness 
myoclonus 
ataxia 
easy fatigability 
mental retardation 
polyneuropathy 
short stature 
ptosis 
retinitis pigmentosa 
optic atrophy 
hearing loss 
cardiomyopathy 
diabetes mellitus 
+ + 
+ 
+ 
+ + + 
+ + 
+ 
-
+ 
+ 
+ 
+ + 
-
. 
5 
5 
F 
-
+ 
+ 
+ 
+ 
-
-
-
+ + 
-
-
-
-
-
-
-
-
-
-
-
. 
oligosypti 
41 
59 
F 
-
-
-
-
-
-
-
-
+ 
-
+ 
+ + 
+ + 
+ 
+ 
-
+ 
-
+ + 
+ + 
+ 
omatic 
8 
16 
F 
-
-
-
-
-
-
-
-
+ + + 
-
-
+ + + 
-
-
+ 
-
+ 
+ 
+ + 
+ 
_ 
40 
61 
F 
-
-
-
-
-
-
-
-
? 
-
-
7 
-
7 
+ 
-
7 
? 
+ 
7 
+ 
asymptomatic 
30 
7 
+ + 
9 
30 
M 
19 
Legend to table I: The pedigree numbers refer to figure I. F = female, M = male, ? = not known, - = absence of 
symptom, + = presence of symptom, + + = more severe symptoms, + + + = most severe symptoms 
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Table II: CHEMICAL, NEUROPHYSIOLOGICAL, RADIOLOGICAL AND PATHOLOGICAL STUDIES 
ON NERVE AND MUSCLE. 
Phenotype 
LABORATORY DATA: 
High lactate level 
in blood 
at rest 
after exercise 
High lactate level 
in CSF 
CSF protein increased 
CT: 
low density areas 
cortical atrophy 
calcifications in 
basal ganglia 
MRI 
MRS: high lactate in brain 
HI-4 
MELAS 
+ 
+ + 
+ + 
+ 
ND 
ND 
ND 
ND 
ND 
III-6 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
H-2 III-l 
oligosymptomatic 
N 
+ 
+ + 
+ 
N 
+ 
+ 
ND 
ND 
+ 
+ + 
+ + 
+ 
ND 
ND 
ND 
ND 
ND 
III-2 
N 
N 
N 
N 
ND 
ND 
ND 
N 
N 
ΠΙ-3 
N 
N 
N 
N 
ND 
ND 
ND 
N 
N 
III-5 
asymptomatic 
N 
N 
N 
N 
ND 
ND 
ND 
N 
N 
MUSCLE EXAMINATION: 
Light microscopy: 
RRF 
SDH-reactive 
blood vessels 
variation in fiber 
size 
fiber type atrophy 
increased lipid 
droplets 
EEG 
EMG 
Nerve conduction velocities 
decreased 
+ + 
N 
+ 
+ 
N 
+ 
+ 
+ 
ND 
ND 
ND 
ND 
ND 
+ 
ND 
ND 
+ 
N 
+ + 
+ 
N 
+ 
+ 
+ 
+ + + 
N 
+ + 
+ 
+ 
N 
+ 
N 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
Legend to table II: The pedigree nummers refer to figure I. CSF = cerebrospinal fluid, CT = computerized 
tomography, MRI = magnetic resonance imaging, MRS = magnetic resonance spectroscopy, RRF = ragged red 
fibers, SDH = succinate dehydrogenase, EEG = electroencephalogram, EMG = electromyogram, ND = not done, 
N = normal, + = presence of symptom, + + = more severe, + + + = most severe symptoms. 
60 
METHODS 
Measurement of the mitochondrial enzyme activities 
Muscle tissue of the patients ΠΙ-1 and ΠΙ-4 was studied in 1975 and 1983 (13,14). The 
tissue was obtained by a surgical biopsy of the quadriceps muscle in both patients. 
Biochemical studies on isolated muscle mitochondria and on muscle homogenates were 
restricted to cytochrome oxidase and performed as described for patient Ш-4 by Prick et 
al. (13; case 2). 
In patient II-2 surgical quadriceps muscle biopsy was performed in 1991. Substrate 
oxidation and ATP production rate studies were performed in 600 g supernatant of the 
fresh muscle. These studies, and the measurement of the activities of citrate synthase, 
cytochrome с oxidase, and succinate: cytochrome с oxidoreductase, and of the 
concentrations of carnitine and protein were performed as previously described (15). 
Isolation of genomic DNA 
Blood DNA was prepared according to standard procedures (16). Total DNA was 
extracted from muscle as described by De Vries et al (17) except that the DNA was 
concentrated by ethanol precipitation. 
Polymerase chain reaction 
The polymerase chain reaction (PCR) to detect the A3243G mutation in the mtDNA was 
performed according to Goto et al. (7). The restriction enzyme Apal was used to cleave 
mutant but not wild type mtDNA. When the heteroplasmic A-*G mutation on bp 3243 is 
present the 162 bp PCR fragment is cut into a 104 bp fragment and a smaller, 
undetectable, 58 bp fragment. To increase the sensitivity for this mutation, the PCR was 
performed with HP-labeled primer B, as described (18). The products were separated on 
a 6 % polyacryamide gel with 10 % glycerol. The percentage mutated mtDNA was 
estimated using autoradiography as the ratio of the amount of digested PCR product 
versus the amount of undigested product on the Polyacrylamide gel. The proportion of 
mutant mtDNA obtained by the method described above compared favourably to the 
proportion derived under conditions when only during the last extension reaction the 
radiolabelled reverse primer was present (19). 
RESULTS 
Clinical characteristics and muscle and nerve pathology 
MELAS syndrome was diagnosed in the patients ГП-4 and III-6 (Fig. I and Table I). 
Also, the patients II-2 and III-l presented with severe multi-systemic disease manifestati­
ons (Fig. 1 and Table I). Patient III-l and III-4 showed elevated lactate levels in blood at 
rest (Table II). After exercise, the patients II-2, III-l and III-4 showed abnormally high 
lactate levels in blood and cerebrospinal fluid (CSF) (Table II). Patients 11-2, III-l and 
III-4 showed ragged red fibers in muscle (Table П). Moreover, they all showed neuronal 
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loss in the cerebellum, in III-4 associated with gliosis, and patients II-2 and III-4 showed 
neuronal loss in the cortex also, again in III-4 associated with gliosis (Table II). 
The patient 1-2, II-l, III-2 and ΙΠ-3 showed one or more of the following features: 
deafness, retinitis pigmentosa, short stature and diabetes (Fig. I and Table I). In the 
oligosymtomatic family members ΠΙ-2, III-3 and in the asymtomatologic sib ΙΠ-5 lactate 
levels in blood and CSF as well as in cerebellum, striatum and cortex were normal (Table 
II). 
Mitochondrial enzyme activities 
Biochemical studies on muscle tissue from patients II-l and III-4 revealed a severely 
decreased cytochrome с oxidase activity (10% residual activity) (13,14). In patient II-2 no 
specific defect of the respiratory chain enzymes was found. Enzyme histochemical 
examination was performed only on the quadriceps muscle from patient II-2 and revealed 
a moderately decreased cytochrome с oxidase staining. 
Mitochondrial DNA 
PCR and restriction enzyme analysis of the mtDNA to detect the A3243G mutation is 
shown in Fig.2. The percentages mutated mtDNA in blood and muscle for the family 
members analysed are given in Fig.l. Patient II-2 had 60 % mutated mtDNA in skeletal 
muscle. Her children, III-2, Ш-3 and III-5 had 10, 25 and 15% mutated mtDNA in 
blood, respectively. 
in 
162 bp 
<«104bp 
1 
Fig.2 Autoradiogram of Apal digested 32P-labeled PCR fragments of different members of the pedigree 
separated on a Polyacrylamide gel. The tissues studied were muscle from patient 11-2 (lane 2) and blood 
from the family members III -2 (lane 3), III-3 (lane 4) and 111-5 (lane S). Lane 1 represents the undigested 
PCR product. 
The patients were also screened for other mutations in the mtDNA. Restriction enzyme 
analysis and Southern blotting of mtDNA from blood and fibroblasts did not reveal any 
deletions or rearrangements. Moreover, the diagnostic tests described for the bp 3271 and 
the bp 4317 mtDNA mutation, also found in patients with MELAS (9,10), the bp 8344 
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mtDNA mutation found in patients with MERRF (20), and the bp 8356 mtDNA mutation 
found in patients with MERRF-MELAS overlap syndrome did not reveal a mutation 
(11,12). 
COMMENT 
In this family the presence of a mitochondrial encephalomyopathy with maternal inheri­
tance could be established in 3 generations. The clinical expression of the disease in the 
present family varied. Patient III-4 suffered from MELAS syndrome. Patient III-6 did 
show episodic headache with vomiting, unconsciousness, convulsions and muscle 
weakness and died suddenly at the age of 5 years. Despite the limited clinical data on 
patient ΓΠ-6, we assume that she also suffered from MELAS syndrome. Patient Ш-1 
suffered from muscle weakness, easy fatigability, cardiomyopathy, optic atrophy, hearing 
loss, retinitis pigmentosa, and short stature. Patient 11-2 suffered also from these symtoms 
(except optic atrophy) besides mental retardation, ataxia, polyneuropathy and diabetes 
mellitus. Three other family members were suffering from less severe clinical symptoms. 
As such, patient Ш-2 suffered from hearing loss, patient Ш-3 suffered from hearing loss 
and retinitis pigmentosa and patient 1-2 and II-1 presented with hearing loss, short stature 
and diabetes mellitus. Patient III-5 was asymptomatic up to now (32 years of age). 
Although circumstantial evidence in 1983 demonstrated that patient III-4 suffered from 
Alpers' disease, reinvestigation of the clinical features in this patient, including the 
absence of hepatic disease, and the maternal inheritance of the disease manifestations in 
this family, clearly revealed that he suffered from MELAS syndrome 
(2,3,5,7,13,21,22,23,24). In 1983 the definite diagnosis of Alpers' disease in patient III-4 
was made by studying the neuropathology of the brain (13). However, the neuropathology 
of the brain of patient III-4, with laminar necrosis of the cortex, previously associated 
with Alpers' disease, is also observed in MELAS-syndrome (2,3,13,21,22,23,24,25). 
According to Harding et al. Alpers' disease is a restricted entity, the exact etiology of 
Alpers' disease remaining unsolved (23,24). 
The polymerase chain reaction and restriction enzyme analysis of the mtDNA revealed the 
A3243G mutation in the tRNAtaKUUR) in the mtDNA from patient II-2, III-2, III-3 and ΠΙ-
5. Unfortunately no tissue was available of the deceased MELAS patients III-4 and III-6. 
But since the A3243G mutation in the mtDNA is often associated with the MELAS 
syndrome and both MELAS patients have inherited their mtDNA from their mother (II-
2), it is very likely that the A3243G mutation was present in various tissues in patient III-
4 and ΙΠ-6. Since all the clinical symptoms in this family are transmitted in the maternal 
line, we concluded that the variable clinical manifestations in this family are the result of 
variable intrafamilial phenotypic expression of the MELAS syndrome, associated with the 
presence of the A3243G tRNA^^""1 0 mutation in the mtDNA. A comparable intrafa­
milial clinical variation was described recently in other MELAS pedigrees (4,26-28). 
The proportion of mutated mtDNA in blood in the family members III-2, III-3 and III-5 
are in agreement with recent studies by Remes et al., who showed that low proportions of 
the A3243G mutation are associated with oligosymptomatic disease manifestations, like 
diabetes and hearing loss (28). Probably, similar to findings in other MELAS pedigrees, 
the percentage of mutation in muscle in these patients will be substantially higher than in 
blood (4,29,30). In their mother, patient II-2, with 60% mutated mtDNA in muscle at age 
59, the onset of disease was at age 41. It is possible that the late presentation of clinical 
symptoms in this patient was the result of an age related decline in oxidative 
phosphorylation (31). Miyabayashi and coworkers also suggested that exceeding the 
63 
quantitative threshold of about 60% mutated genome in muscle causes mitochondrial 
enzyme deficiencies giving rise to the MELAS syndrome (32). In this respect, it is 
interesting that in muscle from patient II-2, who suffered from severe clinical 
manifestations associated with an amount of 60% of the A3243G mutation in muscle, no 
biochemical oxidation defect was measured. However, on enzyme histochemical staining 
of the muscle biopsy, a moderately decreased cytochrome с oxidase activity could be 
discerned. 
Muscle biopsies from the patients П-2, Ш-1 and ΠΙ-4 showed RRF, which in association 
with increased blood and CSF lactate levels, are similar to the findings in the patients 
described by Remes et al. (28). Whereas, in the less affected oligosymptomatic patients 
(III-2 and III-3) like in the oligosymptomatic patients studied by Remes et al., and in the 
asymptomatic sib III-S, normal lactate levels are measured in blood and CSF (28). 
Moreover, in the latter three sibs MRS in cerebellum, striatum and cortex revealed no 
increased lactate levels. 
This study confirms the clinical variability of familial MELAS syndrome associated with 
the A3243G tRNALEU(UUR) mutation. Moreover, the presence of the A3243G tRNALEU(UUR) 
mutation has been identified in families with progressive ophthalmoplegia (PEO), with 
PEO and additional symptoms and in families with diabetes mellitus and hearing loss 
(4,33,34). We may conclude that screening of the A3243G mutation has diagnostic value 
in patients that suffer from varying symptoms and signs of mitochondrial (encephalomyo­
pathies either with or without having reached a phenotype of a distinct syndromal entity. 
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CHAPTER IV 
Point mutations in protein coding regions of the mitochondrial 
DNA 

A Second Missense 
Mutation in the 
Mitochondrial ATPase 6 
Gene in Leigh's Syndrome 
D Danielle de Vries. MSc.' 
Ba2iel G M van Lngelen, MD.t 
Fons J M Gabreels, MD, PhD.t Wim Ruitenbeek. PhD,* 
and Bernard A van Oost, PhD* 
By direct sequencing, we have discovered a novel het-
eroplasmic mutation (T—»Q at nucleotide position 899} 
in the mitochondrial ATPase 6 gene in a family with 
Leigh's syndrome Another mutation in the same codon 
(T8993G) has been reported before in Leigh's syndrome 
As these two mutations led to different amino acid sub­
stitutions, it provides strong evidence for the relevance 
of ATP synthase dysfunction in maternally inherited 
Leigh's syndrome. 
de Vries DD, van Engelen BGM, Gabreels FJM, 
Ruitenbeek W, van Oost BA A second missense 
mutation in the mitochondrial ATPase 6 gene in 
Leigh's syndrome Ann Neurol 1993,3-ί Ί 10-412 
Subacute necrotizing encephalomyelopathy or Leigh's 
syndrome is a progressive degenerative disorder of the 
central nervous system Definite diagnosis of Leigh's 
syndrome has to be based on well-characterized neuro-
parhological changes by postmortem examination or 
magnetic resonance (MR) imaging [ 1 , 2 ] The onset of 
Leigh's syndrome is usually in early infancy or child­
hood, but clinical signs and symptoms and course of 
the disease show a considerable variability [ 1 , 2 ] The 
clinical features are often accompanied by mitochon­
drial oxidation defects [2] 
Previously, we have described 4 siblings of one fam-
il> with the autosomal recessive juvenile type of Leigh's 
syndrome, confirmed by postmortem examination [3] 
Recently, however, the mother also showed symptoms 
of the same disorder Therefore, the inheritance of a 
mitochondrial defect in this family was reconsidered 
In this study we demonstrate by direct sequencing a 
hitherto undesenbed mitochondrial T—»C mutation on 
nucleotide position (np) 8993 in the ATPase 6 gene 
in Leigh's syndrome 
Trom the Departments of 'Human Genetiis. ^Neurologi, and +Pe 
diatncs. University Hospital. Niimcftcn The Netherlands 
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шгу Department of Human Genetics. Universi!* Hospital Nij­
megen, PO Dox 9101. 6500 HD Niimegen The Netherlands 
Laboratory Methods 
DNA Preparation. Amplification, and 
Sequencing of the ATPase 6 Gene 
Blood and muscle DNA was prepared according to standard 
procedures Oligonucleotides (Pharmacia lnc, Woerden, The 
Netherlands) used for priming the polymerase chain reaction 
(PCR) and sequencing were as follows (A) np 8577-859" 
(sense) ACC CGC CGC AGT ACT GAT CAT, (В) np 
9190-9210 (antisense) TCA TTA TGT GTT GTC GTG 
CAG. (C) np 8922-8943 (sense) CAC ACC TAC ACC 
CCT TAT CCC The mtDNA nucleotide numbering is ac­
cording to Anderson and colleagues [4] 
Total DNA (0 1-1 μg) from blood cells was submitted tc 
PCR amplification with oligonucleotide primers A and В as 
described previously [5] The cycle conditions were as fol­
lows denaturation 60 seconds at 90°C, annealing 90 seconds 
at 50°C, primer extension 90 seconds at 72QC Purification 
of the PCR product was performed as described by van de 
Ouweland and associates [6] Cycle sequencing of both 
strands of the PCR product with primers В and C, respec­
tively, was performed with the Taq dyedeoxy terminator cy­
cle sequencing kit (Applied Biosystems, Maatsscn. The 
Netherlands) according to the manufacturer's instructions 
and loaded onto the Applied Biosystems 373A DNA se­
quencer 
Restriction Endonuclease Analysis 
From blood and muscle tissue from the family members af­
fected with Leigh s syndrome and 100 control subiccts, frag­
ments of 634 nucleotides encompassing the mutation site 
were amplified by PCR with primer A and f-^P-labeled 
primer В as described above The products were separated 
on a (s'/r polyacrylamide/hisacrylamide gel »ith 10rr glyc­
erol The percentage ofmutatcd mtDNA was estimated trom 
the autoradiograph at various exposure times as the ratio of 
the amount of digested PCR product versus the amount of 
undigested product on the Polyacrylamide gel 
Results 
Reimestigation of the Family uith Leigh s Syndrome 
The updated pedigree and a summary of the clinical 
and MR imaging hndings of the previously described 
family [3] are shown in the Figure (A) and the Table, 
respectively Patients II— 1 » II-2, 11-3. and II-4 were se­
verely affected and Patient II-1 died at 17 years of age 
Recently, the mother complained of weakness in her 
left leg, easy fatigability, and sensory disturbances in 
her feet Neurological examination revealed slight sen­
sory disturbances and pyramidal signs in both legs An­
cillary investigations were compatible with the diagno­
sis of Leigh's syndrome (see Table) 
Mitochondrial DNA Analysts 
The ATPase ó gene of the mtDNA from blood from 
Patients 1-1, 11-2, 11-3. and IM was sequenced A nu-
cleotide substitution (T—»O occurring at np 8993 in 
comparison with the reference sequence [-Í] was de-
tected The T—»C substitution on base pair (bp) 8993 
in the ATPase 6 gene generates an Hpall site (CTGG 
—» CCGG) When the heteroplasmic T—»C mutation 
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1 2 3 4 5 6 7 8 9 
Pedigree of the family и ith Leigh's syndrome and autoradio-
graph ofHpall digested '-P-labeled polymerase chain reaction 
samples separated on a Polyacrylamide gel. (Al D is a male and 
О is a female person: • and · are affected persons: 0 has 
died. <Bi As only the reverse primer uas labeled, only the 218-
bp Hpa// fragment is ι isible after autoradiography. The tissues 
studied nere blood from Patients 1-1 ilane 2l. 11-2 (lane 3l. 
Π-3 ilane 4l. and 11-4 (lane 5). muscle from Patient 11-2 ilane 
Gi. and blood from controls (lanes 1 and 7—9l. 
on bp 8993 is present, the 634-bp PCR fragment is 
cut into a 218-bp fragment and a 416-bp fragment. In a 
muscle specimen from Patient 11-2 almost all m t D N A 
could be cleaved by Hpall, in contrast to the controls 
(Fig B, lane 6 and lanes 1, 7, 8, and 9, respectively). 
Heteroplasmy for the mutation could be clearly ob­
served in the blood sample of Patient 11-2, as well as 
in the blood samples of his sisters and mother (Fig B, 
lanes 3, 4, 5, and 2, respectively). In all 3 children, and 
to a lesser extent in the mother, the mutated m t D N A 
was the main species. 
m t D N A from blood from 100 controls was homo-
plasmic for the wild-type sequence. Screening for gross 
rearrangements and the point mutations in tRNA' 1 " 
(3243) and t R N A l l s (8344) was negative in this family. 
Discussion 
In the family presented here a heteroplasmic T8893C 
point mutation was found in the ATPase 6 gene. The 
nucleotide substitution causes a proline for leucine re­
placement in a spatially strongly conserved helical do­
main of one of the subunits of the proton channel of 
the ATP synthetase complex. That this mutation most 
likely does not represent a neutral polymorphism is 
also supported by our observation that the mutation 
was not present in 100 controls tested. 
The mutation described in this report is distinct 
from the T8993G mutation discovered by Holt and 
colleagues [7] and Tatuch and co-workers [8]. The 
T8993G mutation generates an ЛглІ restriction site 
Summary of Clinical. Cerebrospinal Fluid fCSFi. and Magneln Résonante (MR ι Imaging Findings in Familial Leigh's Syndrome 
Age of 
Patient Onset CSF 
N o ' (yr) Lactate 
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II ι 
II ι 
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Ì 
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ecognition sequence. C(T/OCG(A/G)G] reponed 
ι 5 more Leigh's syndrome patients in conference ab-
racts [9, 10] The T8993C point mutation described 
ere does not generate an Atal site but does so for 
\pa\\ Recently, Sakuta and associates [11] described 
ie use of Hpail in the screening of 23 Japanese 
eigh's syndrome patients for mutations in the ATPase 
gene. In 1 patient the Hpail restriction site was 
jund However, it remains to be determined which 
oinc mutation was actually involved. 
The F„F,-ATPase enzyme complex catalyzes the ter-
unal step in oxidative phosphorylation and is located 
ι the inner mitochondrial membrane [12] The struc-
jre is highly conserved and the complex can be readily 
issociated into two fractions, the water soluble F,-
iTPase and the membrane-bound F„ portion, which 
jrms a proton pore In Eschernhm coll mutations in 
ie genes encoding the subunits of the F0 portion have 
esulted in the identification of key amino acids in the 
о subunits a and с with respect to proton translocation 
13] The mutations in the a subunit, which is homolo-
ous to the ATPase 6 gene, are within a region of 
trong evolutionary and spatial conservation and are 
jcated on both sides of the leucine residue mutated 
ι Leigh's syndrome It is conceivable that a change of 
tie helical configuration of the ATPase 6 subunit by 
he replacement of leucine for proline could hamper 
he function of the F
u
 subunits to act as a direct path­
way for proton conduction [14] However, even with 
he very high proportion of mutated mtDNA in this 
araily, no failure in ATP production was found [3] 
'his was also observed by Tatuch and colleagues [8] 
и the Leigh's syndrome patient with the also nearly 
lomoplasuc arginine for leucine substitution in the 
ATPase 6 gene 
As the proportion of mutated mtDNA in the blood 
pecimens was quite high for all the family members, 
ι is difficult to infer any relation with the severcness 
nd age of onset of Leigh's syndrome in this family. 
:
urther studies on the segregation and (tissue-specific) 
xpression of mtDNA mutations in mtDNA as well 
5 generation of these mutations in E coli and possibly 
ugher organisms are needed to resolve these issues. 
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SUMMARY 
In a large Dutch family a rare form of Leber hereditary optic neuropathy associated 
with hereditary spastic dystonia has been reported. Neurological and ophthalmological 
lesions were both present in some family members, whereas only one type of 
abnormality was found in others. Sequence analysis of the mitochondrial genes 
encoding subunits of respiratory chain complex I (NADH-dehydrogenase) and complex 
III revealed two hitherto unknown mitochondrial DNA mutations. A heteroplasmic A to 
G transition at nucleotide position 11696 in the ND4 gene results in the substitution of 
an isoleucine for a valine at amino acid residue 312. A second mutation, a 
homoplasmic Τ to A transition at nucleotide position 14S96 in the ND6 gene, results in 
the substitution of a methionine for an isoleucine at amino acid residue 26. The family 
does not cany any of fifteen mitochondrial DNA mutations previously identified in 
LHON patients. A novel analytical approach has been applied to quantitate the degree 
of heteroplasmy of the mutations, as well as to assess the frequency of the nucleotide 
substitutions in a large population of controls. 
INTRODUCTION 
Leber hereditary optic neuropathy (LHON) is a maternally inherited form of acute or 
subacute adult-onset blindness, with a mean age of onset of 27 years, with a wide 
range from 6-60 years (Wallace 1992). Central vision is lost rapidly in both eyes but 
peripheral vision is usually retained (McKusick 1988). Complete blindness rarely 
results. There is a substantial sex bias, with around 85% of affected persons being 
males, although in Japan only 60% of 911 patients are males (Imachi 1969). As a 
general rule, the loss of vision is permanent, although improvement in some affected 
individuals has been reported (Mackey and Howell 1992, Johns et al. 1993). 
A large Dutch family in which a hereditary spastic dystonia and LHON manifested 
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either separately or in combination among 24 individuals of a kindred of 549 members 
over 7 generations has been described previously (Bruyn and Went 1964, Went 
1964a,b, Bruyn et al. 1991, Bruyn et al. 1992). Prominent features of the disease are 
visual loss, spasticity, rigidity, bradykinesia, dystonia, athetoid dyskinesias, and 
occasional amyotrophy. Neuropathological findings obtained in one patient of this 
family revealed that the pathogenic lesions were limited to certain neuronal populations 
with high energy turnover (Bruyn et al. 1992). The affected individuals did neither 
show cardiac conduction abnormalities nor behavioral abnormalities. Some other 
pedigrees with a possibly comparable 'dystonia-Leber syndrome" have been reported so 
far (Marsden et al. 1986, Novotny et al 1986, Larsson et al 1991). 
A number of mitochondrial DNA (mtDNA) mutations are associated with LHON. 
Approximately 40-60% of LHON cases are associated with the G11778A mutation 
(Wallace et al. 1988), and approximately 20% are associated with the G3460A 
mutation (Howell et al. 1991b, Huoponen et al. 1991). Moreover, mutations at position 
4160 , and at position 15257, as well as several synergistic mutations, are found in 
most of the remaining cases (Shoffner and Wallace 1992, Wallace 1992). 
It was found in previous studies that the 11778 and the 13708 mutations were not 
present in this LHON family (Bruyn et al. 1992). We have made the choice to 
sequence in detail those mtDNA regions in which 12 of the 15 mutations associated 
with Leber's disease have been found. The sequece analysis of the complex I and III 
genes revealed two novel mtDNA mutations: A11696G and T14596A. Whether 
heteroplasmy is involved could not be assessed by restriction enzyme analysis, since 
the mutations do not alter restriction enzyme recognition sites. Therefore, we 
developed a single nucleotide primer extension technique using dyedeoxy terminators to 
determine the degree of heteroplasmy and to assess the frequency of the nucleotide 
substitutions in a large population of controls. 
PATIENTS AND METHODS 
Clinical status of family members 
The pedigree of the large Dutch LHON family described by Went (1964b) is presented 
in part in Fig.l. The family has been extensively described in several studies (Bruyn 
and Went 1964, Went 1964a, b, Bruyn et al 1992). Optic atrophy was present in 
patient V-21, V-22, VI-12, VI-31, VI-32, VI-33, VI-55, VII-26; neurological 
abnormalities were found in V-22, VI-2, VI-12, VI-32, VI-33, VI-55, VII-54. In 
patients VI-2 and VI-33 the neurological abnormalities are unilateral. 
The optic atrophy was to all extents and purposes typical for LHON: acute bilateral 
visual loss with pale optic discs notably on the temporal side and variable centrocecal 
scotomata; average age at onset of visual loss is 22 years (range 8-36). Only in four 
individuals with a relatively recent onset of the optic atrophy fluorescence angiography 
was performed directly after the onset of the visual loss and revealed more or less 
marked turtuosity of peripapillary vessels. No cardiological abnormalities were found 
or documented. 
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Fig. 1 Part of the pedigree of the LHON-dystonia family (Bruyn and Went, Went 1964a, 1964b). The 
pedigree numbers are identical to those presented in the complete pedigree by Went (1964b) and Bruyn 
et al. (1992), with the exception of VII-54»who was VII-18 in the original publication by Went (1964b). 
The symbols used indicate: J M male, female, P J unilateral neurological symptoms, | 
bilateral neurological symptoms, I LHON, ^ | LHON + unilateral neurological symptoms, 
| LHON + bilateral neurologicaTsymptoms. 
The percentages below the symbols are the percentages wild-type ND4/A11696G in blood. - not 
determined. 
DNA methods 
Isolation of genomic DNA. 
Blood DNA from the family members V-21, V-22, VI-2, VI-5, VI-12, VI-30, VI-31, 
VI-33, VI-55, VI-57, VII-26, VII-54, VII-55 and fibroblast DNA from patient VI-32 
was prepared according to standard procedures (Miller et al. 1988). Total DNA was 
extracted from five different parts of the brain from patient VI-32 as described for 
muscle tissue by De Vries et al. (1992), with the modification that DNA was 
concentrated by ethanol precipitation. 
Polymerase chain reaction and mtDNA sequence analysis. 
The total region of the Complex I and III genes has been sequenced as described 
previously (De Vries et al. 1993). In brief, synthetic oligonucleotide primers were used 
to PCR-amplify fragments of the mitochondrial genome spanning the seven Complex I 
genes and the Complex III gene. The nucleotide sequences from both strands were 
analysed by the fluorescent dyedeoxy chain-termination method on an Automated DNA 
Sequencer (Applied Biosystems and Perkin Elmer). 
The ND4 gene containing the A11696G mutation was amplified by PCR with primers 
positioned at nucleotide position (np) 11489-11509 and 11750-11770 (nucleotide 
numbering according to Anderson et al. 1981). The ND6 gene containing the T14596A 
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mutation was amplified with the primers positioned at np 14108-14128 and 14652-
14673. 
Single nucleotide primer extension. 
The detection primer for the single nucleotide extension reaction of the ND4/A11696G 
mutation was forward primer A complementary to np 11676-11695, immediately 
adjacent to the mutation. The detection primer for the single nucleotide extension 
reaction of the ND6/T14596A mutation was forward primer В complementary to np 
14574-14595. For each subject, the DNA fragment containing the mutation site was 
amplified by the PCR as described above. Purification of the template PCR fragments 
was performed as described (De Vries et al. 1993). In the primer extension reaction, 
0.1-1/ig template DNA and 25 ng detection primer in a total volume of 10.5 μί, 
overlaid with mineral oil, were denatured (96°C for 2 min) in the Perkin-Elmer Cetus 
thermal cycler. Subsequently, after cooling the samples to 60CC, they were combined 
with a premix of 1 μί of each of the DyeDeoxy Terminators and 4 μΐ 5 χ TACS buffer 
(Perkin Elmer / Applied Biosystems) and 0.5 μί AmpliTaqTJNA polymerase (Cetus, 
Perkin Elmer / Applied Biosystems). Deionized water was added to a final volume of 
9.5 μί. For primer A we modified the premix for the extension reaction with 0.5 μί 
dyedGTP, 2 mM ddGTP and 1 μί dyedATP, instead of 1 μ\ of each of the dyedNTPs. 
The samples were cycled in a thermal cycler as follows: 96°C for 30 sec; 50eC for 15 
sec and 60°C for 15 sec; 25-35 cycles. Excess dye terminators were removed by 
phenol/chloroform extraction and the DNA was precipitated as described in the 
protocol for the TAQ DyeDeoxy™ Terminator Cycle Sequencing Kit (Perkin Elmer / 
Applied Biosystems). The pellets were dissolved in 3 μί 50 mM EDTA/formamide 
(l/5,v/v) and denatured for 2 min at 90°C and run on a 20% polyacrylamide/bisacryla-
midegel with 7M urea for 9 hours. The electrophoretic runs were analysed on an 
automated 370A DNA sequencer with the use of the Genescan 672 software (Perkin 
Elmer / Applied Biosystems). The migration pattern of the four different 
dyedeoxynucleotides on the 20% Polyacrylamide gel was corrected for using Taq 
dyedeoxy™ terminator matrix standards (Perkin Elmer / Applied Biosystems). 
Quantification of degree of heteroplasmy 
Quantification of the degree of heteroplasmy of the ND4 mutation A11696G in tissues 
was accomplished by constructing a standard curve of known amounts of wild-type and 
mutated ND4 template. The heteroplasmic ND4 PCR product from one of the family 
members was cloned with the pCR-Script™ SK(+) cloning kit (Statagene, Westburg). 
Isolation of plasmid DNA was performed by the midi plasmid isolation kit according to 
the manufacturer's recommendations (Qiagen, Westburg). The plasmids were checked 
for the presence of either wild type or mutant ND4 fragments by direct primer 
extension with primer A, as described above. A standard curve was constructed of 
known amounts of wild-type and mutated mtDNA. The ratios of the signal intensities 
were calcutated from the peak-areas of the elution profiles of mutant and wild-type 
reactions of the titrated plasmid mixtures on the automated 370A sequencer with the 
use of the Genescan 672 software. 
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RESULTS 
Sequence analysis of the complex I and III genes 
The DNA sequence of the seven mitochondrial Complex I genes and the Complex III 
gene from family member VI-12 was analysed. Compared with the Cambridge 
sequence (Anderson et al. 1981), a total of 8 nucleotide changes were found. Four of 
the nucleotide substitutions result in silent polymorphisms (in ND2: A4769G, G4985A, 
G5228G and in ND4: T11335C). Two others result in amino acid changes, which 
previously have been reported as normal variants (in ND5: G13702C resulting in the 
substitution of an arginine for a glycine and in ND6: G14199T resulting in the 
substitution of a threonine for a proline) (Wallace et al 1991a, Marzuki et al 1991). 
The remaining two were hitherto unknown nucleotide alterations which alter the 
corresponding amino acid sequence. Blood DNA from the other family members, 
fibroblast DNA from patient VI-32 and DNA from five different parts of the brain 
from this same patient were analysed for both new nucleotide alterations by sequencing 
the relevant DNA regions involved. In the ND4 gene at np 11696 of the coding strand, 
an A to G transition which resulted in substitution of an isoleucine for valine at amino 
acid position 312 was found in blood from all family members and in addition in the 
fibroblasts and brain specimen from patient VI-32. The second mutation, in the ND6 
gene at np 14596, was a Τ to A transition which resulted in the substitution of 
methionine for isoleucine at amino acid residue 26. Also this mutation was found in all 
family members analysed. Neither of these mutations were reported before in patients 
with mitochondrial or neurological diseases, including LHON. 
Patient VI-12 was also screened for other mutations in his mtDNA. Restriction enzyme 
analysis and Southern blotting of mtDNA from blood did not reveal any deletions or 
rearrangements. However, no muscle tissue was available from any of the patients for 
mtDNA deletion detection. The primary mtDNA mutations described in association 
with LHON at np 3460 (Huoponen et al. 1991, Howell et al. 1991b), 4136 and 4160 
(Howell 1991a), 11778 (Wallace et al. 1988), 14484 (Johns et al. 1992, Johns and 
Neufeld 1993a) and 15257 (Johns and Neufeld 1991, Brown et al 1992b, 1992c) and 
those who play a secondary role in LHON at np 3394 (Johns et al 1992), 4216 (Johns 
and Berman 1991), 4917 (Johns and Berman 1991), 5244 (Wallace et al. 1991, Brown 
et al. 1992c), 13708 (Johns and Neufeld 1991, Brown et al. 1992b), and 15812 (Johns 
and Neufeld 1991, Brown et al. 1992b) were all tested by either restriction enzyme 
analysis or sequence analysis and turned out to be absent. Moreover, the mutations 
described at np 7444 (Brown et al. 1992a), 9438 and 9804 (Johns and Neufeld 1993b) 
were absent. The diagnostic tests described for the np 3243 (Goto et al. 1990) and np 
4317 (Tanaka et al. 1990) mtDNA mutations found in patients with mitochondrial 
encephalomyopathy, lactic ácidos and stroke-like episodes (MELAS), the np 8344 
(Zeviani et al. 1991) mtDNA mutation found in patients with myoclonus epilepsy and 
ragged red fibers (MERRF), and the np 8356 (Silvestri et al. 1992) mtDNA mutation 
found in the MERRF-MELAS syndrome with hyperthyroidy, were also negative in 
patient VI-12. 
Mutation detection using dyedeoxy terminators 
To discriminate between the mutant and wild type sequences we modified the single 
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nucleotide primer extension technique described by Kuppuswamy et al. (1991) using 
DyeDeoxy™ Terminators. With this method we were able to evaluate not only the 
presence, but also the degree of heteroplasmy of mutations. In this method the base 
located immediately adjacent to the 3' end of the template-bound primer is the one 
altered in the mutant. Analysis of the detection primer for incorporation of fluorescent 
nucleotide on a denaturing 20% gel revealed that the ND4/A11696G substitution was 
present in all family members tested. However, in some family members the 
incorporation of dyedATP was also observed, indicating heteroplasmy. The primer 
extension applied to the ND6/T14596A mutation showed no evidence of heteroplasmy, 
since only the incorporation of dyedATP was observed in all family members tested. In 
100 control subjects, in 10 non-related Dutch LHON families and in 10 complex I 
deficient patients with a mitochondrial myopathy only the wild-type nucleotide was 
incorporated for both primers. 
Estimation of the amount of heteroplasmy of the A11696G point 
mutation 
To determine the level of heteroplasmy of the ND4/A11696G mutation a standard 
curve was constructed with different mixtures of wild-type A1,6% and mutant G1169* 
Plasmids. After analysis by the genescan software on the automated sequencer, the 
obtained ratios of the signal intensities for the wild-type : wild type + mutant were 
plotted as a function of the percentage wild-type sequences in the mixture. The ratios 
were reproduced in several subsequent primer extension reactions. 
The degree of heteroplasmy for the ND4/A11696G mutation in blood from the family 
members is presented in Figure 1. Figure 2 represents the degree of heteroplasmy 
occurring in blood for the various phenotypes of the family members. The amount of 
wild type mtDNA in optic nerve from patient VI-32 was 12 %. 
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Fig. 2 Degree of heteroplasmy for the ND4/A11696G mutation occurring in blood from the various 
phenotypes of the family members. The symbols used are explained in the legend of Figure 1. 
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DISCUSSION 
Hereditary spastic dystonia with LHON is a rare disease. In some members of the 
family presented here the neurological or ophthalmological lesions occur separately, in 
others they occur both. As in LHON, also in our family the neurological abnormalities 
and ophthalmological abnormalities occurred more frequently in males than in females 
(Bruyn and Went 1964). Although there are other LHON families with neurological 
abnormalities (Palan et al. 1989, Howell et al. 1991a), the prominent features of the 
disease appear unique for this family. 
The sequence analysis of the mitochondrial complex I and III genes did not reveal any 
of the known point mutations associated with LHON. We found two hitherto unknown 
mutations, the G11696A and the T14596A mutations, in two different NADH 
dehydrogenase genes in all 13 family members studied. We did not find these two 
mutations in 100 controls, in 10 members of non-related Dutch LHON families and in 
10 patients with mitochondrial myopathies. In all mitochondrial myopathy patients, 
including LHON patients, that were completely sequenced and described in the 
literature, these two mutations were also not found. Thus the G11696A and the 
T14569A mutation are specifically associated with the dystonia-LHON phenotype in 
this family, as was the case with the two rare but different mutations T4160C and 
A4136G occurring in the mtDNA from a family with LHON and neurological 
abnormalities in Queensland (Howell et al. 1991a). The differences between our family 
and the family described by Howell et al. (1991a) are that in Howell's family a greater 
proportion of maternal relatives became blind and males and females were equally 
affected. Moreover, the presence of both homoplasmic mutations only occurred in a 
branch of Howell's family with a milder phenotype, suggesting that one of the 
mutations behaved as a suppressor mutation (Howell et al. 1991a). 
With the primer extension method we determined that the T14596A mutation in ND6 is 
homoplasmic and the A11696G mutation in ND4 is heteroplasmic in the members of 
our family tested. As can be seen from Figure 2 there might be some correlation 
between the amount of heteroplasmy of the ND4 mutation and the most extreme 
clinical phenotypes shown, especially since 11-15% of wild-type ND4/A11696G is 
detected in blood from all four non-affected family members (two male and two 
female; VI-5, VI-30, VI-57, VII-55), whereas no wild-type ND4/A11696G was found 
in blood from the three family members with LHON and bilateral spastic dystonia 
(V-22, VI-12, VI-55). It may be that, the absence of wild-type ND4/A11696G results 
in a predisposition to the clinical abnormalities described. On the other hand, however, 
one male (VI-2), who is now 66 years old, developed a neurological defect, that is 
typical for the disorder in the family, at the age of five. The defect is only on the right 
side of his body and he has no LHON, whereas his blood lacks wild-type mtDNA. 
Also for the other clinical phenotypes no obvious correlation with the degree of 
heteroplasmy is observed, neither when sex or age of the family members is taken into 
account. In general, the range in the percentages wild-type ND4/A11696G in blood and 
optic nerve from the family members, either affected or not, is very narrow, between 0 
and 23 %. Low amounts of wild-type mtDNA have previously been described for the 
most prevalent LHON mutations at nt 11778 and 3460 (Holt et al. 1989, Sweeney et 
al. 1992). However, according to Holt et al. (1989), the relative proportions of mutant 
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mtDNA found in blood may have some clinical correlation in their families. 
So far, little is known about the tertiary structure of ND4 and ND6 subunits, in which 
our mutations are found, and their exact localisation in the NADH dehydrogenase 
Table I. Interspecies comparison of the amino acid variants of the mitochondrial translation products. 
Species 
Human 
Bovine 
Mouse 
Rat 
Seal 
Chicken 
Frog 
Drosophila melanogaster 
ND4 
V 
Τ 
Τ 
Τ 
τ 
M 
M 
Y 
ND6 
I 
I 
I 
I 
I 
Y 
F 
L 
complex (Walker 1992). Interspecies comparison of these two mutation sites (Table I) 
show that the isoleucine at position 26 of ND6 is identical in man and four other 
species, whereas the amino acid valine at position 312 of ND4 is different in the other 
mammals investigated. Variable interspecies conservation has been previously observed 
in LHON mutations (Table II). In fact, in all reported LHON families, the correlation 
between the degree of heteroplasmy of the mutation and the clinical phenotype is not 
straightforward. The uniqueness of both mutations reported here and the heteroplasmic 
nature of one of these mutations strongly suggests a causal relationship with the disease 
phenotype in this family. Possibly, the two mutations have accumulated sequentially 
along the mtDNA lineage and act synergistically. Since the ND6/T14596A mutation is 
homoplasmic, this mutation event may have occurred before the ND4/A11696G 
mutation. Interestingly, the ND4/A11696G mutation is heteroplasmic over at least six 
generations in this family without any remarkable shift in degree of heteroplasmy. This 
is similar to findings decribed by Howell et al. (1992). However, also rapid shifts of 
human mtDNA alterations in pedigrees with a mitochondrial disease are found (Bolhuis 
et al. 1990, De Vries et al. 1994). The exact mechanism behind the change in degree 
in heteroplasmy of mitochondrial DNA is yet unknown. It is thought that in the normal 
population heteroplasmy is a transitory state, while the homoplasmic state is more 
stable, because rapid cellular segregation from the heteroplasmic state to the 
homoplasmic state takes place in various organisms (Birky et al. 1989, Hauswirth and 
Laipis 1985, King and Attardi 1988, De Stordeur et al. 1989, Niki et al. 1989, Koehler 
et al. 1991). 
Nucleotide sequence analysis itself is not an accurate method for determining the 
presence and amount of heteroplasmy. Unfortunately, both nucleotide changes did not 
give rise to the generation or the loss of a restriction enzyme site. With the single 
nucleotide primer extension technique using DyeDeoxy™ Terminators we were able to 
evaluate the degree of heteroplasmy of both mutations. A similar method, the solid-
phase minisequencing technique with the use of radio-actively labeled dNTPs has also 
been used to detect the point mutations in mtDNA (Suomalainen et al. 1993a, 1993b, 
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Table II. mlDNA mutations associated with LHON. 
GENE NT AA CONS HOMO HETERO references 
ND1 
ND2 
COI 
com 
Т3394С 
СЭ460А 
A4136G 
T4160C 
T4216C 
A4917G 
G5244A 
G7444A 
G9438A 
Y-H 
A-»T 
Y-*C 
L-P 
Y-H 
D-»N 
C—S 
TERM-K 
G-S 
H 
M 
M 
H 
L 
H 
H 
L 
H 
ND 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
ND4 
ND5 
cytb 
G9804A 
A11696G 
G11778A 
G13708A 
A-T 
V-I 
R-H 
A-T 
ND6 T14484C M-*V 
T14596A 
G15257A 
G15812A 
I-M 
D-N 
V-M 
L 
H 
M 
M 
M 
H 
M 
+ 
+ 
ND 
+ 
+ 
ND 
+ 
+ 
ND 
Johns et al. 1992 
Huoponen et al. 
1991, 
Howell et al. 1991b 
Howell et al. 1991a 
Howell et al. 1991a 
Johns and Berman 
1991 
Johns and Berman 
1991 
Wallace et al. 1991, 
Brown et al. 1992a 
Brown et al. 1992a 
Johns and Neufeld 
1993b 
Johns and Neufeld 
1993b 
this study 
Wallace et al. 1988 
Johns and Neufeld, 
1991, Brown et al. 
1992b 
Johns et al. 1992, 
Johns and Neufeld 
1993a 
this study 
Johns and Neufeld 
1991, Brown et al. 
1992b, 1992c 
Johns et al. 1992, 
Johns and Neufeld 
1993b 
NT : nucleotide substitution 
AA : amino acid replacement 
Cons : interspecies conservation of the substituted nucleotide. 
H=high,M=medium, L=low 
HOMO : homoplasmy 
HETERO : heteroplasmy 
TERM : termination codon 
ND :not determined 
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Juvonen et al. 1994). However, the method presented here has several advantages 
compared to the restriction enzyme test or the solid-phase minisequencing. First, we 
deal with direct analysis of the incorporated nucleotide and not with indirect 
autoradiography of radiolabeled samples. Second, it circumvents the pitfalls in 
molecular genetic analysis of LHON mutations by using restriction sites, as described 
by Johns and Neufeld (1993a). The same pitfalls can also influence the solid-phase 
minisequencing technique using 'H-dNTP, because the presence of polymorphic 
nucleotides adjacent and identical to the mutation site will result in the incorporation of 
more
 3H labeled dNTPs by DNA polymerase, giving a bias in the quantification of a 
mtDNA point mutation. MtDNA polymorphisms occurring adjacent to the mutation of 
interest, will have either no influence on the primer extension reaction, or if it does, it 
will affect nucleotide incorporation for both dyedNTPs. Third, the solid-phase 
minisequencing technique needs different nucleotides labeled with unstable radio 
isotopes in the laboratory. Finally, in the solid-phase minisequencing technique the 
incorporation of each nucleotide has to be detected in separate reactions. 
In conclusion, the two mutations found in the two genes coding for different subunits 
of NADH dehydrogenase, are probable candidates for causing combined LHON and 
neurological abnormalities in this family. Like Howell et al. already suggested, LHON 
is probably a set of related mitochondrial genetic diseases which share a characteristic 
pattern of ophthalmological changes (1991a, 1991b). The differences in neurological 
abnormalities among LHON families might be determined by the mitochondrial gene 
mutations or by additional genetic factors, nuclear or mitochondrial. 
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CHAPTER V 
Insertion in a non-coding region of the mitochondrial DNA 
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ABSTRACT 
A patient who presented with benign infantile mitochondrial encephalomyopathy in 
association with a NADH dehydrogenase deficiency was found to have a heteroplasmic 
tandem triplication in the non-coding region between the genes for subunit 2 of cytochro-
me с oxidase (COII) and tRNA15" of the mitochondrial DNA (mtDNA). The heteroplasmic 
triplication was also found in the mother of the patient but not in 200 controls. The 
presence of the heteroplasmic triplication suggests involvement in the pathogenesis of the 
mitochondrial encephalomyopathy in this patient. 
INTRODUCTION 
Mitochondrial encephalomyopathies are very heterogeneous disorders and can be 
associated with a broad spectrum of clinical manifestations, including blindness, deafness, 
dementia, movement disorders, weakness, cardiac failure, diabetes, renal dysfunction, and 
liver disease. Respiratory chain enzyme deficiencies in infancy usually cause severe 
mitochondrial encephalomyopathies, often leading to death at an early age. Three cases of 
benign infantile mitochondrial myopathies have been described so far [1, 2, 3]. 
Large scale heteroplasmic deletions and duplications of mtDNA can be found in patients 
with progressive external ophthalmoplegia, Keams Sayre syndrome and Pearson syndrome 
[4, 5, 6]. Recently, a heteroplasmic tandem duplication was described in the D-loop, an 
important region for the replication and transcription of the mtDNA, in patients with 
Keams Sayre syndrome and their mothers [7]. Besides these rearrangements, numerous 
point mutations have been found. In the protein coding genes of the mtDNA, different 
homoplasmic as well as heteroplasmic point mutations were identified in patients with 
Leber's hereditary optic neuropathy (LHON) [8] and two other heteroplasmic point 
mutations were found in patients with necrotizing ataxia and retinitis pigmentosa (NARP) 
and in Leigh syndrome [9, 10, 11]. Other heteroplasmic point mutations were identified 
in the tRNA genes of the mtDNA, for example in the tRNA for leucine in patients with 
mitochondrial encephalomyopathy, lactic acidosis and stroke like episodes "MELAS" [12, 
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13], and in the tRNA for lysine in patients with myoclonic epilepsy and ragged red fibers 
"MERRF" [14]. Moreover, one point mutation has been described in a ribosomal RNA 
gene [15]. We now report of a case of mitochondrial encephalopathy associated with a 
heteroplasmic tandem triplication in a region of the mtDNA to which no function has 
been described as yet, the COII/tRNA11" intervening region. 
MATERIALS AND METHODS 
Muscle Tissue study 
The quadriceps muscle specimen obtained at the age of 3 months, was processed for 
histochemistry and biochemistry. The oxidation rates for pyruvate and malate, the ATP + 
creatine phosphate production rates, and activities of enzyme complexes of the respiratory 
chain and the pyruvate dehydrogenase complex were measured as described previously 
[16, 17]. Enzyme activities were measured in supernatant from fresh muscle. 
Polymerase chain reaction and sequencing 
Two hundred patients, referred to our laboratory because their symptoms indicated a 
mitochondrial dysfunction, were screened for the T8356C transition in the tRNA15" gene. 
The region around this mutation was amplified with the PCR assay with genomic DNA as 
template. The PCR to screen for the T8356C mutation [18, 19] was performed, with a 
wild-type forward primer (nucleotide position (np) 8211-8230) and a reverse primer (np 
8357-8380), which was modified as described by Silvestri et al. [18]. The mtDNA 
nucleotide numbering used is according to Anderson et al. [20]. The PCR fragments were 
separated on a 3% agarose gel and visualized by ethidium bromide staining. 
The expected 170 bp PCR product and a slightly enlarged PCR product found in one 
patient were cloned with the pCR-Script™ SK(+) cloning kit (Stratagene, Westburg, 
Leusden, The Netherlands). Preparation of plasmid DNA was performed by the modified 
mini alkaline-lysis/PEG precipitation procedure as described in the protocol for the Taq 
DyeDeoxy™ terminator cycle sequencing kit (Applied Biosystems and Perkin Elmer, 
Gouda, The Netherlands). The only modification of the protocol was the use of PEG^o, 
instead of PEG8000. Direct sequencing, performed with the same PCR primers, was 
performed as described [11]. 
RESULTS 
Clinical Findings and skeletal muscle studies 
The patient, a girl, was bom a terme as the first child to Turkish parents after a caesarian 
section, with a brief period of asphyxia. The parents of the patient were related; the 
mother from the patient's mother and the father from the patient's father were sibs. The 
mother of the patient suffers from convulsions but stopped anti-convulsive medication 
during pregnancy. From birth on the patient showed hypotonia and failure to thrive. 
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Sequential laboratory investigations up to three months of age revealed lactic acidemia in 
blood, cerebrospinal fluid and urine, and hypoglycemia, which was not caused by 
hyperinsulinaemia. She suffered from many upper respiratory tract infections. Her height 
was below the tenth percentile. EEG, EMG and cerebral CT-scan at two months of age 
were normal. Because of low hemoglobin and serum iron concentrations she received one 
blood transfusion at two months of age. A quadriceps muscle biopsy was performed at 
three months of age. Abnormal laboratory results were the following: at two months of 
age lactate was elevated in blood (6512 μτηοΐ/ΐ, normal: 600-1800 /лпоі/і), in CSF (5220 
μπιοΐ/ΐ, normal: 1400-1900 μπιοΐ/ΐ) and in urine (246 μπιοΐ/mmol creatinine, normal: 0-
140 /tmol/mmol creatinine). Pyruvate was elevated in blood (202 /tmol/1, normal: 40-80 
μιηοΐ/ΐ) and in CSF (242 μΐηοΐ/ΐ, normal: 100-140 μΐηοΐ/ΐ). CSF protein was elevated (733 
mg/1, normal: 240-650 mg/1). At three months of age blood lactate was 4615 μπιοΐ/ΐ, 
blood pyruvate was 149 μΐηοΐ/ΐ. 
Table I. Biochemical studies in 600 g supematants in the quadriceps muscle. 
Oxidation rates" 
[l- l4C] pyruvate + malate 
[1-MC] pyruvate + carnitine 
[U-'4C] malate + acetylcarnitine + matonaie 
ATP plus phosphocreatine production rates": 
from pyruvate + malate 
from succinate + acetylcarnitine 
Enzyme activities-": 
cytochrome с oxidase 
NADH: Q| oxidoreductase 
succinate: cytochrome с oxidoreductase 
pyruvate dehydrogenase complex 
Carnitine concentrations-": 
non-esteri fi ed 
total 
patient 
1.6 
2.8 
2.1 
9.8 
17.8 
1.7 
0.048 
0.29 
0.11 
0.7 
1.4 
control mean ± SD 
5.5±1.0(n=14) 
5.7±1.4(n=14) 
5.5±1.2(n=14) 
64±10(n=14) 
13.1±3.7(n=14) 
1.8±0.7(n=16) 
0.141±0.061 (n=28) 
0.45±0.15(n=35) 
0.081 ±0.024 (n=25) 
3.2±1.1 (n=21) 
3.6±0.5(n=21) 
SD: standard deviation; *: in nmoles substrate oxidized per hour per mU citrate synthase; **: in nmoles 
product formed per hour per mU citrate synthase; ***: in mU per mU citrate synthase; ****: in /¿moles per 
g muscle (measured in total homogenate) 
The clinical course was favourable. At the age of one year, she showed a normal motor 
development. Speech developed slowly and respiratory infections still occurred frequently. 
Neither lactic acid nor other organic acids in urine were found in elevated concentrations. 
The patient is now 5 years old, has a normal mental and motor development, no infec-
tions and normal lactic acid concentration in blood and urine. Her height is slightly below 
the tenth percentile. 
Histochemical examination of the muscle tissue revealed a fiber type II predominance 
89 
(66%; normal 50%). Moreover, the diameter of the muscle fibers was reduced (range 6-
17 μ for type I fibers and range 6-13 μ for type II fibers was found; the normal range for 
type I and II is 10-30 μ). The biopsy showed inter- and intrafascicular fibrosis and 
accumulation of glycogen. The enzymhistochemical reaction for cytochrome с oxidase 
was normal. 
Electronmicroscopical studies revealed an increased amount of glycogen and neutral lipid 
droplets spatially related to the mitochondria. The latter organelles were rather small with 
compact cristae, suggesting a highly energized state. Neither subsarcolemnal aggregates, 
nor cristals were noted. 
The biochemical study on fresh muscle 600g supernatant revealed diminished rates for 
pyruvate and malate oxidation and for ATP plus phosphocreatine production rate with 
pyruvate plus malate as substrates (Table I). With succinate as substrate the production of 
the high-energy compounds was normal. These results can be explained by a defect in 
complex I of the respiratory chain. Direct measurement of the various mitochondrial 
enzyme activities demonstrated that indeed the NADH:Q, oxidoreductase activity had a 
clearly decreased activity in the muscle mitochondria (34% of the control mean). The 
residual activity of succinate: cytochrome с oxidoreductase (= complex II, complex III + 
coenzyme Q) was low normal (64% of the control mean). The other mitochondrial 
enzymes showed normal activities. Total and non-esterified carnitine levels were found to 
be decreased. 
Genetic studies 
Figure I. Sequencing analysis of the cloned PCR products of the COH/tRNA11" intervening region of the 
patient: A. wild-type nucleotide sequence B. mutant nucleotide sequence. The PCR product was cloned as 
described in the materials and methods section. The elution profile of the fluorescent automated sequencer is 
shown with the assigned nucleotides depicted above the corresponding peaks. 
The PCR to screen for the T8356C mutation revealed, besides the expected 170 bp PCR 
fragment, a second PCR fragment of slightly larger size in one of the patients. Direct 
sequencing analysis showed a 9 basepair insertion (C)5TCTA (Fig LB) adjacent to a 
tandem repeat of two 9 basepair sequences ((С),ТСТА)2 at np [8272-8289] normally 
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present in the COII/tRNA11" intervening region (fig I.A). The abnormal fragment was 
present in blood and muscle from the patient and in blood from the patient's mother, as is 
summarized in table II. The 9 bp insertion was not found in 200 mitochondrial myopathy 
patients that were tested. The patient was also screened for other mutations in the 
mtDNA. Restriction enzyme analysis and Southern blotting of mtDNA from blood did not 
reveal any deletions or rearrangements. Unfortunately, there was not enough muscle 
tissue to perform this test in muscle. Moreover, the diagnostic tests described for the 
A3243G [12], A4317G [21] mtDNA mutations found in patients with MELAS and the 
A8344G [22] mutation found in patients with MERRF were negative. The genes for 
ATPase 6 and 8 were sequenced completely but did not harbour any mutation resulting in 
a non-conservative aminoacid replacement. 
Table II. The amount of mutated mtDNA estimated as a percentage of the total amount of mtDNA present. 
patient (3 m) 
muscle 
40% 
patient (3 y) 
blood 
40% 
patient (5 y) 
blood 
40% 
mother 
blood 
40% 
m = months of age 
y = years of age 
DISCUSSION 
Like the patients with benign infantile myopathy associated with cytochrome с oxidase 
deficiency [1, 2, 3], our patient suffered from failure to thrive and lactic acidemia early 
in life. She improved gradually during the second half of the first year. She was clinically 
normal when reexamined at five years of age. 
The biochemical analysis of the mitochondrial enzymes revealed a defect of the respirato­
ry chain in our patient. The biochemical abnormalities and lactic acidosis are best 
explained by a reduced activity of the NADH dehydrogenase complex. The carnitine 
reduction is most likely of a secondary nature; many respiratory chain defects are 
associated with a low carnitine concentration in muscle tissue. We have demonstrated a 
heteroplasmic tandem triplication involving the COII/tRNA*1" intervening region of the 
mtDNA. The heteroplasmic triplication in the mtDNA was present in muscle and blood 
from the patient as well as in blood from the mother of the patient. A very important 
finding indicative for the pathogenic nature of the mutation is the heteroplasmy of the 
triplication in both the patient and her mother. In the normal population heteroplasmy has 
not been described as yet. Several studies have shown that when mtDNA heteroplasmy 
occurs, it is a transitory state, while the homoplasmic state is more stable [23]. This rapid 
cellular segregation from a heteroplasmic state to a homoplasmic state takes place in 
various organisms [24-28]. However, for all pathological mtDNA mutations described so 
far heteroplasmy can be found in the majority of the patients. 
Interestingly, the heteroplasmic triplication was found by Fabrizi et al. in two families 
suffering from a clinically distinguishable mitochondrial encephalomyopathy, indicating 
that different syndromes can be found with the same genetic defect [29]. The phenomenon 
that the same mutation is associated with different clinical manifestations, was so far only 
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ascribed to mutations in the tRNA genes of the mtDNA [8]. This in contrast to the 
different mutations in the protein coding genes found in LHON and in Leigh syndrome, 
that all account for one and the same phenotype [8, 10, 11]. 
Extensive studies in more than 2000 unrelated individuals of different etnie origin in the 
literature revealed that the COII/tRNA15" intervening region is frequently involved in 
deletion and partial triplication events, suggesting that this region of two 9-bp repeats is a 
hot spot of rearrangements [30-38]. Moreover, the complete triplication was found twice 
in these population studies [35, 39]. Unfortunately, no information is available on the 
heteroplasmic or homoplasmic nature of the triplication in these two individuals. That the 
triplication can have a pathological effect in some but not all individuals, could be 
explained by other factors that may play a role in phenotypic expression, such as 
heteroplasmy, age, environmental agents and the genetic background. A contributive 
mutation on one of the autosomes or sex chromosomes can not be ruled out. Especially 
since the parents of the patient are consanguineous, a recessive mutation in a developmen-
tally regulated gene, might play a role in the disease phenotype of this patient. 
In our patient with a benign course of the myopathy, the activity of the mitochondrial 
enzyme NADH dehydrogenase was decreased, in contrast to the three published benign 
cases with a cytochrome с oxidase deficiency [1-3]. The cytochrome с oxidase activity 
was found to be normal in both the enzymatical and histochemical assay. The benign 
course of the myopathy might be due to a relative increased proportion of normal mtDNA 
molecules. In this respect it is noteworthy that the level of mutated mtDNA in the 
clinically affected individuals described by Fabrizi et al. is substantially higher than in our 
recovered patient [29]. 
The COII/tRNA11" intervening region in the human mtDNA is not conserved in evolution. 
Comparison of mammalian species revealed that the COII/tRNA11" intervening region is 
specific for the human mtDNA [40-43]. No function has been assigned to the non-
conserved COII/tRNA11" intervening region as yet. However, a heteroplasmic change of 
this region might imply a "gain of function" mutation. Further experiments on the cellular 
phenotype of the mutation, e.g. on the expression of the neighbouring genes might be of 
help to define the pathogenic mechanism of this mutation. 
ACKNOWLEDGEMENTS 
Gratefully acknowledged are Prof. Dr. A.M. Stadhouders and Dr. H.J. ter Laak for the 
muscle morphology studies, and the technicians of the laboratory of Pediatrics and 
Neurology for performing the biochemical analysis. This study was supported by a 
research grant from the Prinses Beatrix Fonds, grant number 91-3261 
REFERENCES 
1. DiMauro S, Nicholson JF, Hays AP, et al. Benign infantile mitochondrial myopathy due to reversible 
cytochrome с oxidase deficiency. Ann Neurol 1983;14:226-234 
2. Zeviam M, Servidei S, Bonilla E, DiMauro S. Benign reversible muscle cytochrome с oxidase 
deficiency: a second case. Neurology 1987;3:64-67 
3. Servidei S, Bertim E, Dionisi-Vici C, et al. Benign infantile mitochondrial myopathy due to reversible 
cytochrome с oxidase deficiency: a third case. Clin Neuropath 1988;7:209-210 
92 
*. Holt U, Harding АЕ, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with 
mitochondrial myopathies. Nature 1988,331:717-719 
5. Poulton J, Deadman ME, Gardiner RM. Duplications of mlDNA in mitochondrial myopathy. Τ anrrt 
1989;i:236-240 
6. Zcviani M, Moroes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Keams-Sayre 
syndrome. Neurology 1988;38:1339-1346 
7. Broclangton M, Sweeney MG, Hammans SR, Morgan-Hughes J, Harding AE. A tandem duplication 
ш the D-loop of human mitochondrial DNA associated with deletions in mitochondrial myopathies. 
Nature Genet 1993;4:67-71 
8. Wallace DC. Mitochondrial disease: genotype versus phenotype. Trends Genet 1993,9.128-133 
9. Holt IJ, Harding AE, Petty RKH, Morgan-Hughes JA. A new mitochondrial disease associated with 
mitochondrial DNA heteroplasmy. Am J Hum Genet 1990,46:428-433 
10. Tatuch Y, Chnstodoulou J, Feigenbaum A, et al. Heteroplasmic mtDNA mutation (Т-ЧЗ) at 8993 can 
cause Leigh disease when the percentage of abnormal mtDNA is high. Am J Hum Genet 1992;50:852-
858 
11. De Vnes DD, van Engelen BGM, Cabreéis FJM, Ruitenbeek W, von Oost BA. A second mutation 
missense mutation in the ATPase 6 gene m Leigh's syndrome. Arm Neurol 1993;34:410-412 
12. Goto Y, Nonaka I, Horai S. A mutation in the tRNAk*4UURI gene associated with the MELAS subgroup 
of mitochondrial encephalomyopathies. Nature 1990;348:651-653 
13. Kobayashi Y, Moraoi MY, Tominaga K, et αϊ. A point mutation in the mitochondrial tRNA-LEU<ulm) 
gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes). 
Biochem Biophys Res Commun 1990;173:816-822 
14. Shoffner JM, Lott MT, Lezza AMS, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and 
ragged-red fibers disease (MERRF) is associated with α mitochondrial DNA tRNA1** mutation. Cell 
1990;61:931-937 
15. Prezont TR, Agapian JV, Bohlman MC, et al. Mitochondrial nbosomal RNA mutation associated with 
both antibiotic-uiduced and non-syndromic deafness. Nature Genet 1993;4.289-294 
16. Fischer JC, Ruitenbeek W, Gabreêls FJM, et al. Mitochondrial encephalomyopalhy: the first case with 
on established defect at the level of coenzyme Q. Eur J Pediatr 1986,144:441-444 
17. Speri W, Ruitenbeek W, Kerkhof CMC, et al. Deficiency of о and D subumts of pyruvate 
dehydrogenase in α patient with lactic acidosis and unexpected sudden death. Eur J Pediatr 
1990;149:487-492 
18. Silvestri G, Monies CT, Shonske S, Oh SJ, DiMauro S. A new mtDNA mutation in the tRNA1" gene 
associated with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 1992;51:1213-
1217 
19. Zeviani M, Muntoni F, Savarese N, et al. A MERRF/MELAS overlap syndrome associated with a 
new point mutation m the mitochondrial DNA tRNA1" gene. Eur J Hum Genet 1993;1:80-87 
20. Anderson S, Bankier AT, Barell BG, el al. Sequence and organization of the human mitochondrial 
genome. Nature 1981;140:758-765 
21. Tanaka M, Ino H, Ohno К, et αϊ. Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet 
1990:336:1452 
22. Zeviani M, Amati Ρ, Bresolm Ν, et al. Rapid detection of the A-КЗ °" mutation of mtDNA in Italian 
families with myoclonus epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 1991;48:203-211 
23. Birky CW Jr, Feurst P, Maruyama T. Organelle gene diversity under migration, mutation, and drift: 
equilibrium expectations, approach to equilibrium, effects of heteroplasmic cells, and comparison to 
nuclear genes. Genetics 1989;121:613-627 
24. Hauswirth WW, Laipis PJ. Transmission genetics of mammalian mitochondria: a molecular model and 
experimental evidence; in Euaglianello E, Slater EC, Palmieri F, Saccone С, Kroon AM, eds. 
Achievements and perspectives of mitochondrial research. New York: Elsevier, 1985: 49-59 
25. King MP, Attardi G. Injection of mitochondria into human cells leads to α rapid replacement of the 
endogenous mitochondrial DNA. Cell 1988;52:811-819 
26. De Stordeur E, Solignac M, Monnerot M, Mounolou JC. The generation of Iransplasntic Drosophila 
imulans by cytoplasmic injection: Effects of segregation and selection on the perpetuation of 
mitochondrial DNA heteroplasmy. Mol Gen Genet 1989,220:127-132 
27. Niki Y, CHigusa SI, Matsuura ET. Complete replacement of mitochondrial DNA in Drosophila. 
93 
Nature 1989;341:551-552 
28. Koehler CM, Lindberg GL, Brown DR, et al Replacement of bovine mitochondrial DNA by a 
sequence venant within one generation. Genetics 1991,129.247-255 
29. Fabnzi GM, Guazzi G, DiDonato S, et al. A 9-bp microduplication ш the mitochondrial DNA 
associated with a new maternally inherited encephalomyopathy. Neurol 1993;43-A401 
30. Cann RL, Wilson AC. Length mutations in human mitochondrial DNA. Genetics 1983,104-699-711 
31. Wnschnik LA, Higuchi RG, Stoneking M, Erlich H, Arnheim N, Wilson AC. Length mutations in 
human mitochondrial DNA: direct sequencing of enzymatically amplified DNA. Nucí Acids Res 
1987; 15.529-542 
32. Hertzberg M, Mickleson KNP, Serjeantson SW, Prior JF, Trent RJ. An asían- specific 9-bp deletion 
of mitochondrial DNA is frequently found m Polynesians. Am J Hum Genet 1989,44 504-510 
33. Ballinger SW, Schurr TG, Torroni A, et al. Southeast asían mitochondrial DNA analysis reveals 
genetic continuity of ancient mongoloid migrations Genetics 1992,130:139-152 
34. Torroni A, Schurr TG, Yang C-C, et al. Native American mitochondrial DNA analysis indicates that 
the Amennd and the Nadene populations were founded by two mdependent migrations. Genetics 
1992;130153-162 
35. Passanno G, Semino О, Modiano G, Santachiara-Benerecetti AS COII/tRNAl>* in tergerne 9-bp 
deletion and other mtDNA markers clearly reveal that the Tharus (Southern Nepal) have oriental 
affinities. Am J Hum Genet 1993;53:609-618 
36 Shields GF, Schmiechen AM, Frazier BL, et al. mtDNA sequences suggest a recent evolutionary 
divergence for Bengian and North American populations. Am J Hum Genet 1993,53 549-562 
37. Torroni A, Schurr TG, Cabell MF, et al I. Asian affinities and continental radiation of four founding 
native American mtDNAs. Ara J Hum Genet 1993,53 563-590 
38. Torroni A, Sukemik RI, Schurr TG, et al. II. MtDNA variation of Aboriginal Siberians reveals 
distinct genetic affinities with native Americans Am J Hum Genet 1993,53-591-608 
39. Shields GF, Hecker K, Voevoda MI, Reed JK. Absence of the asian-specific region V mitochondrial 
marker m native Bengians. Am J Hum Genet 1992,50:758-765 
40. Bibb MJ, Van Ellen RA, Wnght CT, Walberg MW, Clayton DA. Sequence and gene organization of 
mouse mitochondrial DNA. Cell 1981,26.167-180 
41. Amason U, Gullberg A, Widegren B. The complete nucleotide sequence of the mitochondrial DNa of 
the Fin Whale, Balaenoptera physalus. J Mol Evol 1991,33.556-568 
42. Anderson S, de Bruijn MHL, Coulson AR, Eperon 1С, Sanger F, Young. Complete sequence of 
bovine mitochondrial DNA: Conserved features of the mammalian mitochondrial genome. J Mol Biol 
1982;156 683-717 
43. Gadaleta G, Pepe G, De Candía G, Quaglianello С, Sbisà E, Saccone С. The complete nucleotide 
sequence of the Rattus norvegicus mitochondrial genome. Cryptic signals revealed by competitive 
analysis between vertebrates. J Mol Evol 1989,28.497-516 
94 
CHAPTER VI 
Respiratory chain enzyme and mitochondrial DNA studies in 
patients with mitochondrial myopathies 
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The molecular basis of most types of deficiency in mitochondrial energy metabolism 
is still unknown. Application of newly developed DNA technology to the relatively 
small mtDNA molecule with known base sequence has resulted in the detection of 
deletions, duplications and point mutations in many patients (Zeviani and Antozzi 
1992). However, the relatively large group of patients with disturbance in the 
respiratory chain has not yet been characterized at the DNA level. Thirteen proteins 
of the oxidative phosphorylation system are encoded by mitochondrial DNA 
(mtDNA), which also encodes for the ribosomal and transfer RNA of the organelle. 
The nuclear genome encodes for the other mitochondrial proteins and regulates the 
biogenesis of mitochondria (Attardi and Schatz 1988). 
In the present study we describe the results of mtDNA analysis in 66 patients with 
clinical symptoms and/or clinical-chemical abnormalities making them suspected of 
suffering from a mitochondrial (encephalo-)myopathy (Trijbels et al 1988), and whose 
muscle has been examined biochemically. The added value of the mtDNA studies is 
evaluated. 
MATERIALS AND METHODS 
The biochemical and DNA investigations were performed in tissues of 66 patients, 
among them patients with well-known syndromes such as Leigh, Alpers, Kearns-
Sayre, Pearson and MELAS syndromes, but also patients without a well-known 
syndrome. An extended diagnostic biochemical programme was applied including 
determination of substrate oxidation and ATP production rates by intact mitochon­
dria, and measurement of the activity of the enzyme complexes of the respiratory 
chain and the pyruvate dehydrogenase complex as described previously (Fischer et 
al 1986). The patient material was analysed for deletions in the mitochondrial DNA 
using various restriction enzymes (De Vries et al 1992) as well as for point mutations 
on nucleotide positions 3243 and 4317 (both 'MELAS mutations'), and 8344 ('MERRF 
mutation'; Zeviani and Antozzi 1992). The procedures for this analysis are based 
upon published methods (Goto et al 1990; Shoffner et al 1990; Tanaka et al 1990). 
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RESULTS AND DISCUSSION 
The results of the biochemical examinations are summarized in Table 1. Muscle from 
18 patients showed normal substrate oxidation and ATP production rates, while the 
other 48 muscle specimens showed diminished rates. Subsequent measurement of the 
respiratory chain complexes and the pyruvate dehydrogenase complex activity 
resulted in localization of the defect in complex I, complex III or complex IV in 20 
cases. In 5 cases the diminished oxidative capacity could be ascribed to a combination 
of defects in two enzyme complexes of the respiratory chain. In 10 patients a decreased 
NADH : 0 2 oxidoreductase activity revealed that the overall activity of the chain 
was insufficient, although the defect was not present in complexes I, III or IV. In the 
residual 13 muscle specimens all mentioned enzyme activities were found to be 
normal. The cause of the decreased capacity for oxidative phosphorylation in these 
cases can only be hypothesized. 
Analysis of mtDNA revealed abnormalities in 12 of the 66 patients examined. In 
6 patients deleted mtDNA was found besides wild-type mtDNA. The deletions found 
were localized in the well-known deletion-sensitive region between the origins of 
replication of the heavy and light mtDNA strand (Zeviani and Antozzi 1992). Deleted 
mtDNA was found in 3 patients with progressive external ophthalmoplegia, in 2 
patients with the Keams-Sayre syndrome, and in 1 patient with the Pearson marrow 
and pancreas syndrome (De Vries et al 1992). In four of these patients the 
mitochondrial energy metabolism did not show an in vitro disturbance, while the 
other two showed reduced oxidative capacity of unknown origin. One can conclude 
that analysis of mtDNA is important in the three patient categories mentioned, the 
more so as deletions can be detected by the one technique. 
In 6 other patients a heteroplasmic A->G mutation on nucleotide position 3243 
was demonstrated. It concerned 3 patients with clear features of the MELAS 
Table 1 Summary of the biochemical and mtDNA findings in the examined 
patients 
Number mtDNA 
Biochemical defect of patients abnormality' 
No defective oxidative phosphorylation 18 4 χ D, 1 χ M 
Defective oxidative phosphorylation due to: 
Complex I defectb 
Complex 111 defect' 
Complex IV defectd 
Complex I + III defect' 
Complex I + IV defectf 
Complex III + IV defect» 
Non-localized defect in respiratory chainh 
Non-localized defect in pyruvate oxidation' 
*D = deletion, M = point mutation on nucleotide position 3242 
ь
 'Decreased activity of bN ADH Q, oxidoreductase, 'succinate cytochrome с oxidoreductase; 
"•cytochrome с oxidase; 'NADH Q t and succinate cytochrome с oxidoreductase. 'NADH Q | 
oxidoreductase and cytochrome с oxidase, Succinate cytochrome с oxidoreductase and 
cytochrome с oxidase, hNADH 0 2 oxidoreductase, 'substrate oxidation and ATP production 
rates 
13 
1 
6 
1 
3 
1 
10 
13 
2 χ M 
1 χ M 
1 χ M 
1 χ M 
2 χ D 
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syndrome, while 2 patients showed MELAS-like characteristics, and one patient 
had Alpers syndrome. This last patient did not show disturbed energy metabolism 
in her muscle mitochondria. In the other 5 patients with the mutation a (localized 
or non-localized) defect in different parts of the respiratory chain was observed 
(see Table 1). 
Examination of mtDNA from family members of one of the complex I deficient 
patients revealed that the 3242 mutation was inherited maternally. Moreover, the 
mutation could be demonstrated in more members than could the complex I 
deficiency. It is remarkable that the 3243 mutation was found in association with 
different enzymatic defects of the respiratory chain or, as in the case of the Alpers 
patient, with no enzyme defect. From the present data and from recent publications 
it becomes clear that this mutation cannot be considered as specific for the MELAS 
syndrome. Mutations on nucleotide positions 4317 and 8344 were not found in the 
present group of patients. 
It can be concluded that mtDNA analysis must have its own place in the diagnostic 
procedure for mitochondrial (encephalo-)myopathies. Especially when it is combined 
with an extensive biochemical programme, the diagnosis of suspected patients can 
thus be handled in a reliable way. At present it is important to study the relationship 
between the mtDNA abnormalities and clinical and enzymatic characteristics, because 
the significance of the described mtDNA abnormalities is not always unambiguous. 
Despite this lack of insight, application of mtDNA investigations, in both prenatal 
and postnatal diagnosis, must be stimulated, particularly as the pattern of inheritance 
can easily be established. 
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ABSTRACT 
Deficiencies of complex I are observed most frequently in mitochondrial myopathies, but 
the exact molecular basis of the deficiencies in mitochondrial energy metabolism is still 
unknown. Since mitochondrial DNA fixes mutations more than ten times quicker than 
nuclear genes, deleterious mutations in mitochondrial genes would be expected to be a 
frequent cause of mitochondrial myopathies. 
We report eight children suffering from a mitochondrial (encephalo)myopathy, whose 
muscle showed a NADH dehydrogenase deficiency. Clinical heterogeneity was observed. 
The mtDNA in these patients did not harbour any of the more frequent tRNA point 
mutations or structural rearrangements. Direct sequencing of the seven mitochondrial 
NADH dehydrogenase genes did not reveal pathological mutations, indicating that 
mutations in the coding region of the mitochondrial genes for complex I are not a 
frequent cause for isolated complex I deficiency. 
INTRODUCTION 
The term mitochondrial (encephalo)myopathy is applied to a clinically, biochemically and 
genetically heterogeneous group of diseases that usually show mitochondrial structural or 
functional abnormalities in skeletal muscle (1). Pure myopathies vary considerably in age 
of onset, course, and distribution of weakness (2). Multisystem disorders are especially 
difficult to classify because of the many overlapping symptoms and signs (2). Some cases 
of mitochondrial encephalomyopathy involve distinctive clinical syndromes, such as 
Keams Sayre syndrome, progressive external ophthalmoplegia, myoclonus epilepsy and 
ragged red fibers (MERRF), mitochondrial encephalopathy, lactic acidosis and stroke like 
episodes (MELAS) and Leigh syndrome. Besides clinical classifications of the 
mitochondrial (encephalo)myopathies, these diseases are defined by specific biochemical 
defects. Most patients with mitochondrial (encephalo)myopathy show a pathological 
increase in serum lactate concentration during and/or after exercise, and different 
biochemical defects, especially in the respiratory chain enzymes, have been described (2). 
Deficiencies of complex I belong to the most frequently found ones in mitochondrial 
myopathies. 
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Thirteen proteins of the oxidative phosphorylation system are encoded by mitochondria] 
DNA (mtDNA), which also encodes for both ribosomal and all transfer RNAs of the 
organel (3). The nuclear genome encodes for the other mitochondrial proteins and 
regulates the biogenesis of mitochondria (4). The first enzyme complex of the respiratory 
chain, NADH dehydrogenase or complex I, is the largest enzyme complex and consists of 
at least 41 subunits, of which seven are encoded for by mtDNA (5-8). In Neurospora 
crassa, the complex has been shown to have ал L-shaped structure, and it is thought that 
this model also applies to the mammalian enzyme (9,10). The mitochondrial^ encoded 
subunits are positioned in that part of the 'L' form, which is buried in the inner 
mitochondrial membrane. The other arm most likely protrudes into the matrix and 
contains most of the prosthetic groups that are involved in the redox reactions (9). With 
the exception of the ND1 gene product nothing is known about the functions of the 
mtDNA encoded subunits (11-13). 
In several patients with a mitochondrial myopathy associated with defects in various 
enzymes of the oxidative phosphorylation, mutated mitochondrial DNA (mtDNA) has 
been found in one or more tissues (14-24). The majority of mutations described so far are 
point mutations found in the mitochondria] tRNA genes (15,17-21,24). 
Since the first description of a patient with a complex I deficiency in 1979 by Morgan-
Hughes et al. (25), many patients with biochemically established complex I deficiency in 
muscle have been reported in the literature (2). The molecular basis of most types of 
deficiency in mitochondrial energy metabolism is still unknown. Comparison of the rate 
of mutation of respiratory proteins that are encoded by mtDNA with others that are 
encoded by nuclear DNA has shown that mtDNA fixes mutations more than ten times 
quicker than nuclear genes (26). As a result, deleterious mutations in mitochondrial genes 
occur much more frequently than in nuclear DNA. Therefore, we hypothesized a direct 
correlation between a complex I deficiency and an underlying defect in one of the ND 
genes coding for the subunits of complex I. 
In the present study we report the mtDNA sequence analysis of the seven ND genes in 8 
patients with clinical symptoms from a mitochondrial (encephalo)myopathy and whose 
muscle showed a NADH dehydrogenase deficiency. 
MATERIALS AND METHODS 
Muscle tissue study 
The quadriceps muscle specimen from the patients was processed for histochemistry and 
biochemistry. The oxidation rates for pyruvate and malate, the ATP + creatine phosphate 
production rates, and activities of enzyme complexes of the respiratory chain were 
measured as described previously (27). Enzyme activities were measured in 600 g 
supernatant or total homogenate, prepared from fresh muscle. 
DNA preparation, amplification and sequencing of the ND genes 
Blood, fibroblast and muscle DNA was prepared according to standard procedures. The 
patient's material, blood from patient 1,2,4 and 5, fibroblasts from patient 5 and muscle 
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'rom patient 2-8, was analysed for deletions in mtDNA (14), as well as for point mutati-
ms on nucleotide positions (np) 3243 (15,20), 4317 (18), 8344 (17) and 8356 (21,24). 
ìlood from patient 1 and muscle from the patients 2,6 and 8 were also screened for the 
ip 8993 mutation (16,22,23) and blood from patient 4 and muscle from patient 8 were 
creened for the np 3271 mutation (19). 
oligonucleotides (Pharmacia, Perkin Elmer/ Applied Biosystems) used for priming the 
x>lymerase chain reaction (PCR) and sequencing the ND genes are mentioned in Table I. 
Die mtDNA nucleotide numbering is according to Anderson et al. (3). Total DNA (0.1-
Ipg) from blood (patient 1,2,4,5) and muscle (3,6,7,8) was subjected to PCR 
implification with oligonucleotide primer pairs 1 and 8 for ND1, 9 and 14 for ND2, 15 
ind 18 for ND3, 19 and 26, and 25 and 30 for ND4L and ND4, 31 and 38, and 37 and 
О for ND5, and 44 and 47 for ND6 (Table Γ). Purification of the PCR products was 
>erformed as described by Van de Ouweland et al. (28). Cycle-sequencing of both strands 
)f the PCR products with the primers mentioned in table I, was performed with the Taq 
lyedeoxy™ terminator cycle sequencing kit (Perkin Elmer / Applied-Biosystems) 
iccording to the manufacturer's instructions and loaded onto the Applied Biosystems 
)73A DNA sequencer. 
RESULTS 
fable II. Summary of the clinical, imaging, neurophysiological and morphological findings in the patients. 
ГАТ SEX 
ЛИ 
1 f 
Ζ M 
J M 
4 F 
S F 
6 M 
1 F 
Я F 
CLASSIFICATION 
ENCEPHALOPATHY 
ENCEPHALOPATHY 
ENCEPHALOPATHY' 
MYOPATHY 
ENCEPHALOPATHY/ 
MYOPATHY 
MYOPATHY 
ENCEPHALOPATHY' 
MYOPATHY 
MYOPATHY 
MYOPATHY 
ONSET 
INFANTILE 
14 YEARS 
INFANTILE 
INFANTILE 
< 10 YEARS 
INFANTILE 
I I YEARS 
< 10 YEARS 
CLINICAL SYMPTOMS/ 
LACTIC Adi 1»· 
OIPLECIA SPASTICA/ 
NORMAL 
MENTAL RETARDA­
TION. CONVULSIONS. 
PARKINSONISM' 
NORMAL 
CONVULSIONS CAR­
DIOMYOPATHY' 
STRONG LV ELEVATED 
CONVULSIONS. HY 
POTONIA/ 
STRONGLY ELEVATED 
EXERCISE INTOLERAN­
CE/ ELEVATED 
CONVULSIONS. COR­
TICAL BLINDNESS. 
HYPERTONIA/ 
STRONGLY ELEVATED 
EXERCISE INTOLERAN­
CE/ 
STRONGLY ELEVATED 
EXERCISE INTOLERAN­
CE/ 
STRONGLY ELEVATED 
COLRSE. 
PROGRESSION 
STABLE 
SLOWLY 
SEPSIS. 
Τ J MONTHS 
RESPIRATORY 
INSUFFICIENCY, 
METABOLIC 
ACIDOSIS. 
t 1 MONTH 
STABLE 
RESPIRATORY 
INSUFFICIENCY, 
t 15 MONTHS 
STABLE 
STABLE 
CT/MBI 
N/N 
CORTICAL 
ATROPHY'ND 
HYPOMYEL BASAL 
CANGLLVND 
PERIVENTRICULAR 
CYSTS' 
HYPOMYELIN KATION 
LARGE VENTRJCLE5 
N/ND/MR5* 
MODERATELY 
DILATED VENTRICLES 
/ND 
N/N 
N7ND/MR5' 
EEC'EMC 
N'N 
ABNORMAL/N 
ABNORM AL/ND 
N/MYOPATHIC 
N/MTOPATHIC 
ABNORM AL/ND 
N/N 
N/ND 
MORPHOLOGY" 
M N 
Ν N 
M N 
M N 
ND 
M STRUNG SDH 
AND C O X -
REACTIONS 
M DISCRETE FŒBE 
VARIATIONS 
M RACKED RED 
FIBERS 
M SURSAACOLEMM 
AL BLESS. 
ABNORMAL 
MITOCHONDRIA 
4: normal result; ND: not done; * MRS spectroscopy: muscle energy metabolism by "P-MR detected a 
owered pbosphocrealine/ATP ratio;** M: muscle biopsy, musculus vastus lateralis quadriceps; N: nerve 
>iopsy, nervus surahs; *** COX: cytochrome с oxidase; SDH: succinate dehydrogenase; # respiratory 
:nzyme abnormalities see Table III; ' lactic acid in blood: normal 0.7 - 1.8 mmol/l, elevated: 1.8 - 2.5 
nmol/l, strongly elevated: > 2.S mmol/l 
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The clinical characteristics of the patients are summarized in Table Π. The patients 
studied represent combinations of the striking features of the mitochondrial 
(encephalo)myopathies. Of the eight patients, case 1 had two affected and deceased 
Table I. Nucleotide position* and sequences of the primers used in the PCR and direct sequencing. 
DIRECTION POSITION SEQUENCE GENE 
NDl [3307-4262] 
1 F 
2 R 
3 F 
4 R 
5 F 
6 R 
7 F 
8 R 
ND2 [4470-5511] 
9 F 
10 R 
11 F 
12 R 
13 F 
14 R 
ND3 [10059-10404] 
15 F 
16 F 
17 R 
18 R 
ND4L [10470-10766] 
19 F 
20 R 
21 F 
ND4 [10760-12137] 
22 R 
23 F 
24 R 
25 F 
3189-3210 
3635-3656 
3611-3632 
3937-3956 
3922-3943 
4225-4246 
410M120 
4489-4510 
4470-4491 
4790-4810 
4662-4682 
4956-4975 
4924-4944 
5585-5604 
9912-9931 
10059-10080 
10383-10404 
10536-10555 
10499-10519 
10746-10765 
10744-10764 
11020-11039 
11021-11041 
11230-11249 
11230-11249 
CAA CTT AGT ATT ATA CCC АСА iRNA Ll 
AGG ATT GAG TAA ACG GCT AGG С NDl 
TCC TAT ТТЛ TTC TAG CCA CCT С NDl 
GCG GCG TAT TCG ATO TTG AA NDl 
GAA СТА GTC ТСА GGC TTC AAC A NDl 
TGC TGG AG A TTG TAA TGG GTA Τ NDl 
TCT AAC CTC CCT GTT CTT AT NDl 
AAG ATG GTA GAG TAG ATG ACG G iRNA IQM 
ATT AAT CCC CTG GCC CAA CCC G ND2 
CAG AAG TGA AAG GGG GCT ATT ND2 
ACC GCA TCC ATA АТС CTT СТА ND2 
CCA CCT CAA CTG CCT GCT AT ND2 
GCC TTC TCC TCA CTC TCT CAA ND2 
GGG GTT TTG CAG TCC TTA GC ND2 
GAA GCC GCC GCC TGA TAC TG tRNA G 
ATA AAC TTC GCC TTA ATT TTA A ND3 
ATT CGG TTC AGT СТА АТС CTT Τ ND3 
GAG GAT ATG AGG TGT GAG CG ND3 
AGC ATT TAC CAT CTC ACT TCT ND4 
TAG CAT TGG AGT AGG TTT AG ND4 
ACC TAA ACC TAC TCC AAT GCT ND4 
GTT TTT TTC GTG ATA GTG TGT ND4 
CCA СТА TCA CGA AAA AAA CTC ND4 
GTG CGA TGA GTA GGG GAA GG ND4 
CCT TCC CCT ACT CAT CGC AC ND4 
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Table I continued 
26 R 
27 F 
28 R 
29 F 
30 R 
ND5 [12337-14148] 
31 F 
32 R 
33 F 
34 R 
35 F 
36 R 
37 F 
38 R 
39 F 
40 R 
41 F 
42 R 
43 R 
ND6 [14149-14673] 
44 F 
45 F 
46 R 
47 R 
11489-11508 AGA ATG AGT GTG AGG CGT AT 
11490-11510 TAC GCC TCA CAC TCA TTC TCA 
11750-11769 GTG CGT TCG TAG TTT GAG TT 
11751-11771 ACT CAA ACT ACG AAC GCA CTC 
12090-12109 GTT GAG GGA TAG GAG GAG AA 
12250-12270 CAA CAT GGC TTT CTC AAC TTT 
12566-12585 GTC TAG TTT GAA GCT TAG GG 
12601-12621 TTC АТС CCT GTA GCA TTG TTC 
12877-12896 GCT AAG GCG AGG ATG AAA CC 
12828-12847 CAA CAC AGC AGC CAT TCA AG 
13105-13124 AAG CGG ATG AGT AAG AAG AT 
13106-13126 TCT TCT TAC TCA TCC GCT TCC 
13414-13433 ATG GTT TTG AGT AGT CCT CC 
13350-13369 ACT ATT TAT GTG CTC CGG GT 
13825-13844 TCT AGG GCT GTT AGA AGT CC 
13722-13742 ATT CGC AGG ATT TCT CAT TAC 
14117-14137 GGA GTA GGG TTA GGA TGA GTG 
14257-14278 AGG GTT CAT TCG GGA GGA TCC Τ 
14108-14128 TCT TCT TCC CAC TCA TCC TAA 
14553-14572 CAC ACC CGA CCA CAC CGC TA 
14652-14673 ATG ATG TAT GCT TTG TTT CTG Τ 
15211-15230 GAA СТА GGT CTG TCC CAA TG 
ND4 
ND4 
ND4 
ND4 
ND4 
tRNAS2 
ND5 
ND5 
ND5 
ND5 
ND5 
ND5 
ND5 
ND5 
ND5 
ND5 
ND5 
ND6 
ND5 
ND6 
ND6 
Cytb 
F = forward primer 
R = reverse primer 
" = nucleotide numbering according to Anderson et al. (3) 
siblings and case six has one affected sibling. The remaining six cases were sporadic. We 
distinguished three main clinical syndromes according to DiMauro (2). 
1. Patient 5, 7 and 8 show a "myopathic" form with only a discrete raised blood lactic 
acid. On exercise a sharp rise in blood lactic acid occurs. This disease type is slightly 
progressive. 
2. Patient 1 and 2 show an "encephalopathic" form which causes a more severe handicap. 
After puberty the course is more or less stable. 
3. Patient 3, 4 and 6 showed a "generalised" form with onset in the neonatal period and a 
severe prognosis. The results of the biochemical examination are summarized in Table 
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III. Oxidation rates with radiolabelled pyruvate and malate and ATP production rates 
were decreased in all patients. The patients have in common a complex I deficiency in 
muscle tissue. The clinical and biochemical features of patient 1, 2 and 7, respectively, 
have been described previously (29-31). The complex I defect in patient 2-8 is concluded 
from a diminished activity of NADH:Q, oxidoreductase and of NADH:02 oxidoreductase. 
This last activity reflects the overall capacity of the respiratory chain except for complex 
II (32). In patient 7 the cytochrome с oxidase activity is mildly reduced if expressed per 
citrate synthase activity. The residual activity of complex I, however, is relatively much 
more decreased. Patient 1 has been reported earlier (29). A complex I deficiency was at 
that time concluded based on the decreased substrate oxidation rates and normal 
cytochrome contents. Citrate synthase activity has not been measured in patient 8. The 
enzyme activities in muscle homogenate from patient 8 are expressed as percentages from 
the mean value of activity in controls (33), showing a clear complex I defect. 
Table III. Enzyme activities in 600 g supematants in the quadriceps muscle (in mU per U citrate synthase, 
except the citrate synthase, which is in mU per mg protein). 
Enzyme activities 
NADH: Q, oxidoreductase 
succinate: cytochrome с 
oxidoreductase 
cytochrome с oxidase 
NADH: Oj oxidoreductase 
citrate synthase 
Г 
ND 
Ν 
Ν 
ND 
ND 
2 
86 7 
383 
2897 
149 
57 
3 
20 0 
278 
1961 
49.6 
87 
4 
180 
551 
1688 
66.0 
44 
S 
22 
433 
2143 
42.0 
293 
6 
24 
418 
1479 
75 
146 
7 
5.0 
440 
517 
9.2 
236 
controls 
mean ± SD 
141±61 
450 ±150 
1780 ±720 
460 ±130 
91 ±32 
8 " 
18% 
140% 
200% 
ND 
ND 
N: 
ND: 
Biochemical features in muscle from patient 1 and controls as described previously (29). 
Enzyme activities in muscle homogenate from patient 8 are expressed as percentages from the mean 
activity in controls. In this case the control values of the mitochondrial enzymes in muscle are 
measured in homogenate m mU per mg wet weight as described by Bakker et al (33). 
enzyme activity is within control range 
enzyme activity is not determined 
Restriction enzyme analysis and Southern blotting of mtDNA from blood, fibroblasts and 
muscle did not reveal any deletions or rearrangements. Moreover, the diagnostic tests 
described for the np 3243, 3271, 4317, 8344, 8356 and the np 8993 mutations did not 
reveal any abnormalities in blood, fibroblasts and muscle. The mtDNA sequencing 
analysis revealed various homoplasmic nucleotide substitutions in the ND genes in the 
patients. As summarized in table IV however, these were all normal mtDNA variants. 
Normal variants are defined as those nucleotide changes that were already observed in 
other studies as normal nucleotide variants. As such, Marzukd et al (34) reported a 
reference data base of various normal variants in mtDNA, and Wallace et al (35) reported 
a number of restriction site polymorphisms in the mtDNA. More nucleotide changes 
found in the present patient group were already reported as normal variants by Howell et 
al (36,37) and Brown et al (38), Johns et al (39) and van de Ouweland et al (40). The 
hitherto unreported nucleotide changes found in the ND genes were considered as normal 
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variants by us, because they did not result in an amino acid change, or because they were 
observed in control samples in our laboratory. 
Table Г : Normal nucleotide variants of mtDNA, and amino acid variants of mitochondrial translation 
products, found in the present study. 
GENE 
ND1 
ND2 
ND4 
ND5 
ND6 
NUCLEOTIDE 
POSITION 
G3423T 
A3505G 
G353IA 
A3828G 
T4216C 
A4769G 
G498SA 
G5147A 
G5460A 
A10831G 
A11251G 
T11335C 
G11719A 
G12372A 
G12406A 
GI3368A 
C13464G 
T13617C 
G13702C 
C13746T 
C13749T 
G14199T 
C14365G 
C14368G 
AMINO АСШ 
Val 
Thr-»Ala 
Pro 
Leu 
Tyr-»His 
Met 
Gin 
Thr 
Ala-»Thr 
Trp 
Leu 
Asn 
Gly 
Leu 
Val-Ile 
Gly 
Gly 
He 
Gly-»Arg 
Asn 
Asn 
Pro-»Thr 
Val 
Phe-«Leu 
PATIENTS/ 
CONTROL 
1,3,4,7,8 
control 
control 
6 
8 
1,2,3 
1,2,3 
8 
control 
2,3,4,5,8 
7,8 
7 
6,8 
6 
6 
8 
5.7 
6 
1-8, control 
1 
1 
1-3,5-7 
5,6,control 
1-8,control 
LITERATURE 
34,35 
this study 
this study 
this study 
35,38 
35,36,38 
35,37,38 
34 
40 
this study 
34,38 
34,36-39 
34,36-39 
34,36,37 
35 
34 
this study 
this study 
35,36,38 
this study 
this study 
35-38 
36-38 
34,36-38 
DISCUSSION 
The mitochondrial diseases in the patients studied could be divided clinically into a 
"slightly progressive mitochondrial myopathy", a "more severe mitochondrial 
encephalopathy" and a "very severe mitochondrial encephalomyopathy" (2). They had in 
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common a complex I deficiency of the respiratory chain. 
Various nucleotide substitutions were found by sequencing the mitochondrial ND genes, 
all resulting in normal or silent mtDNA variants. We have also excluded large deletions 
and the point mutations, which have been described in patients with some types of 
mitochondrial (encephalo)myopathies (14-24). Moreover, from patient 1 and 2, who have 
been described previously as suffering from Leigh syndrome (29,30), the ATPase 6 and 8 
genes of the mtDNA have been sequenced. Two point mutations in the ATPase 6 gene 
have been described in patients with Leigh syndrome recently (22,23), but no 
abnormalities are found in the ATPase genes from patient 1 and 2. 
The significance of the silent mtDNA variants is difficult to assess as yet. A particular 
nucleotide sequence may have more than one function. For example, part of the 
tRNALn,(UUR) gene functions also as a transcription terminator (41). Also a change in the 
preferential codon usage may affect the efficiency of the assembly of the amino acid 
chain. For instance, the A10831G transition we found in the ND4 gene in 5 of the 
patients changed the tryptophane codon UGA, which is used 93 times in wild type 
mtDNA (3) to the tryptophane codon UGG which is used only 11 times. Although it is 
unlikely that this mutation by itself can cause disease, it might be a contributory factor. 
It is striking that all complex I deficient patients studied do not carry pathological 
mutations in the mitochondrial genes coding for this enzyme complex. Regarding the 
literature, several point mutations have been reported in the mitochondrial protein coding 
genes, especially in the complex I genes, but all patients involved suffered from Leber 
hereditary optic neuropathy (LHON) (42). From the present study and what is known 
from the literature up to now, we assume that there is no association between mutations 
in the mitochondrial NADH dehydrogenase genes and the complex I deficiency in muscle 
in the majority of patients with mitochondrial (encephalo)myopathy, except in LHON 
patients. 
Recently, Rho° cell lines have been used to introduce patient's mitochondria into a 
mitochondria-free standard cell. The ultimate goal of this method is the ability to 
discriminate between the nuclear and mitochondrial genetic origin of respiratory chain 
deficiencies (43,44). This system may be very usefull in the prescreening of nuclear or 
mitochondrially caused respiratory chain deficiencies. However, the application of this 
promising technique to detect unknown mutations has not been demonstrated as yet. 
Moreover, during the application of this technique on known mutations, shifts in the 
degree of heteroplasmy are observed during the culturing conditions (45-48). 
Since point mutations in the tRNA genes have been found in many mitochondrial 
(encephalo)myopathy patients with a complex I deficiency (42,49), the tRNA genes are 
candidates for further detailed study in our patients. Of course, it is also possible that 
these cases of mitochondrial (encephalo)myopathy are due to defects of the nuclear 
genome, since nuclear genes code for the majority of the respiratory chain subunits, 
which will be the goal of further studies. 
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CHAPTER VII 
An inventory of mitochondrial DNA mutations 
Part of this chapter will be published in Clinical Neurology and 
Neurosurgery as an invited review. 

AN INVENTORY OF MITOCHONDRIAL DNA 
MUTATIONS. 
The involvement of mtDNA in mitochondriopathies has become apparent only in the past 
6 years, during which pathogenic mutations have been described in increasing number. In 
this thesis, several mitochondrial DNA (mtDNA) mutations have been discussed (chapters 
II-VI), some of which give rise to defects in enzymes involved in energy metabolism. 
Defects of mtDNA include deletions and insertions, which are usually sporadic (chapter 
II), and point mutations, which are familial (chapter III, IV). In the literature mtDNA 
depletion has also been reported, of which the inheritance has not been resolved yet 
(150). The spectrum of clinically relevant mtDNA mutations is broad, as shown below. 
DELETIONS-INSERTIONS OF MITOCHONDRIAL DNA 
Single sporadic deletions 
Heteroplasmic mtDNA deletions are associated with different mitochondrial disorders. 
Spontaneous, large scale deletions are found in 40% of patients with ocular myopathy, in 
most patients with Pearson syndrome, and with Wolfram syndrome (1-14) (chapter II-l 
and II-2). Ocular myopathy patients show a continuous spectrum of symptoms. Patients 
with progressive external ophthalmoplegia (PEO) suffer from ophthalmoplegia, ptosis, 
and mitochondrial myopathy (15). Patients with Keams-Sayre syndrome (KSS) suffer 
from retinitis pigmentosa, lactic acidosis, neurosensory hearing loss, ataxia, heart 
conduction defects, elevated CSF protein, and dementia (16). Pearson marrow and 
pancreas syndrome is an often fatal childhood disorder with pancytopenia, in which 
pancreatic fibrosis and insufficiency, and splenic atrophy are frequently seen (14,17). 
Individuals who survive can develop the KSS phenotype (18-22). Wolfram syndrome is a 
disease characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness 
(14). 
Patients suffering from ocular myopathy or Pearson syndrome generally harbor a 
single heteroplasmic mtDNA deletion, but the size and site of the deletion may differ 
between patients (19). Although the size of the mtDNA deletion ranges from 1.3 to 8 
kilobase pairs (kb), a 4.9 kb deletion occurs more frequently and is therefore referred to 
as the "common deletion". Mita et al. (20) defined two classes of mtDNA deletions: those 
that are flanked by short repeat sequences at the boundaries of the deletion, called direct 
repeats, and those that are not. The "common deletion" is flanked by direct repeats of a 
13-nucleotide sequence (5'-ACCTCCCTCACCA) (21,23). All known deletions are 
confined to two sectors delineated by the Η-strand and L-strand origins of replication, the 
0 H and 0 L (Fig 4 in chapter I) (19). Ninety-five percent of the deletions occur between 
0 H and O L (see righthand sector of Fig 4 in chapter I). A minority of the deletions occur 
upstream of (\ (see lefthand sector of Fig 4 in chapter I). Most deletions do not include 
0 L and 0H . It has been assumed that deleted molecules, that retain both origins of 
replication would replicate faster and would become progressively enriched in muscle 
tissue (18). Some deletions have been described in which the heavy strand promotor (Рн) 
has been removed but the light strand promotor (PJ has been spared, demonstrating that 
transcription of the Η-strand is not required for maintenance of the mtDNA (19). 
Deleted genomes are usually competent for replication and transcription (24). In chapter 
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Π is discussed that deletions often result in impaired synthesis of the fusion protein, 
making it a less likely component of the pathogenetic mechanism (14). Most frequently, 
the deletions encompass not only many of the genes encoding the 13 proteins of the 
oxidative phosphorylation but also several tRNAs. The loss of a number of tRNAs would 
be expected to affect the synthesis of all of the mitochondrially encoded respiratory chain 
subunits. Nevertheless, in some patients defects were found of complex I or IV (2,25-27), 
whereas in others a variety of defects of the respiratory chain and oxidative 
phosphorylation have been found (3,5,28). Moreover, patients with identical deletions 
may have different biochemical features and some patients with a deletion have a normal 
biochemistry of the respiratory chain (2). Thus, the correlation between genetic features 
and biochemical function is currently unresolved. The correlation between the proportion 
of deleted mtDNA per tissue and clinical severity is not straightforward either (3,13,29). 
Recently, a heteroplasmic length polymorphism (a duplicated region) in the 
mtDNA D-loop was described in KSS patients, with a mtDNA deletion, and in their 
mothers (30). The authors suggested that the location of the length polymorphism in a 
region that controls both replication and transcription of mtDNA could explain a predis­
position to deletion. 
Single large insertions 
In some patients with PEO, KSS and Pearson syndrome, large insertions in mtDNA have 
been described (31-35). Presumably, these large duplicated mtDNA molecules can better 
be interpreted as deleted circular dimers of mtDNA (unpublished results). 
Maternally inherited deletion 
A 10.4 kb mtDNA deletion has been described in a family with maternally inherited 
diabetes mellitus and deafness (36). In contrast to the above described mtDNA deletion 
syndromes, this deletion is not associated with ptosis, ophthalmoplegia, and mitochondrial 
myopathy, and is not sporadic. Since the 0 L is lost in this deletion, the deleted molecules 
can not replicate faster than a wild type mtDNA molecule (36). The authors suggested 
that the 10.4 kb deleted mtDNA remains in balance with the normal mtDNA causing a 
chronic, generalised defect of the oxidative phosphorylation, rather than a progressive one 
(36). 
Autosomally inherited multiple deletions 
Some cases of PEO appear to result from mutations in nuclear genes which likely can 
induce mtDNA deletions (37-44). In these patients, multiple deletions are associated with 
mitochondrial myopathy (39). Up to now, multiple deletions of mtDNA have been 
reported in familial PEO (37,38,39), in familial mitochondrial myopathy (40), in a case 
of progressive encephalomyopathy (41), in inherited recurrent myoglobinuria (42) and in 
inherited idiopathic dilated cardiomyopathy (43,44). The PEO families with multiple 
deletions of different sizes show an autosomal dominant mode of transmission. It has been 
suggested that a mutation of a nucleus-encoded protein may result in the loss of the 
integrity of the mitochondrial genome (37,38). Different biochemical deficiencies of all 
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enzyme complexes of the respiratory chain (including complex II) have been reported, 
ranging from isolated enzyme deficiencies (38,41) to more generalized enzyme defects 
(39). 
Maternally inherited 9 base-pair insertion 
In chapter V, we have discussed a patient with benign mitochondrial myopathy and a 
moderately decreased complex I activity (45). She showed a heteroplasmic length 
polymorphism in the COII/tRNALi" intervening region, a region to which no function has 
been assigned until now (45). The length polymorphism was due to a 9 base-pair 
insertion, (C)STCTA, adjacent to a tandem repeat of two 9 basepair sequences ((C)s. 
TCTA)j which occupy positions 8272 to 8289 in normal mtDNA (nucleotide numbering 
used is according to Anderson et al (46).) The heteroplasmic 9 base-pair insertion was 
also found by Fabrizi et al. (47) in two families suffering from a clinically different 
mitochondrial encephalomyopathy. Extensive studies in more than 2000 unrelated 
individuals of different etnie origin in the literature revealed that the COII/tRNA11" 
intervening region is a hot-spot for rearrangements, frequently resulting in a deletion of 
one of the repeats (48-57). The 9 basepair insertion was found only twice in these 
population studies (53,57). It remains unsolved whether this 9-bp insertion is involved in 
the disease etiology of the patients. 
A compilation of the point mutations in the mtDNA that are associated with mitochondrial 
neuromuscular diseases and often with impaired oxidative phosphorylation is given below 
(see Table I, page 127-131). 
POINT MUTATIONS IN TRANSFER RNA 
tRNAUu(UUR) 
The heteroplasmic A3243G mutation in the tRNAUu(Uim) has been demonstrated in 80% of 
the patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like 
episodes (MELAS) as discussed in chapter III-2 and III-3 (58,59). MELAS patients 
present with recurrent stroke-like episodes and vomiting, seizures, lactic acidosis, and 
retarded growth during infancy (3 to 11 years) (60,61,62). Measurements of the respirato-
ry chain enzyme activities in muscle revealed that more than half of the MELAS patients 
have a complex I or I + IV deficiency (61,62). Miyabashi et al. demonstrated a clear 
correlation between age of onset of MELAS and the proportion of the 3243 mutation, and 
a decrease of complex I activity with increasing proportion of mfDNAs carrying this 
mutation (63). We have studied two MELAS families with variable clinical expression of 
the disease (Chapter II-2 and II-3; 64,65). In one of the two families, a clear correlation 
between amount of heteroplasmy for the A3243G mutation in muscle and blood and 
clinical severity of the disease manifestations was demonstrated (Chapter II-2; 64). 
The A at position 3243 is located at a highly conserved position in the dihydrouri-
dine loop of the tRNA molecule and is embedded in the binding region of the mito-
chondrial transcription termination factor (58,59,66). Three possible disease mechanisms 
have been suggested: firstly, the mutation could influence translation (58), secondly, it 
could impair RNA transcription (66) and thirdly, it could impair RNA processing (67). 
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The exact disease mechanism is unresolved so far. 
The same mutation has also been demonstrated in the mtDNA from patients with 
PEO and patients with diabetes and deafness (68,69). 
In two unrelated MELAS patients with a complex I deficiency carrying the 
A3243G mutation in the tRNA ,Ä, additional mutations have been described (70). In one 
of the two patients, the additional mutations A4833G in ND2, the C11553G in ND4 and 
the G5601A mutation in tRNAAU were present, causing replacement of two evolutionarily 
conserved amino acids and a conserved nucleotide, respectively. In the other patient, the 
additional mutations C3968G in ND1, C8002A in COII and A8938G in ATPase 6 were 
present, affecting three evolutionarily conserved amino acids. Sequence analysis in the 
latter patient revealed also a substitution of the non-conserved amino acid A8929G in 
ATPase 6, 2 mutations in the rRNA genes A2270C and A2706G and 1 mutation in the D-
loop C16193T, which were not found in controls. 
In two other MELAS patients with the A3243G tRNALH,(UUR) mutation the entire 
mtDNA was sequenced and several additional mutations were found as well (71). In one 
of the two patients, the mutations T3338C in ND1, A8906G in ATPase 6 and A8308G in 
tRNALy' were found. In the other patient the mutations C964A in 12S rRNA, A1041G in 
12S rRNA, T3394C in ND1, G4491A in ND2 and G11963A in ND4 were detected. No 
information is given on the presence of heteroplasmy (70,71) nor on biochemical 
abnormalities (71). 
One family with mitochondrial myopathy and complex I deficiency in muscle has been 
described with a heteroplasmic T3250C mutation in the tRNALB,(UUR) (72). The degree of 
heteroplasmy was not exactly determined, but it was shown that the mutation was heter-
oplasmic in blood and muscle of four related patients, as well as in blood from their 
(affected or unaffected) mothers. Like the A3243G mutation, this mutation was also 
located in the dihydrouridine loop of the tRNA and was embedded in the binding region 
of mitochondrial transcription termination factor (72,66). However, the nucleotide at 
position 3250 is non-conserved during evolution, and the authors suggest that this 
mutation has little effect on the tRNA structure and function (72). 
One patient with mitochondrial encephalomyopathy, pigmentary retinopathy, dementia, 
hypoparathyroidism and diabetes mellitus has been described with a maternally inherited 
heteroplasmic A3252G mutation in the tRNAUu(UUR) (73 ). The phenotype of this family 
has features in common with MELAS. The mutation was present in blood (30% mutant 
mtDNA) and in muscle (76% mutant mtDNA). A less severely affected family member 
had 50% mutant mtDNA in muscle. Heteroplasmy was found in several family members. 
The mutation segregated with the disease and was absent in controls. The site of the 
mutation is a highly conserved position in the termination factor binding site of the tRNA" 
Uu (UUR) 
Measurement of the respiratory chain enzymes revealed a decreased complex I 
activity in muscle from the proband. 
A mutation C3256T in the tRNALa,aJUR) has been associated with a neurological syndrome 
resembling myoclonus epilepsy and ragged red fibers plus optic neuropathy, retinopathy, 
and diabetes (74). The mutation was located at a highly conserved position in the 
dihydrouridine stem of the tRNA. The mutation was heteroplasmic, the percentage of 
mutant mtDNA was 64% in muscle, 8% in white blood cells, 48% in first passage 
cultured fibroblasts, 18% in hair roots. No mutant population was detected in white blood 
cells from his sister. Biochemical investigations of the respiratory chain enzymes revealed 
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a deficiency of complex I, III and IV. Analysis of single muscle fibers indicated that 
morphological and biochemical alterations appeared only when the proportion of mutant 
mtDNA exceeded 90% of the total cellular mtDNA pool. 
Two families with maternally inherited myopathy and cardiomyopathy (MIMAC) have 
been described with a heteroplasmic A3260G mutation in tRNALn,(UUR) (75,76). The 
mutation is located in a 4 bp palindrome that forms the anticodon stem of the 
tRNA^"*""10, and will presumably affect the stability of the anticodon stem (75). The 
mutation was not found in controls, segregates with the disease and there was a 
correlation between degree of heteroplasmy in blood and the clinical severity (75,76). In 
one of the families, significant negative correlations between the proportion of mutant 
mtDNA and the complex I and IV activities were found (75). In the other family, one of 
the patients had a complex I deficiency (76). 
The heteroplasmic T3271C mutation in the tRNAUu(UUR) has been described in a small 
group of MELAS patients, that were negative for the A3243G mutation (77). The 
mutation is in the anticodon stem of the tRNA. These sequences have not remained 
constant during evolution, but the conserved nucleotides forming the anticodon stem 
proper have to be complementary to each other. The mutation is not found in controls. 
Sakuta et al. compared 38 MELAS patients with the A3243G mutation and 6 MELAS 
patients with the T3271C mutation (78). This study revealed that except for the later onset 
of disease in the patients with the T3271C mutation, there were no clinical, biochemical 
and pathological differences between the two groups. Since the T3271C mutation is not 
located in the transcription termination binding site, which has been proposed to be 
defective in the A3243G mutation, the authors concluded that a functional defect in tRNA 
itself might be responsible for the enzyme defects in MELAS patients (78). 
Bindoff et al (79) reported a patient with mitochondrial myopathy and biochemically 
proven profound complex I deficiency with the A3302G mutation in the tRNAUu(UUR). The 
mutation was found to be present at levels close to homoplasmy in muscle from the 
patient, as well as in fibroblasts from both the patient and her affected mother. It has 
been suggested that the mutation induces abnormal mitochondrial RNA processing, 
resulting in qualitative or quantitative abnormalities in the ND1 mRNA. Northern blot 
analysis demonstrated marked accumulation of a polycistronic RNA precursor, containing 
sequences for 16S rRNA, tRNA1^"1" and ND1. Fibroblasts do not express a 
biochemical defect despite the fact that they carry the mutation (79). Bindoff et al. (79) 
suggested that the biochemical defect occurs in skeletal muscle, but not in fibroblasts, 
because only in muscle appreciable amounts of the mRNA precursor are seen. 
tRNA1* 
A patient with mitochondrial encephalomyopathy, short stature, deafness, focal glomeru-
losclerosis, epilepsy and dilated cardiomyopathy with a complex IV deficiency in skeletal 
muscle showed a maternally inherited heteroplasmic A4269G mutation in the tRNA1" 
(80). Mutated mtDNA was predominant in heart muscle, skeletal muscle and blood of the 
patient, whereas in blood of the healthy mother the proportion of mutant mtDNA was 
much lower than that of wild type mtDNA. The mutation, at a well-conserved nucleotide 
position of the tRNA"1 gene, was not found in controls. The activity of complex IV was 
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30% lower than levels in skeletal muscle of controls. Histopathologic^ findings 
demonstrated mitochondrial myopathy with ragged red fibers and focal complex IV 
deficient fibers in skeletal muscle and cardiac muscles. 
One patient with MELAS-like encephalopathy and fatal infantile cardiomyopathy has been 
described with a heteroplasmic A4317G mutation in tRNA"' (81). The degree of heter-
oplasmy was not mentioned. Isolated mitochondria from the patient's heart showed 
combined defects of complex I and IV. 
In another patient with fatale infantile cardiomyopathy and a complex I and IV deficiency 
in isolated heart mitochondria, three point mutations in the tRNA genes, tRNALa,(UUR) 
C3254T, tRNA1" A4317G and tRNA7"' C5554T were detected (71,82). Moreover, the 
amino acid replacements T4216C in ND1, A5301G and T5442C in ND2, A7129G in 
COI, A7673G in COII, A14927G and G15737A in cytochrome b, and the point mutation 
T1107 in 12S rRNA were observed (71). Ito et al. and Obayashi et al. do not comment 
on the presence of heteroplasmy (71,82). 
tRNA*» 
The G5703A mutation in tRNA*™ was associated with isolated ophthalmoplegia (74). The 
mutation disrupts a highly conserved base pair at the "base" of the anticodon stem. The 
mutant mtDNA was heteroplasmic in the tissues investigated and represented 69% in 
muscle, 4% in white blood cells, and 6% in first passage fibroblasts of total mtDNA. No 
mutant mtDNA was detected in white blood cells from the healthy mother or from two 
healthy maternal aunts of the patient. All respiratory chain complexes (with the exception 
of complex II) showed markedly decreased activities in muscle homogenate. Analysis of 
single muscle fibers indicated that morphological and biochemical alterations appeared 
only when the proportion of mutant mtDNA exceeded 90% of the total cellular mtDNA 
pool. 
tRNAc,s 
In a patient with hypertrophic cardiomyopathy associated with left ventricular dilatation 
and a 7079 basepair deletion (from nucleotide position 8992 to 16072) in heart muscle, 
skeletal muscle and liver, two additional unique point mutations G5821A in the tRNA05" 
and A15951G in the tRNAThr were found (82). The same patient was also reported by 
Obayashi et al. (71), who did not mention the deletion. The authors reported the above 
mentioned tRNA point mutations together with 2 amino acid replacements caused by an 
A13258T transversion in ND5 and a T14180C transition in ND6 and an A2246G 
transition in the 16S rRNA. Nothing is mentioned about heteroplasmy or biochemistry. 
tRNALys 
As has been discussed in chapter III-1, a heteroplasmic A8344G transition in the tRNAL)" 
gene has been demonstrated in several patients with myoclonic epilepsy with ragged red 
fibers (MERRF) (83-99). MERRF is characterized by early-onset myoclonus, seizures, 
severe cerebellar ataxia and tremor, and ragged red fibers in muscle (100). The nucleotide 
at position 8344 is evolutionarily conserved (84). Studies have demonstrated that the 
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A8344G mutation inhibits mitochondrial protein synthesis (101). Approximately 15% of 
wild type mtDNA can maintain translation and enzyme activity in cultured myoblasts at 
near normal levels (101). Results of respiratory chain enzyme assays in MERRF are 
variable (102-104). The percentage of mutant mtDNAs and clinical phenotypes vary 
markedly between maternal relatives, and according to several studies there is a correlati-
on between the amount of mutant mtDNA in muscle and blood and the clinical severity, 
as discussed in Chapter I1I-1 (94,96-98). However, in another study the percentage of 
mutant mtDNA was not directly correlated with the severity of the symptoms or the 
respiratory chain activities (105). The latter study demonstrated that the presence of 
tRNALy* mutation results in an age-related decline of respiratory chain enzyme activities. 
A heteroplasmic T8356C mutation in the tRNAL)" has been reported in a family with 
MERRF and in another one with symptoms of MERRF and MELAS, both associated with 
hyperthyroidism (106,107). In the latter family, the degree of mtDNA heteroplasmy 
seemed to correlate with the severity of the clinical manifestations and/or the biochemical 
features of the mitochondrial disorder. The mutation, which disrupts a highly conserved 
base pair in the tRNA, has never been observed in controls. No biochemical analysis of 
the respiratory chain was performed. 
tRNAG,y 
A heteroplasmic T9997C mutation in tRNAaly was found to be asssociated with maternally 
inherited hypertrophic cardiomyopathy (108). In different family members the degree of 
heteroplasmy correlated with the severity of symptoms. In affected family members the 
mutant mtDNA was always present in a high proportion, but absent in unaffected family 
members and in 22 controls from various etnie groups. In general, the degree of 
heteroplasmy in lymphoblast cultures was found to be correlated with the level of enzyme 
activity of complex III and IV. The T9997C transition affects a position which is highly 
conserved in various organisms and probably causes disruption of hydrogen bonds in the 
region adjacent to the acceptor stem arm of the tRNA molecule. 
tRNA^"^0» 
An A12308G mutation in the tRNAUu(UAa) was identified in a patient with chronic 
intestinal pseudo-obstruction with myopathy and ophthalmoplegia (CIPO) and in a patient 
with CPEO (109). Moreover, the mutations C12246A in the tRNAs"<acU) and A10006G in 
the tRNAa* were found in the patient with CIPO (109). All three mutations occur at 
positions which are highly conserved during evolution. No biochemical analysis of the 
respiratory chain was performed. 
tRNA11' 
Yoon et al. described a case of lethal infantile mitochondrial myopathy (LIMM) with 
severe complex III and IV deficiency in liver, kidney, and muscle with the heteroplasmic 
A15923G mutation in the tRNA11" (110). The mutation was not seen in the patient's 
healthy mother and the mother's healthy identical twin sister. The patient's mother had 
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previously given birth to a male infant who died after 1.5 days and both the mother and 
her twin sister had had multiple miscarriages. The authors further reported that DNA 
analysis of amniocytes obtained from the mother's twin sister revealed no mutation. Also 
the umbilical cord blood was normal, and this child was healthy at birth and remained so 
afterwards. It is likely that the mutation is the cause of the fatal disease, as a highly 
conserved base of the anticodon loop of tRNA11" is altered. The 1S923 mutation was not 
delected in a group of 200 controls. 
In another patient with LIMM, a homoplasmic mutation, A15924G in the tRNA"", was 
found (111). However, Brown et al. observed a high frequency (11%) of the 15924 
mutation in the human population (112), strongly suggesting that this mutation is a 
common mtDNA polymorphism. 
Obayashi et al. sequenced the entire mtDNA of a sporadic patient with hypertrophic 
cardiomyopathy and detected the G15927A mutation in the tRNA11" and 4 additional non-
conserved missense mutations, G8584A in ATPase 6, A12361G and G13477A in ND5, 
A15851G in cytochrome b (71). Moreover, 3 mutations in the rRNA genes were found in 
the mtDNA, the G709A and G1598A mutations in 12S rRNA and the A2065G mutation 
in 16S rRNA. 
Nothing has been reported about the presence of heteroplasmy nor about aberrant 
biochemistry in this patient. 
The mutation A15951G tRNA71" was found associated with the G5821A mutation in the 
tRNA0»' and a 7 kb deletion, as has been discussed under the tRNA^' (71,82). 
tRNA*0 
A mutation in the tRNAPre G15990A resulted in an anticodon alteration (113). The proline 
tRNA anticodon (UGG) was changed to one found in serine tRNA (UGA). The NGG 
anticodon is a hallmark of tRNAPro genes, not only in the mitochondrial genome, but in 
all nuclear or chloroplast tRNA''0 genes described (113). The mutant mtDNA was 
heteroplasmic in muscle of the patient (85% mutant), but was undetectable in white blood 
cells of both the patient and her mother. This tRNA mutation most likely caused severe 
impairment of mitochondrial protein synthesis and oxidative phosphorylation in muscle. 
However, 5-10% of wild type sequences seemed to be sufficient to compensate for the 
deleterious effect of the tRNAPre anticodon mutation at the cellular level. 
POINT MUTATIONS IN RIBOSOMAL RNA 
16S rRNA 
Analysis of the entire mtDNA sequence of a sporadic patient with hypertrophic cardiomy-
opathy revealed a change in a conserved nucleotide in the 16S rRNA, the T1977C 
mutation, as well as two additional non-conserved amino acid changes, G6018A in COI 
and G8581A in ATPase 6 (71). The publication by Obayashi et al. reveals no details on 
the presence of heteroplasmy or biochemical abnormalities in the patient (71). 
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12S rRNA 
The A1555G mutation in the mitochondrial 12S rRNA was found to be associated with 
deafness (114). The mutated nucleotide in the 12S rRNA is in the region known to bind 
aminoglycosides. Mutations in this region give rise to aminoglycoside-resistance in other 
species. The above mentioned deafness is similar to deafness induced by aminoglycosides, 
which is especially prevalent in the Chinese population, where aminoglycosides are a 
frequently used drug. The authors assume that the additional mtDNA mutations found in 
the affected non-syndromic deafness families may participate in reducing oxidative 
phosphorylation below a threshold required for the development of the cochlea (114). The 
A1555G mutation was shared by four affected families, but was not found in 278 
controls. It changes a nucleotide in a highly conserved region of the 12S rRNA. All of 
the family members tested had the pathogenic haplotype, with each mtDNA mutation 
appearing homoplasmic. The presence of unaffected family members with the identical 
mtDNA sequence was ascribed to the absence of homozygosity for a putative autosomal 
recessive mutation (115). 
POINT MUTATIONS IN PROTEIN CODING GENES 
Cytochrome с oxidase 
Our group detected a heteroplasmic T6681C mutation in the gene coding for the first 
subunit of cytochrome с oxidase in muscle of a deceased patient with mitochondrial 
myopathy and cytochrome с oxidase deficiency. The mutation resulted in the exchange of 
a moderately conserved tyrosine by a histidine, and was not found in 30 controls. The 
patient and an affected sister died at five years of age. No tissues for DNA analysis were 
available of the affected sister. We were not able to detect the mutation in fibroblasts of 
the patient, nor in blood of the healthy mother and a third sister of the patient, who was 
also unaffected (unpublished results). 
Two sibs with failure to thrive and severe hyperlactic acidemia, who died at one and two 
months of age, respectively, have been described with a heteroplasmic C7955G mutation 
in the gene coding for the second subunit of cytochrome с oxidase (116). The mutation 
converts a highly conserved proline to an alanine, and was not detected in several 
controls. Biochemical investigation of the respiratory chain enzymes in muscle and 
fibroblasts revealed a deficiency of cytochrome с oxidase activity. 
ATPase 
Two amino acid substitution (missense) mutations have been associated with neurogenic 
muscle weakness, ataxia, and retinitis pigmentosa (NARP) and Leigh's syndrome (1 Π­
Ι 24). A T8993G mutation in the ATPase 6 gene of the mtDNA has been reported in 
NARP and Leigh syndrome, as is discussed in chapter IV-1 (117-124). By direct 
sequencing, we have discovered the heteroplasmic mutation T8993C in the mitochondrial 
ATPase 6 gene in a family with Leigh syndrome (122). In chapter IV-1, the clinical, 
biochemical and genetic background of the family with Leigh syndrome is given (122). 
We were able to study blood of 11 individuals from three generations and could establish 
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a clear correlation between degree of heteroplasmy for the T8993C mutation and the 
manifestations of the disease (unpublished results), similar to that described for the 
T8993G mutation (125). We studied the mitochondrial ATPase 6 and 8 genes in 7 other 
families suspected to suffer from Leigh syndrome, but did not find any mutations by 
sequence analysis (unpublished results). 
According to Tatuch and Robinson (126) the rate of ATP synthesis is lowered in 
lymphoblasts from patients with the T8993G ATPase 6 mutation, but we were not able to 
confirm this finding in muscle from a NARP patient with the T8993G mutation 
(unpublished results). We also found normal ATP production in muscle from a Leigh 
patient, despite high percentage of the T8993C mutation in muscle (127). Another group 
described three pedigrees with the T8993G mutation and reported a complex I defect in 
muscle of several patients and a combined complex I and III defect in muscle of others. 
In this study a patient with 86% mutated mtDNA in muscle and blood had defects in 
complex I and III, whereas his affected brother with 90% mutated mtDNA in muscle and 
blood had an isolated complex I defect. The authors suggest that the enzyme activities 
may be influenced by differences in distribution of mutant mtDNAs in muscle due to 
replicative segregation (127). 
Obayashi et al. reported on a patient with hypertrophic cardiomyopathy, retinitis 
pigmentosa and ataxia, whose entire mtDNA was sequenced (71). Besides the T8993G 
mutation in ATPase 6, this analysis revealed a G709A mutation in 12S rRNA and a 
C9270T mutation in COIII. 
NADH-deh yd rogenase 
Letrit et al. (128) reported a heteroplasmic mutation A11084G in the ND4 gene associated 
with MELAS syndrome in a Caucasian female. The presence of the normal mtDNA 
population could not be demonstrated in the patient's skeletal muscle, but heteroplasmy of 
the mtDNA was clearly seen in her healthy sister. Letrit et al. did not find the mutation 
in 100 controls, and showed conservation of the affected amino acid residues during 
evolution. Although the adenosine at position 11084 is evolutionarily conserved, and the 
amino acid residue was highly invariant in various species, Sakuta et al. showed a high 
incidence (14%) of the A11084G mutation in the Japanese population, strongly suggesting 
that in Japan this substitution is a common mtDNA polymorphism (129). According to the 
authors the A11084G substitution is not responsible for inducing the clinical phenotype 
MELAS. The restriction enzyme test for the A11084G mutation revealed a homoplasmic 
nucleotide exchange in all persons tested. 
Mutations in Leber hereditary optic neuropathy 
As reported in chapter IV-2, many point mutations in the protein coding genes have been 
associated with Leber's hereditary optic neuropathy (LHON) (130-144), a maternally 
inherited form of acute or subacute adult-onset blindness resulting from degeneration of 
the optic nerve (145). Central vision is rapidly lost in both eyes but peripheral vision is 
retained. Blindness frequently occurs in mid-life, with a mean age of onset of about 27 
years, but varying from 6 to 60 years. There is a substantial sex bias, with around 85% 
of affected persons being males. In Japan this percentage was found to be only 60%. 
Affected individuals may also have cardiac conduction defects, behavior abnormalities and 
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in some families, neurological complications. 
The known mtDNA mutations associated with LHON are summarized in Table I. 
The identification of LHON mutations in complex I (ND1, ND2, ND4, ND5 and ND6), 
complex III (cyt b) and complex IV (COI and COIII) genes, as well as the cumulative 
nature of the mutations, has led to the suggestion that the probability of vision loss is 
mainly a function of the extent of dysfunctioning of the electron transport chain, which 
can be caused by a deficiency in any of the respiratory chain enzymes (146). It is known 
that optic atrophy is common after chronic exposure to respiratory inhibitors (146,147). 
The inheritance of a LHON mutation does not inevitably result in vision loss, but only 
increases its probability. Wallace and Lott (148) tried to classify the LHON mutations on 
the basis of their penetrance, that is the risk of blindness they impart. According to them, 
the most severe LHON mutation is the T4160C transition (133,148). This apparently 
homoplasmic mutation, which changes a highly conserved leucine to a proline, is suffi-
cient to cause blindness and results in blindness in about 80% of individuals (both male 
and female) carrying the mutation. It is frequently associated with other neurological 
symptoms and has never been found in controls (148). The next most severe mutations 
are at the G11778A and the G3460A transitions (130,132,148). These mutations account 
for the majority of LHON cases, are sufficient in themselves to cause blindness, change 
conserved amino acids, result in blindness in 20% to 60% of family members, and are 
frequently associated with cardiac conduction defects (130,132,148). The G11778A and 
G3460A transitions can be either heteroplasmic or homoplasmic and have never been 
found in the normal population. The Gl 1778A mutation has been shown to occur on 
multiple mtDNA haplotypes implying repeated new mutations (130,132,148). According 
to Wallace and Lott (148), these mutations are less severe than the T4160C mutation 
because they cause less radical amino acid substitutions, result in a lower percentage of 
affected individuals, and show a fourfold predominance of affected males. The G15257A 
transition is a common cause of LHON (136,138,139). It changes a highly conserved 
amino acid near a heme binding site of cytochrome b, and, in patients who harbor the 
mutation, it is thought to be the major contributor to blindness (136,138,139,148). 
However, according to Wallace and Lott, this transition is less severe than the G11778A 
and G3460A transitions, since only about 22-55% of the maternal relatives that inherit 
this mutation become blind, and most of these are males (147). Moreover, the transition 
is frequently found in association with other LHON mutations and is present in 0.3% of 
the normal population (136,138,139,148). The G9483A and G9804A transitions are hom-
oplasmic, replace highly conserved amino acids and are not found in controls (142). 
However, these mutations have only recently been published in a few unrelated patients 
and nothing is reported yet about the expressivity of both mutations within families (142). 
Finally, the T14484C transition is probably the least severe of the above mentioned 
mutations, since this mutation is associated with a higher incidence of visual recovery 
than the mutations G3460A, G11778A and G15257A (149). The mutation is associated 
with the T3394C and the G13708A transitions (see below) (141), changes a moderately 
conserved amino acid, and is not found in the normal population. The mutations 
mentioned so far appeared to be sufficient by themselves to predispose for the disease. 
On the other hand, several mutations have been reported that are supposed to act 
synergistically to increase or decrease the probability of clinical expression. As such the 
G5244A transition is associated with other putative LHON mutations, but it has several 
characteristics suggestive of a severe mutation (138). Namely, it alters a highly conserved 
amino acid and is heteroplasmic (138,148). The T3394C transition also changes a highly 
conserved amino acid (141). However, only one third of individuals with the mutation, all 
males, become blind, and in the pedigree where this mutation was found, also the 
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G13708A and the T4216C transitions were present (141,148). Moreover, the T3394C 
transition has been observed in 1% of the general population (141,148). The G7444A 
transition is less severe than the T3394C transition, since few individuals who inherit this 
mutation loose their vision. It has been found to be associated with other LHON mutati-
ons and it is present in about 1% of the general population (140,148). The remaining 
mutations T4216C, A4917G, G13708A and G15812A do not appear to be primary causes 
of blindness (135,136,139,148). Instead, they are frequently associated with one of the 
above mutations in LHON pedigrees and probably act synergistically. They involve amino 
acids that are moderately or not conserved, that can be found to some extent in the 
normal population, and that do not appear to cause blindness by themselves. 
The heteroplasmic G11696A transition and the homoplasmic T14596A transversion 
have been described in chapter IV-2 (144). Most probably they act synergistically and are 
not only associated with LHON but also with neurological symptoms. So far they have 
only been described in one LHON family. They are not present in controls, change a 
non-conserved (11696) and a moderately conserved (14596) amino acid, and result in 
blindness in 5 % of the carriers. Except one, all affected patients were male. According to 
the classification criteria of Wallace and Lott (148), the latter two synergistic mutations 
are not very severe LHON mutations. 
QUANTITATIVE DEFECTS OF MITOCHONDRIAL DNA 
Reduction of mtDNA levels 
Certain lethal infantile diseases can result from reduction in the absolute number of 
mtDNA molecules, so-called mtDNA depletion (150). A lack of mtDNA has been 
described by Moraes et al. in infantile (usually fatal) metabolic syndromes and in 
zidovudine-induced myopathies (151). The severe reduction in mtDNA levels will lead to 
impairment of oxidative phosporylation, due to the lack, or drastic reduction, of mito-
chondrially synthesized proteins (151). The etiology of mtDNA depletion remains 
obscure, but the variable tissue expression, as well as the mosaic pattern observed in 
muscle from children with late-onset form suggest that the primary defect may involve 
nuclear genes controlling the copy number of mtDNA during early development (150). 
Morphological studies showed that the reduction in mtDNA levels in muscle was associa-
ted with mitochondrial proliferation (151). 
Reduction of mitochondria 
Genge et al (152) described another metabolic myopathy, distinguishable from the 
mtDNA depletion syndrome, the last one being associated with proliferating mitochondria 
(151). They reported two siblings from unrelated parents with exercise intolerance, severe 
muscle pain and episodic very high serum creatine kinase activity. Both patients showed 
an abnormal decrease of mitochondria in muscle fibers. 
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CONCLUDING REMARKS 
In this chapter it has been shown that numerous mtDNA mutations are linked to human 
disease and that most, but not all, of these mutations are heteroplasmic. 
The large heteroplasmic deletions are usually non-familial and commonly associated with 
PEO, KSS, Pearson syndrome and Wolfram syndrome (1-14). Multiple small deletions 
can be found in families with autosomally dominantly inherited mitochondrial diseases 
(37-44). Moreover, a maternally inherited heteroplasmic deletion has been described in a 
family with diabetes and deafness (36). The correlation between the proportion of deleted 
mtDNA per tissue and clinical severity or biochemical features remains unresolved. 
Maternal inheritance is commonly observed in diseases associated with mtDNA point 
mutations. The long list of point mutations mentioned in this chapter illustrates the rapid 
progress in defining the role of mtDNA point mutations in disease etiology. It is evident 
that some point mutations play a primary role in disease, whereas others play a putative 
secondary role. The results obtained in the patients whose whole mitochondrial genome 
has been sequenced, reveal that several point mutations summarized in Table I are found 
in association with one of the following four mutations; the A1SSSG in the 12S rRNA 
(114), the A3243G mutation in the tRNA1" (70,71), the A4317G in the tRNA1" (71,82), 
or the T8993G mutation in ATPase6 (71). These latter four mutations are located at 
highly conserved positions in the mtDNA, have not been found in controls and segregate 
with the disease. The A155SG mutation is homoplasmic and is associated with deafness in 
three unrelated pedigrees. The authors have sequenced the entire mtDNA of one patient 
and assumed that the mutations found in association with the A1555G mutation, which are 
all homoplasmic, play a contributary role in the disease etiology. The A3243G, A4317G 
and the T8993G mutations have been found in several unrelated patients with mito-
chondrial encephalomyopathies (whose mtDNA has not always been sequenced entirely) 
and are heteroplasmic (58-65,68-71,81,82,117-125). Moreover, the degree of heter-
oplasmy in muscle and blood of the A3243G mutation and of the T8993G mutation has 
been shown to correlate with severity of disease manifestations among different family 
members (64,65,68,125,153-157). Probably, several point mutations found in association 
with the mutations at A3243G, A4317G and T8993G contribute to the disease etiology, 
especially those involving highly conserved positions in the mtDNA and not found in 
controls. 
Furthermore, in Table I some missense mutations are mentioned in association 
with the mutation G15927A in the tRNA""". These mutations, including the G15927A 
mutation itself, involve positions that are not conserved in evolution (71). The authors 
have not looked at heteroplasmy, nor at the incidence of these point mutations in controls. 
It has to be resolved whether these point mutations are involved in disease etiology. 
Finally, some point mutations mentioned in Table I are associated with a deletion in the 
mtDNA. Of these point mutations, the mutations G5821 in tRNA0"" and A15951G in 
tRNA11* involve highly conserved positions in the mtDNA, as discussed in this chapter 
(71,82). The role of these mutations is hard to predict, especially because the mtDNA 
deletion may play a role in the disease etiology as well. Unfortunately, nothing has been 
reported on the presence of heteroplasmy of the mutations, segregation of the mutations 
with disease and incidence of the nucleotide changes in controls. 
For many mitochondrial mutations, however, associations with other changes in 
the mitochondrial genome have not been reported because the mtDNA has not entirely 
been sequenced. Most tRNA mutations fall into this category (see Table I). Striking is the 
high incidence of mutations in the tRNAUu(UU,,) gene, suggesting that this region is an 
etiologic hot spot in mitochondrial disease (74). 
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In general, tRNA mutations are heteroplasmic. We and other groups have demon-
strated that the degree of heteroplasmy is correlated with the clinical phenotype within a 
given family. Higher percentages of mutant mtDNA in muscle and blood of affected 
family members than in the same tissues of less or non-affected relatives could be 
demonstrated for the A3243G mutation (chapter II-1; 64,65,68,153-157), A3252G (73) 
and A3260 (75,76) in the tKSALa"vxm\ the A4269G mutation in the tRNA* (80), the 
A8344G (chapter II-1; 94,96-98) and the T8356C (107) mutations in the tRNAL)". 
Houshmand and coworkers (158) sequenced all tRNA genes in a group of neuromuscular 
patients and found several homoplasmic point mutations. The authors suggested that these 
mutations were not pathogenic, because either they were present in controls, or they 
concerned evolutionarily non-conserved nucleotides. 
Except for LHON, only few missense mutations have been found. In one patient 
we found a heteroplasmic missense mutation in the COI gene in muscle (unpublished 
result). Another group described a missense mutation in the COII gene in two sibs (116). 
Moreover, the T8993G and T8993C mutations have been found (117,122). We and other 
groups were able to demonstrate that the degree of heteroplasmy of the T8993G/C 
mtDNA point mutations correlated with the clinical phenotypes within families with 
NARP and Leigh syndrome (125). 
Furthermore, multiple mutations in different genes are associated with one and the 
same phenotype of LHON (chapter IV-2, VII) (144). Involvement of other factors, i.e. 
nuclear factors, would explain why some family members sharing the same mutation in 
their mtDNA are affected with LHON while others are not. 
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Table I. Point mutations in mtDNA are associated with disease: a 
compilation. 
nucí 
pos 
С 709 А 
S 769 А 
Τ 825 А 
А 851 G 
G 930 А 
С 964 А 
G 1018 А 
А 1041 G 
Τ 1107 С 
А 1555 G 
G 1598 А 
Τ 1822 С 
Τ 1977 С 
А 2065 G 
А 2246 G 
А 2270 С 
А 2706 G 
А 3243 G 
Τ 3250 С 
А 3252 G 
С 3254 Τ 
С 3256 Τ 
А 3260 G 
Τ 3271 С 
А 3302 G 
Τ 3338 С 
Τ 3394 С 
G 3460 А 
het/ AA evoΙ ine clinic 
hom subst cons centг 
biochemical 
defect 
remarks 
-/• 
-/+ 
-/• 
-/• 
-/• 
7 
-Л 
1 
7 
-/+ 
7 
-/• 
12SrRNA 
12SrRNA 
liSrRNA 
12SrRNA 
12SrRNA 
12SrRNA 
12SrRNA 
12SrRNA 
12SrRNA 
12SrRNA 
12SrRNA 
16SrRNA 
16SrRNA ' 
16SrRNA » 
16SrRNA ' 
16SrRNA ? 
16SrRNA ' 
tRNAleu(UUR) •/-
tRNAleu(UUR) +/-
tRNAleu(UUR) */• 
tRNAleu(UUR) 7 
tRNAleu(UUR) •/-
tRNAIeu(UUR) •/-
tRNAIeu(UUR) •/-
tRNAleu(UUR) •/-
N01 ' 
ND1 7 
Η 
L 
Η 
L 
Η 
Η 
L 
H 
V->A L 
Y->H H 
16 
25 
2 
«1 
5 
20 
NARPHC/deafness ND 
0.3 
0.5 
<2 
<1 
<2 
<2 
deafness 
deafness 
deafness 
dea I net* 
HC*DB 
deafness 
HODS 
HC 
deafness 
HC 
deafness 
HC 
HC 
HC 
HELAS 
HELAS 
MELAS etc 
ΜΗ 
MM • OB 
FICM, HC 
MM*LHON+DB 
MHC 
HELAS 
ass 8993G/15927/1555 
associated w A1555G 
associated u A1555G 
associated w A155SG 
associated w A1555G 
associated и A3243G 
associated u A1555G 
associated u A3243G 
complex I*IV associated ы A4317G 
normal in LCL additional mutations 
ND1 -/+ A->T Η <1 
ND associated w G15927A 
ND associated u A1555G 
ND additional mutations 
ND associated ы G15927A 
ND ass ы G5821A/A15951G 
complex I associated и A3243G 
complexl associated u A3243G 
complexI/IV etc many disorders 
complex I 
complex I 
complex 1*IV associated ы A4317G 
complex l+IV 
complex l/HIV -
complex l/IV 
MM complex I abn. RNA processing 
HC»SS*HR»SD ND associated ы A3243G 
HC+DB/LHON ND ass 3243/attriDutive 
LHON ND essential 
references 
71,11* 
114 
114 
114 
114 
71 
114 
71 
71,82 
114 
71 
114 
71 
71 
71 
71 
70 
58,59,68,69 
72 
73 
71,82 
74 
75,76 
77 
79 
71 
71,141 
132,134 
127 
с 
А 
Τ 
Τ 
λ 
А 
G 
A 
A 
G 
A 
Τ 
С 
G 
G 
С 
A 
G 
G 
G 
Τ 
A 
G 
С 
G 
A 
С 
G 
nucl 
pas 
3968 G 
4136 G 
4160 С 
4216 С 
4269 G 
4317 G 
4491 A 
4833 G 
4917 G 
5244 A 
5301 G 
5442 С 
5554 Τ 
5601 A 
5703 A 
5704 Τ 
5811 G 
5821 A 
5824 A 
6018 A 
6681 С 
7129 G 
7444 A 
7476 Τ 
7521 A 
7673 G 
7955 G 
8002 A 
gene 
ND1 
ND1 
N01 
ND1 
tRNAile 
tRNAile 
N02 
N02 
ND2 
N02 
ND2 
ND2 
tRNAtrp 
tRNAala 
tRNAasn 
tRNAasn 
tRNAcys 
tRNAcys 
tRNAcys 
COI 
COI 
COI 
COI 
tRNAser(UCN) 
tRNAasp 
COU 
COU 
COU 
het/ 
hom 
7 
-/• 
-/+ 
-/• 
•Λ 
•/· 
7 
7 
-/• 
•/-
7 
Ί 
7 
7 
•/-
-/• 
-/• 
7 
-/• 
7 
•Λ 
7 
-/• 
-/• 
-ι* 
7 
•/-
1 
ΑΑ 
S übst 
A->G 
Y->C 
ι->» 
Y->H 
-
-
ν->ι 
T->A 
D->N 
G->S 
I->V 
F->L 
-
-
-
-
-
-
-
A->T 
Y->H 
Y->C 
ST->K 
-
-
I->V 
P->» 
0->E 
evol 
cons 
Η 
Η 
Η 
ι 
Η 
и 
ι 
Η 
Η 
Η 
ι 
L 
L 
Η 
Η 
Η 
L 
L 
L 
L 
H 
L 
H 
L 
L 
H 
H 
H 
ine 
eontr 
-
<6 
<6 
7.3 
<3 
<0.5 
-
-
36 
<0.05 
-
• 
-
-
• 
<1 
<1 
• 
<1 
-
<0.3 
-
1 
<1 
16 
-
. 
clinic 
HELAS 
LHON 
LHON 
LHON, HC 
F CM 
FICM, HC 
HC+DB 
HELAS 
LHON 
LHON 
HC 
HC 
KMC, HC 
HELAS 
PEO 
deafness 
HERRF 
HC 
НЕНС 
HC 
MM 
HC 
LHON 
MM 
deafnes9 
HC 
НИ 
HELAS 
biochemical 
defect 
complex 
NO 
NO 
complex 
complex 
complex 
NO 
complex 
NO 
NO 
complex 
complex 
complex 
complex 
complex 
NO 
complex 
NO 
complex 
NO 
complex 
complex 
NO 
complex 
NO 
complex 
complex 
complex 
I 
I+IV 
IV 
HIV 
I 
I + IV 
I + IV 
I + IV 
I 
I + IV 
I + IV 
IV 
IV 
I + IV 
1 + IV 
I + IV 
IV 
I 
remarks 
associated w A3243G 
suppressor of T4160C 
essential 
normal variant 
-
additional mutations 
associated ы A3243G 
associated н A3243G 
attributive 
attributive 
associated w A4317G 
associated w A4317G 
associated w A4317G 
associated ы A3243G 
-
associated u А1555Б 
ass и T12308C/deplet 
ass w 15951+deletion 
-
associated ы. T1977C 
muscle+,fibroblast9-
associated u. A4317G 
attributive 
-
associated w A1555G 
associated u. A4317G 
-
associated w. A3243G 
references 
70 
133 
133 
71,82,135,159 
80 
71,74,82 
71 
70 
135 
138 
71,82 
71,82 
71,82 
70 
74 
114 
158 
71,82 
158 
71 
71,82 
140 
158 
114 
71,82 
116 
70 
128 
nucí 
pos 
A 8308 G 
A 8344 G 
Τ 8356 С 
G B5B1 A 
С 8582 Τ 
G 8584 A 
A 8906 G 
A 8929 G 
A 8938 G 
Τ 8993 G 
Τ 8993 С 
С 9270 Τ 
G 9438 A 
G 9804 A 
Τ 9997 С 
A 10006 G 
G 10143 A 
A 10463 G 
Τ 11025 С 
A 11084 G 
С 11553 G 
G 11696 A 
G 11778 A 
G 11963 A 
G 12236 A 
С 12246 A 
A 12308 G 
A 12361 G 
gene 
tRNAlys 
tRNA lys 
tRNAlys 
ATPasei 
ATPase6 
ATPase6 
ATPase6 
ATPase6 
ATPasen 
ATPase6 
ATPase6 
COI M 
COIII 
COIII 
tRNAgly 
tRNAgly 
ND3 
tRNAarg 
N04 
N04 
ND4 
N04 
ND4 
N04 
tRNAser(AGY) 
tRNAser(GCU) 
tRNAIeu(UAG) 
ND5 
het/ AA evol ine clinic 
hom subst cons contr 
biochemical 
defect 
7 
•/-
•/-
L 
H 
И 
A->T L 
A->T L 
A->T L 
H->R H 
T->A L 
I->V H 
• /- L->R H 
•/- T->P H 
7 L->F L 
-/• C->S H 
-/• A->T H 
•/- · H 
-/• - N 
-/• G->S L 
-/+ - H 
-/• 1->P H 
•/- T->A H 
7 S->C H 
•/- V->I L 
•/• R->H H 
•> V->1 ι 
-/• - M 
-/• - H 
•/• - H 
' T->A L 
HC+SS+MR+SD 
<0.5 HERRF/CPEO/И variable 
MERRf-MELAS 
remarks 
associated u. A3243G 
HC 
deafness 
HC 
ND 
ND 
ND 
HC+SS+MR+SO ND 
MELAS complex I 
<0.2 
<0.2 
<4 
1 
SX 
<1 
<1 
<1 
<0.2 
MELAS 
NARP/Leigh 
Leigh 
HC*RP+ataxia ND 
LHON ND 
complex I 
variable 
normal 
associated н. Т1977С 
associated w A1555G 
associated u G15927A 
associated u. A3243G 
associated Ы. A3243G 
associated u. A3243G 
additional mutations 
LHON 
HC 
CIPO 
deafness 
LA/CPEO 
deafness 
MELAS 
MELAS 
associated ы. T8993G 
essential 
ND essential 
complex IV, III -
NO ass A10006G/C12246A 
ND associated w A1555G 
complex I+IV associated w G15928A 
ND 
N0 
complex I 
LHON+neurol ND 
LHON 
HODS 
deafness 
CIPO 
complex 
ND 
ND 
ND 
associated w A1555G 
polymorphism Japan 
associated w. A3243G 
associated u T14596A 
essential 
associated H. A3243G 
associated u A1S55G 
ass A10006G/A12308G 
CIPO.CPEO/MERRF ND/complex l+IV additional mutations 
HC ND associated w G15927A 
129 
references 
71 
84 
106,107 
71 
114 
71 
71 
71 
70 
71,117-124 
122 
71 
142 
142 
108 
109 
114 
158 
114 
128,129 
70 
144 
130 
71 
114 
109 
109,158 
71 
nucí 
pos 
A 12950 G 
A 13105 G 
A 13258 Τ 
G 13477 λ 
G 13708 A 
Τ 14180 С 
Τ 14484 С 
Τ 14596 А 
Τ 14679 С 
А 14927 G 
G 15257 A 
G 15737 A 
G 15812 A 
A 15851 G 
G 15884 A 
С 15904 Τ 
A 15907 G 
A 15923 G 
A 15924 G 
G 15927 A 
G 15928 A 
A 15951 G 
G 15990 A 
С 16193 Τ 
gene 
ND5 
ND5 
ND5 
N05 
ND5 
ND6 
ND6 
ND6 
tRNAglu 
cyt b 
cyt b 
cyt b 
cyt b 
cyt b 
cyt b 
tRNAthr 
tRNAthr 
tRNAthr 
tRNAthr 
tRNAthr 
tRNAthr 
tRNAthr 
tRNApro 
D-loop 
het/ AA «vol ine clinic 
hom subst cons contr 
-/• N->S H 
-/+ l->V N 
7 S->C H 
7 A->T I 
-/• A->T H 
7 Y->C L 
7 H->V M 
-/• 1->И И 
-/• · L 
7 T->A H 
-Л D->N H 
' 0->N L 
-/• V->M H 
7 l->V L 
-/• A->I I 
-/• 
-/• 
•/-
• / • 
7 
-/• 
7 
+/-
<1 deafness 
10 deafness 
HC 
HC 
4.2 LHON 
HC 
<0.4 LHON 
LHON+neurol 
<1 нм 
HC 
0.3 LHON 
HC 
0.1 LHON 
HC 
3 deafness 
5% MERRF 
2% HELAS 
<0.4 LIHM 
Ш LIHM 
HC 
SX LA/CPEO 
HC 
НИ 
<10X HELAS 
biochemical 
defect 
N0 
NO 
ND 
ND 
NO 
ND 
ND 
ND 
complex I + IV 
complex I+IV 
ND 
complex I + IV 
NO 
ND 
ND 
complex I+IV 
complex I+IV 
complex III+IV 
NO 
ND 
complex I+IV 
ND 
complex IV 
complex 1 
remarks 
associated ы A15S5G 
associated u A1555G 
ass H G5821A/A15951G 
associated u G15927A 
attributive 
ass u G5821A/A1S951G 
essential 
associated ы G11696G 
associated и T12308C 
associated ы. A4317G 
essential 
associated w. A4317G 
attributive 
associated u G15927A 
associated ы A1555G 
associated w AB344G 
associated и A3243G 
polymorphism 
associated н A10463G 
ass u 5821+132S8+del 
85X iiuscle/OX blood 
associated u. A3243G 
references 
114 
114 
71 
71 
136,139 
71 
141 
144 
158 
71,82 
136,138,139 
71,82 
136,139 
71 
114 
158 
158 
no 
111,112 
71 
158 
71,82 
113 
70 
130 
Legend to table I. 
nucí pos •= nucleotide change and position 
bet/hom = heteroplasmy/homoplasmy 
AA subst = amino acid substitution 
evol cons ™ evolutionarily conserved position 
conservation: L=low (human to bovine), M = moderate (human to mouse), 
H=high (human lo Xenopus) 
incidence in controls (expressed in %) 
associated with 
chronic intestinal pseudo-obstruction with myopathy and ophthalmoplegia 
chronic progressive external ophthalmoplegia 
diabetes mellitus 
fatal cardiomyopathy 
fatal infantile cardiomyopathy 
hypertrophic cardiomyopathy 
lymphoblastoid cell lines 
Leber hereditary optic neuropathy 
myopathy 
mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like 
episodes 
MERRF = myoclonic epilepsy and ragged red fibers 
MEMC = mitochondrial encephalomyopathy cardiomyopathy 
MM = mitochondrial myopathy 
MMC «• mitochondrial myopathy cardiomyopathy 
MR = mental retardation 
NARP = neurogenic muscle weakness, ataxia, and retinitus pigmentosa 
ND = not done 
RP = retinitis pigmentosa 
SD = sensorineural deafness 
SS = short stature 
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CHAPTER Vili 
General discussion 
Part of this chapter will be published in Clinical Neurology and 
Neurosurgery as an invited review. 

GENERAL DISCUSSION 
MOLECULAR BASIS OF MITOCHONDRIAL DISORDERS 
Neuromuscular diseases with mitochondrial involvement show high clinical and 
biochemical heterogeneity. This is most likely a reflection of the complex molecular basis 
of mitochondrial (encephalo)myopathies, since the primary pathogenic causes can vary 
from : 
1. a mutation in one or more of the mitochondrial DNA (mtDNA) encoding genes; 
2. a mutation in a nuclear encoded gene coding for one of the subunits of the 
complexes involved in the oxidative phosphorylation; 
3. a defect in (the regulation of) replication, transcription or translation of mtDNA; 
4. a defect in protein import or metabolite transport into mitochondria; 
5. a defect in the assembly of the enzyme complexes of the oxidative 
phosphorylation; 
6. a defect in the structure and/or composition of the inner membrane, where the 
enzyme complexes of the oxidative phosphorylation are located. 
Besides the above mentioned primary mitochondrial defects, numerous secondary causes 
of mitochondrial dysfunction are known, such as defects in circulation, malnutrition, 
defects of hormones and neurotransmitters, viral infections and poisoning. 
The aim of this thesis was to improve the diagnosis of mitochondrial disorders by 
studying the mtDNA from a large group of patients with neuromuscular disorders with 
possible mitochondrial involvement. Furthermore, we have studied the relation between 
respiratory chain defects and mtDNA mutations and the relation between clinical 
symptoms and mtDNA mutations. 
MITOCHONDRIAL DNA INVESTIGATIONS IN PATIENTS WITH 
MITOCIIONDRIOPATHIES 
Role of mtDNA analysis ¡n diagnostics 
Defects of cellular respiration are particularly poorly tolerated by organs that consume 
much energy. In decreasing order of vulnerability these organ systems include retina, 
optic nerve, brain, skeletal muscle, heart, kidney, and liver (1,2). If the mtDNA defect 
was uniformly distributed throughout the body in all organ systems, one would expect to 
see the above mentioned pattern of organ involvement. There are various other factors, 
however, which influence organ involvement such as replicative segregation, 
heteroplasmy, additional mutations in mtDNA and nuclear DNA and nuclear genetic 
background. Still, brain and skeletal muscle are particularly vulnerable to mtDNA 
defects. In progressive external ophthalmoplegia (PEO), for example, deletions have 
exclusively been detected in muscle. This is why for mtDNA analysis muscle biopsies are 
preferred. For most mtDNA mutations, however, blood can also be used for diagnostic 
aims. The mtDNA from approximately 500 patients with neuromuscular disorders with 
possible mitochondrial involvement was studied by us for the presence of large deletions, 
depletion and point mutations at nucleotide positions 3243, 3271, 4317, 8344, 8356 and 
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8993. In 80 (16 %) out of approximately 500 unrelated patients, we found a defect in 
mtDNA. Given the small part of the total sequence of 16569 basepairs screened, this 
illustrates that a substantial proportion of mtDNA defects can be detected by means of 
mtDNA diagnostics in patients with mitochondriopathies. 
Relationship between mtDNA mutations and biochemical abnormalities 
In one of the first papers about human mitochondrial disorders Holt et al. (3) reported 
about deletions in the mitochondrial genome frequently associated with respiratory chain 
enzyme deficiencies. We have studied the relation between mutations in the mtDNA and 
the activities of the enzymes involved in the oxidative phosphorylation. 
Firstly, the relation between the mutations, found in the mtDNA investigations in our 
laboratory, and the associated biochemical findings will be discussed. Of the 80 patients 
and their families with a mitochondrial DNA defect mentioned above, 31 were examined 
biochemically in Nijmegen. The results of the investigations in these families are 
summarized below. 
Muscle from 10 patients showed a deletion. Six patients suffered from PEO, 2 
patients from the Keams Say re syndrome (KSS), 1 patient had Pearson marrow and 
pancreas syndrome (chapter II) and 1 patient was diagnosed with non-specified 
mitochondrial myopathy. In 7 of these patients the mitochondrial energy metabolism 
showed normal substrate oxidation rates in vitro, 1 showed reduced oxidative capacity of 
unknown origin, one had a complex I defect and another one showed a complex IV 
defect. 
Muscle from 10 other patients showed the A3243G mutation, 8 with features of 
the MELAS syndrome (chapter III) and 2 with a non-specified mitochondrial myopathy. 
Two patients did not have a disturbed energy metabolism in their muscle mitochondria. In 
the other 8 patients a (localized or non-localized) defect in different parts of the 
respiratory chain was observed. From the latter group of patients, one patient showed a 
pyruvate dehydrogenase deficiency and a slightly decreased complex III activity. 
A patient with neuropathy, ataxia and retinitis pigmentosa (NARP) had the T8993G 
mutation and a patient with Leigh syndrome had the T8993C mutation. In both patients, 
energy metabolism in their muscle mitochondria was not disturbed. 
In 9 patients the mtDNA was more or less depleted. Three of them showed 
normal mitochondrial energy metabolism, 4 patients had overall decreased mitochondrial 
activities, 1 patient showed a non-localized defect in the respiratory chain and another 
patient showed a complex I defect in muscle. 
These results underline that there is no reliable relation between respiratory chain 
enzyme deficiency and mtDNA mutation in most patients, as has already been discussed 
in the chapters II-VII. It can be concluded that mtDNA analysis and biochemical analysis 
of the oxidative phosphorylation are complementary to one another in the diagnosis of 
mitochondrial disorders (chapter VI-1; 4), see also below. 
Secondly, we studied whether a respiratory chain defect of a single enzyme complex was 
associated with a mutation in one of the genes of the mtDNA, coding for subunits of this 
enzyme complex. As has been discussed in chapter VI-2, sequence analysis of the 
complex I genes of 7 patients with a complex I deficiency revealed no abnormalities (5). 
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Sequence analysis in 9 patients with a complex IV deficiency revealed a heteroplasmic 
missense mutation in the gene coding for the first subunit of complex IV in muscle from 
one patient (chapter VII). We have found no abnormalities in the remaining 8 cases 
(unpublished results). All patients selected were negative for large deletions and the 
A3243G, the T3271C, the A4317G, the T8356C and the T8993G/C point mutations. The 
investigations revealed that in the majority of patients with a mitochondrial disorder a 
single enzyme defect is not directly linked to a defect in one of the mitochondrial genes 
coding for the enzyme complex (chapters VI-2 and VII). 
On the other hand, single enzyme complex deficiencies are frequently associated 
with a defect in one of the tRNA genes (chapter ΠΙ-2, VI-1, VII) (6-14), while we had 
expected that tRNA mutations would affect all respiratory chain complexes containing 
mitochondrially encoded subunits. To further complicate the picture, the same tRNA 
mutation associated with a single enzyme defect in one patient, has been associated with 
different enzyme deficiencies in other patients, while in other carriers of this mutation no 
enzyme deficiency has been observed (Table I, chapter VII) (2,8,9,15-20). 
Because specific mitochondrial enzyme complex deficiencies are associated with 
tRNA mutations, and disease associated tRNA mutations are frequently found, the 
mitochondrial tRNA genes in the above mentioned patient groups are currently under 
study. Of course, the nuclear genes coding for the subunits of the complexes involved in 
oxidative phosphorylation should also be studied. 
Relationship between clinical manifestations and mtDNA defect 
Mitochondrial DNA mutations can yield a variety of clinical manifestations, as has 
already been discussed in chapter II-2, II-3 and VII. Within families with a mitochondrial 
disorder the degree of heteroplasmy of the mtDNA point mutations A3243G (chapter III-
1) (6,21-27), A4269G (7), T8356C (28), A8344G (chapter III-l) (29-32) and T8993G 
(chapter VII) (33) in muscle and blood correlated roughly with the clinical phenotypes. 
The same mtDNA mutation has been associated with different clinical syndromes 
in different families. For instance, the A3243G mutation has been demonstrated in 
families with PEO, MELAS, and diabetes mellitus with deafness (22,34,35). The A8344G 
mutation has been associated with MERRF and PEO, the T8356C with MERRF as well 
as with MERRF-MELAS syndrome and the T8993G mutation with NARP and with Leigh 
syndrome (36-40). As suggested in chapter ΠΙ-2, it is not unlikely that the diseases 
associated with the same mtDNA mutation are all manifestations of one and the same 
syndrome. In families with clinical MELAS syndrome family members have been 
described suffering from PEO and diabetes with deafness (21). Similarly, it is not 
unlikely that NARP is a milder phenotype of Leigh syndrome (22). 
Conversely, different mtDNA mutations may be associated with the same 
phenotype (see Table I of chapter VII). This phenomenon has already been demonstrated 
in Leigh syndrome (chapters IV-1 and VII) and in Leber hereditary optic neuropathy 
(chapters IV-2 and VII) (22,34,35). Hypertrophic cardiomyopathy (HC) is associated with 
3 different mutations at highly conserved positions in different tRNAs (15,41) (see Table 
I in chapter VII). In 2 other patients 2 different clusters of tRNA mutations at highly 
conserved positions have been reported in association with HC (15,41). One of the 
mutations in HC is also found in a patient with fatal cardiomyopathy (FCM) (42). 
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Furthermore, FCM is associated with 4 other mutations in the tRNA for leucine and 
isoleucine, 3 of which are situated at highly conserved positions (15,41). Two of these 
mutations in the tRNALiU(l'UR) have also been associated with other clinical manifestations; 
i.e. the mutation at position 3260 with mitochondrial myopathy and cardiomyopathy 
(2,13), and the mutation at position 3271 with MELAS (43). MERRF has been associated 
with two tRNAL>" mutations, namely at position 8344 and 8356 (39,44). 
One can hypothesize that the different clinical expression of the above mentioned 
mtDNA mutations is in part the result of the presence of heteroplasmy and the pheno-
menon of replicative segregation. But also the influence of possible additional mutations 
in mtDNA and the difference in nuclear genetic background between unrelated patients 
has to be taken into consideration. 
Relationship between mtDNA mutations and muscle morphology 
Moraes et al. (45) noted that muscle fibers with massive mitochondrial proliferations, 
called ragged red fibers (RRF), are observed in patients with mtDNA deletions that 
include tRNA or rRNA genes, mtDNA point mutations in tRNA genes, and mtDNA 
depletions. On the other hand, mutations in protein coding genes, such as those observed 
in LHON, or NARP and Leigh syndrome are not associated with RRF. They concluded 
that RRF is due to impairment of mitochondrial protein synthesis in skeletal muscle. 
GENETIC COUNSELING 
The advances in mtDNA studies in human pathology have implications for genetic 
counseling of families with mtDNA associated disorders. The large single deletions 
reported in patients with PEO, KSS and Pearson syndrome are sporadic (3,46-48). 
Therefore, detection of a mtDNA deletion in the patient is of importance for genetic 
counseling of the family. Still, caution should be exercised in genetic counseling of 
deletions in other families than PEO, KSS and Pearson syndrome, since recently a 
maternally inherited deletion has been found in a family with diabetes and deafness (49). 
In the case of multiple deletions autosomal dominant inheritance has been demonstrated 
for all cases (50). Linkage studies to elucidate the nuclear factor involved in the 
autosomal dominantly inherited deletions will be necessary for genetic counseling of the 
families involved. 
In several patients and their family members point mutations in the mtDNA have 
been detected, as has been discussed in chapter VII. Variation in the degree of heteroplas-
my of the mtDNA point mutations is found in different tissues from one person. 
Moreover, enormous variation in the degree of heteroplasmy in muscle and blood have 
been demonstrated in maternal relatives, as has been described in chapter III-l (6). This 
last phenomenon underlines the difficulty of genetic counseling of families with diseases 
associated with a mtDNA point mutation. 
It is evident that there is no recurrence risk of the maternally inherited and 
sporadic mtDNA mutations in paternal lineages of affected families. Sporadic deletions 
neither imply a recurrence risk in the maternal lineage. The degree of heteroplasmy of the 
A8344G tRNALr' mutations in muscle is as abundant as in blood (22). Larsson et al. (51) 
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studied the segregation and manifestation of the A8344G mutation in the tRNA11" 
issociated with MERRF syndrome. These studies revealed that the risk for transmission 
Df mutated mtDNA to the offspring increases if high levels are present in the mother and 
chat, above a threshold level of 33-40% in blood, it is very likely that transmission will 
Dccur to all children. The segregation and manifestation of the A3243G mutation in the 
LRNAUu<uw,) in blood was studied as well, but the recurrence risk could not be predicted 
from these studies in blood (52). Since the degree of heteroplasmy of the A3243G 
mutation in the tRNALa>(UUR> in muscle is higher as in blood (6,22,23), it is important to 
test muscle for the presence of a mtDNA mutation in unaffected maternal relatives from a 
patient carrying this mutation. 
PRENATAL DIAGNOSIS 
So far, only few studies reported of prenatal detection of a mtDNA mutation (18,53). 
Because of the high degree of heteroplasmy of the T8993G mutation associated with 
NARP in chorionic villi, the pregnancy was interrupted (53). Study of the degree of 
heteroplasmy in a variety of fetal tissues revealed a high percentage of mutant mtDNA in 
all tissues examined. Another group (18) excluded the presence of the A15923G mutation 
associated with lethal infantile mitochondrial myopathy in amniocytes and umbilical cord 
blood of a sib as has been discussed in chapter VII. 
Prenatal diagnosis of mitochondrial disorders associated with point mutations has 
not as yet been performed in our laboratory, since we do not know whether observations 
in the chorionic villi sample can be extrapolated to the mtDNA status of other tissues. 
Our knowledge concerning the proportion of mutant mtDNA, its relationship to disease 
severity, possible changes during fetal and postnatal development and its tissue 
distribution is incomplete. Prenatal diagnosis might be considered in those cases in which 
a very informative family with a severe neurological disease shows a straightforward 
relation between the proportion of the mtDNA mutation in various tissues and the clinical 
phenotype. Currently, the predictive value of prenatal diagnosis is questionable and more 
studies are needed. 
DEGENERATIVE DISORDERS AND AGING 
Because mitochondrial disorders frequently exhibit a degenerative course, many groups 
are now studying the mtDNA also in adult onset diabetes, heart disease, Alzheimer 
disease, and Parkinson disease (54-57). Moreover, a great number of reports about the 
association of aging and mtDNA defects have been published the last two years (54-57). 
It has been hypothesized that accumulations of mutations in somatic cells could contribute 
to the aging phenomenon. Nevertheless, it is unclear yet whether the levels of mutated 
mtDNA (approximately 0.\%-\% of total mtDNA) contribute to the progress of age-
related degenerative diseases, and to what extent. 
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FUTURE STUDIES 
The information on treatment of mitochondrial disorders results from single case reports 
or uncontrolled series in which a variety of vitamins and cofactors have been used. 
Unfortunately, only few advances in treatment have been made so far (58). A 
classification of mitochondriopathies on the basis of mtDNA mutation might be promising 
for a better diagnosis of patients and new advances in treatment. 
Besides insight into many clinical syndromes, the reports of mtDNA alterations 
associated with human pathology will add to our understanding of the mtDNA structure 
and function. As such, the A3243G tRNA^"*"1"0 point mutation, which is exactly located 
at the termination site of human mtDNA rRNA transcription (59), permitted a direct test 
for the effect of the mutation on termination of transcription of mtDNA. 
As has been discussed in chapter VI-2 (5), recently Rho° cell lines have been 
used to introduce patient's mitochondria into a mitochondrial DNA-free recipient cell 
(60,61). One important goal of this method is to discriminate between the nuclear and 
mitochondrial genetic origin of the mitochondriopathy. This system may be very useful in 
the prescreening of nuclear or mitochondrially caused respiratory chain deficiencies. 
During the application of the Rho° cell technique on known mutations, shifts in the 
degree of heteroplasmy have been observed during the culturing conditions (10,62-64). As 
a result, the effect of different amounts of heteroplasmy of the mtDNA mutation on the 
oxidative phosphorylation and enzyme activities can be studied in more detail. 
For several tRNA mutations is described that approximately 5-15% wild type 
sequences are sufficient to compensate for the deleterious effect of the mutant population 
at the cellular level. These "protective" wild type percentages have been described for the 
point mutations at positions 3243 in the tRNALni<uuw and 8344 in the tRNAL)" in the Rhoe 
cell system (64-66). Similar amounts of "protective" wild type percentages have been 
demonstrated by histochemical and immunohistochemical studies on single muscle fibers 
of patients; i.e. for the point mutations at positions 3243 and 3256 in the tRNALei(UUR) 
(45,64,65), 5703 in the tRNAAso (45), 8344 in the tRNA1-" (66) and 15990 in the tRNA"40 
(67). On the other hand, the results from the Rho" cell system, which is a homogeneous 
cell population, do not always reflect the situation in a whole muscle specimen. For 
instance, quantification of the degree of heteroplasmy of 3243 mutation in muscle 
specimens from MELAS patients can yield a range of 50% to 95% mutant mtDNA (10). 
Up to 9 point mutations have now been described at different locations in the tRNAUu(UU,° 
associated with different clinical phenotypes and biochemical abnormalities (chapter VII). 
The Rho" cell system could be applied to study the effect of different mutations in the 
tRNALn,(UUR) in the presence of the same nuclear background. However, in this system the 
influence of additional mutations associated with the various tRNALeu(UUR) mutations can 
not be ruled out. To elucidate the effect of mutations at different locations in the same 
tRNA, site directed mutagenesis experiments in prokaryotes might provide an elegant 
model. Similarly, a mutation was introduced in the ATP synthase from Escherichia coli to 
serve as a model for the disease mutation described in NARP and Leigh syndrome (68). 
This work established that it is possible to study mutations of the human oxidative 
phosphorylation pathway in a bacterial system. These and other techniques will deepen 
our insight into the role of mtDNA in health and diseases. 
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CHAPTER IX 
Summary 

SUMMARY 
The studies reported in this thesis were performed to improve the diagnosis of neuromus­
cular disorders with mitochondrial involvement and to increase our understanding of the 
molecular basis of these disorders. More specifically, we investigated the relation between 
respiratory chain defects and mutations of mitochondrial DNA (mtDNA). 
Neuromuscular disorders comprise diverse clinical types. Our interest was focussed on the 
group of neuromuscular disorders associated with structurally or functionally abnormal 
mitochondria in various tissues, but specially affecting muscle and brain. These organs 
are more prone to be affected probably because of the high dependence of these tissues on 
oxidative metabolism. 
In the introduction (chapter I) features concerning the structure and functioning of 
mitochondria and mtDNA have been described. Mitochondria are the major source of 
energy in all mammalian cells. They contain a unique genome that is maternally inherited. 
Mitochondrial DNA is a 16569-base pair, double-stranded, circular molecule that encodes 
22 transfer RNAs, 2 ribosomal RNAs and 13 proteins of the oxidative phosphorylation: 7 
subunits of complex I, 1 of complex III, 3 of complex IV and 2 of complex V. These 
subunits are synthesized within the mitochondrion where they are assembled together with 
their nuclear counterparts, which are encoded by nuclear DNA, synthesized in the 
cytoplasm and transported into the mitochondria. 
The results of mtDNA mutation analysis in various patients with neuromuscular diseases 
with mitochondrial involvement are presented in the chapters П- І. In these chapters 
particular mtDNA mutations are described, which were discovered in our laboratory. In 
chapter II the myopathologic symptoms and mtDNA deletion of a patient with the Pearson 
marrow and pancreas syndrome is described in more detail. We were able to demonstrate 
the de novo deletion in all tissues of the patient tested. The degree of heteroplasmy 
differed in the various tissues studied and did not correlate with clinical tissue involve­
ment. 
In chapter Ш-1, we present the presence of the heteroplasmic tRNALy' A8344G 
mutation in a family, which had been previously described as suffering from X-linked 
myoclonus epilepsy. Maternal inheritance could be demonstrated in this family instead of 
the supposed X-linked pattern of inheritance. Two families with variable clinical 
expression of MELAS syndrome associated with the tRNALEU(UUR) A3243G mutation are 
presented in chapter III-2 and III-3. In chapter III-l and III-2 it has been demonstrated 
that the degree of severity of both disorders in the different family members is reflected 
in the relative quantity of mutated mtDNA in muscle and blood. 
In chapter IV-1 the clinical, biochemical and genetic background of Leigh 
syndrome is discussed. By direct sequencing, we have discovered a novel heteroplasmic 
mutation at nucleotide 8993 in the mitochondrial ATPase 6 gene. Maternal inheritance 
was demonstrated in this family, previously described with the autosomal recessive 
juvenile type of Leigh syndrome. In chapter IV-2 we present the results of mtDNA 
investigations in the protein coding genes for the subunits of complex I of the respiratory 
chain in a large Dutch family with LHON and spastic dystonia. We demonstrated the 
presence of two hitherto unknown mtDNA mutations; i.e. the heteroplasmic A11696G 
mutation in the ND4 gene and the homoplasmic T14596A mutation in the ND6 gene. We 
applied a novel analytical approach to quantitate the degree of heteroplasmy of the 
A11696G mutation, and found overall low amounts of wild-type mtDNA in the affected 
155 
and unaffected family members. No obvious correlation was found between clinical 
phenotypes in the family and degree of heteroplasmy in blood. 
In chapter V we described a patient with benign mitochondrial myopathy and 
NADH dehydrogenase deficiency in muscle. We demonstrated a 9-basepair insertion in 
the intervening region between two genes, the importance of which is still questionable. 
Since deficiencies of various enzymes related to energy metabolism in mitochondria were 
shown to be involved in neuromuscular disorders, enzymological and DNA investigations 
have been compared (chapter VI-1). We evaluated mtDNA analysis performed in 66 
patients with clinical symptoms and/or clinical-chemical abnormalities indicative for a 
mitochondrial disorder, and whose muscle has been examined biochemically. This study 
revealed that mtDNA analysis and enzymological examination are rather complementary 
to one another than overlapping in the diagnosis of mitochondrial disorders. Although the 
pathophysiological significance of abnormalities in the mtDNA is not always 
unambiguous, mtDNA analysis combined with extensive biochemical investigations will 
significantly contribute to the diagnosis in patients with suspected mitochondrial disorders. 
In chapter VI-2 the clinical, biochemical and genetic findings of eight patients with a 
NADH dehydrogenase deficiency in muscle are discussed. Since no pathological 
mutations in the mitochondrial NADH dehydrogenase genes were found, we concluded 
that mutations in the coding regions of the mitochondrial genes for complex I are not a 
frequent cause for complex I deficiency. 
Chapter VII gives an update of all mtDNA mutations described in the literature up 
to now, illustrating the enormous number of mtDNA mutations with a possible 
involvement in the etiology of mitochondrial disease. The role of mtDNA investigations 
in relation with clinical and biochemical studies is emphasized in the general discussion 
(chapter VIII). In conclusion, the relationship between clinical manifestations, biochemical 
abnormalities and mtDNA mutations is not always straightforward. Moreover, the 
importance of mtDNA studies in post- and prenatal diagnostics is evaluated. For genetic 
counseling of affected families the pattern of inheritance of the mutation is important. 
There is no recurrence risk of the maternally inherited and sporadic mtDNA mutations in 
paternal lineages of affected families. Sporadic deletions neither imply a recurrence risk 
in the maternal lineage. Currently, the predictive value of prenatal diagnosis of 
mitochondrial disorders associated with point mutations is questionable and more studies 
are needed. Finally, some future studies to further elucidate the role of mtDNA mutations 
in disease etiology are discussed. 
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SAMENVATTING 
Het onderzoek beschreven in dit proefschrift bevat de resultaten van moleculair 
biologische studies aan patiënten met een neuromusculaire aandoening, al dan niet 
gepaard gaande met een defect van de mitochondriën. Dit defect kan inhouden een 
morfologische afwijking van de mitochondriën, een afwijkend aantal mitochondriën, en/of 
een mitochondriëel enzymdefect. In het bijzonder werd de relatie tussen defecten in de 
enzymcomplexen van de ademhalingsketen en mutaties in het mitochondriële genoom 
bestudeerd. Deze studies maken het mogelijk tot een betere diagnose van patiënten met 
een metabole stofwisselingsstoomis te komen. Hierdoor kan de erfelijkheidsadvisering 
verbeterd worden en meer inzicht worden verkregen in het pathogenetische mechanisme 
van de metabole stoornis. 
Jonge kinderen met een zogenaamde "mitochondriopathie" vertonen dikwijls 
hypotonie en spierzwakte. Bij volwassenen is progressieve inspanningsintolerantie veelal 
een belangrijk klinisch symptoom. De klinische expressie is echter zeer heterogeen. 
Metabole screening levert bij een deel van de patiënten een belangrijke diagnostische 
bijdrage, bijvoorbeeld lactaat meting in serum of liquor. Provocatie-testen tonen bij een 
ander deel van de patiënten een verminderde in vivo capaciteit van de mitochondriën aan. 
Te denken valt aan de orale glucose tolerantie test en inspanningstesten. Een spierbiopsie 
is echter veelal noodzakelijk om via morfologisch, biochemisch en moleculair-biologisch 
onderzoek tot een diagnose te komen. Therapeutische mogelijkheden zijn nog zeer 
beperkt. In sommige gevallen kan via een aangepaste samenstelling van de voeding of het 
supplementeren van farmacologische hoeveelheden van precursors van cofaktoren 
(vitamines) succes bereikt worden. 
Onderzoek gedurende de laatstse decennia heeft uitgewezen dat met name te lage 
aktiviteit van enzymcomplexen uit de ademhalingsketen verantwoordelijk zijn voor de 
symptomen bij mitochondriopathiën. Vooral defekten van complex I (= NADH 
dehydrogenase) en complex IV (= cytochroom с oxydase) blijken relatief vaak voor te 
komen. Naast enkelvoudige worden frequent multipele defekten in mitochondriële 
enzymen gevonden. Het enzymdefekt kan in verscheidene weefsels tot expressie komen. 
Multidisciplinair onderzoek heeft aangetoond dat niet alle patiënten met een bepaalde 
klinische entiteit hetzelfde enzymdefekt bezitten. Omgekeerd kunnen patiënten met een 
bepaald enzymdefekt tot verschillende klinische entiteiten behoren. 
In 1988 werden voor het eerst mutaties in het mitochondriële DNA (mtDNA) van 
patiënten met mitochondriopathiën in de literatuur beschreven. Deze bevindingen waren 
aanleiding tot de start van moleculair genetische onderzoek aan mitochondriopathiën in 
Nijmegen en heeft geleid tot de totstandkoming van dit proefschrift. 
In de introductie (hoofdstuk I) wordt de structuur en het functioneren van mitochondriën 
en het daarin aanwezige DNA (mtDNA) beschreven. Mitochondriën zijn belangrijke 
energie-producenten in onze cellen. Ze bezitten DNA molekulen, die matemaal 
overerven. Het mtDNA van de mens is 16569-baseparen lang, dubbelstrengs en circulair. 
Het mtDNA codeert voor 22 transfer RNA genen, 2 ribosomale RNA genen en 13 
eiwitten van de oxydatieve phosphorylering: 7 eenheden van complex I, 1 van complex 
III, 3 van complex IV en 2 van complex V. Deze eenheden worden gesynthethiseerd in 
het mitochondrion, alwaar ze geassembleerd worden met kem gecodeerde eenheden, die 
in het cytoplasma zijn gesynthetiseerd en daarna in de mitochondriën geïmporteerd zijn. 
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In de hoofdstukken II-VI worden de resultaten beschreven van het onderzoek naar 
mutaties in het mtDNA van verscheidene soorten patiënten met mitochondriopathiën. De 
verschillende mutaties die in ons laboratorium gevonden werden zijn in deze hoofdstukken 
ondergebracht. 
In hoofdstuk II wordt de kliniek, de spier-pathologie en een deletie in het mtDNA van een 
patiënt met het syndroom van Pearson in detail beschreven. Een de novo ontstane deletie 
werd aangetoond in alle onderzochte weefsels van het 16 maanden oude patientje. 
Heteroplasmie, de aanwezigheid van gemuteerd mtDNA naast normaal mtDNA, werd in 
alle bestudeerde weefsels gevonden. De hoeveelheid heteroplasmie verschilde per weefsel, 
maar correleerde niet met de mate waarin het weefsel klinisch was aangedaan. 
In hoofdstuk III-1 wordt een familie beschreven, die voorheen gediagnostiseerd 
was als een X-chromosomaal gebonden myoclonus epilepsy. Wij troffen een 
heteroplastische mutatie aan in het mitochondriële tRNA voor lysine op basepaarpositie 
8344, waardoor een in de evolutie sterk geconserveerd adenine door een guanine 
vervangen wordt. We konden aannemelijk maken dat matemale overerving beter past bij 
het ziektebeeld in deze familie. 
In de hoofdstukken III-2 en III-3 worden twee families gepresenteerd met variabele 
klinische expressie van het syndroom van MELAS (mitochondriële myopathie, 
encephalopathie, lactaat acidóse, en 'stroke-like' episodes). Het ziektebeeld is 
geassocieerd met een heteroplastische puntmutatie in het mitochondriële tRNA voor 
leucine op basepaarpositie 3243, waardoor een evolutionair sterk geconserveerd adenine 
wordt vervangen door een guanine. 
In de hoofdstukken III-1 en III-2 wordt aangetoond dat binnen de beschreven families de 
ernst van het syndroom gereflecteerd wordt in de hoeveelheid gemuteerd mtDNA in spier 
en bloed. 
In hoofdstuk IV-1 wordt de klinische, biochemische en genetische achtergrond van 
een familie met het syndroom van Leigh beschreven. Door middel van de techniek van 
directe sequentie analyse, troffen we een heteroplastische mutatie op basepaarpositie 8993 
in het mitochondriële ATPase 6 gen aan. Ook hier bleek matemale overerving beter te 
passen bij de overerving van het ziektebeeld in deze familie, die voorheen beschreven was 
in de literatuur als een autosomaal recessieve juveniele vorm van het syndroom van 
Leigh. 
In hoofdstuk IV-2 presenteren we een grote familie met het syndroom van Leber 
Hereditary Optic Neuropathy in combinatie met spastische dystonie. Mitochondriëel DNA 
onderzoek aan de genen coderend voor de subunits van complex I van de 
ademhalingsketen toonde de aanwezigheid aan van twee tot nu toe onbekende mutaties; de 
heteroplastische mutatie A11696G in het ND4 gen en de homoplastische mutatie T14S96A 
in het ND6 gen. In dit hoofdstuk is een nieuwe analytische techniek beschreven, waarvan 
we gebruik hebben gemaakt om de hoeveelheid heteroplasmie van de A11696G mutatie te 
quantificeren. We vonden echter lage hoeveelheden normaal mtDNA in zowel de 
aangedane als niet aangedane familieleden. Er was geen duidelijke correlatie tussen de 
klinische fenotypes in de familie en de hoeveelheid heteroplasmie in bloed. De door ons 
gevonden nieuwe mutaties kunnen worden toegevoegd aan de lijst van de 15 eerder 
gepubliceerde mutaties, die geassocieerd worden met het syndroom van Leber. 
In hoofdstuk V wordt een patiënt beschreven met een benigne mitochondriële 
myopathie en een NADH dehydrogenase deficiëntie in spier. We toonden een 9 basepaar 
insertie aan in een DNA regio tussen het mitochondriële gen coderend voor de tweede 
subunit van complex IV en het mitochondriële gen coderend voor het tRNA van lysine. 
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Hoewel heteroplastisch, de betekenis van deze mutatie is tot dusver onbekend. 
Aangezien deficiënties van verscheidene enzymen, die gerelateerd zijn aan het 
energiemetabolisme in mitochondriën, veelvuldig voorkomen bij neuromusculaire 
aandoeningen, hebben we de resultaten van enzymatisch en mtDNA onderzoek vergeleken 
in hoofdstuk VI-1. De resultaten van het mtDNA onderzoek bij 66 patiënten met klinische 
en/of klinisch-chemische afwijkingen duidend op een mitochondriële ziekte, werden 
vergeleken met de uitkomsten van het biochemisch onderzoek aan spier van deze 
patiënten. Uit deze studie bleek dat mtDNA analyse en enzymologisch onderzoek elkaar 
aanvullen in de diagnostiek van mitochondriële ziekten. Alhoewel ook de 
pathofysiologische betekenis van de afwijkingen in het mtDNA niet altijd eenduidig is, 
levert mtDNA analyse gecombineerd met een uitgebreid biochemisch onderzoek een 
belangrijke bijgrage aan de diagnostiek van patiënten die verdacht worden van een 
mitochondriële aandoening. Deleties in het mtDNA gaan doorgaans niet gepaard met 
duidelijke enzymatische afwijkingen. 
In hoofdstuk VI-2 worden de klinische, biochemische en genetische bevindingen in 8 
patiënten met een NADH dehydrogenase deficiëntie in de spier beschreven. Er werden 
geen pathologische mutaties in de mitochondriële NADH dehydrogenase genen gevonden, 
implicerend dat mutaties in de coderende regio's van de mitochondriële genen voor 
complex I geen frequente oorzaak zijn van een complex I deficiëntie. 
In hoofdstuk VII is een overzicht gegeven van alle mtDNA mutaties tot op heden 
gepubliceerd in de literatuur. De update illustreert het enorme aantal mtDNA mutaties 
met mogelijke betrokkenheid in de etiologie van mitochondriële ziekten. 
De rol van mtDNA onderzoek in relatie met klinische en biochemische studies 
wordt in de algemene discussie in hoofdstuk VIII besproken. Concluderend kan gezegd 
worden dat de relatie tussen kliniek, biochemie en mtDNA niet altijd eenduidig is. 
Bovendien wordt het belang van mtDNA onderzoek voor post- en prenataal onderzoek 
geëvalueerd. Voor genetische counseling van aangedane families is het overervingspatroon 
van de mutatie van belang. Paternale familieleden van patiënten met een matemaal 
overervende of een sporadisch optredende mtDNA mutatie lopen geen risico voor het 
optreden van de ziekte. Matemale familieleden van een patiënt met een sporadische 
deleties lopen evenmin risico voor het optreden van de aandoening. Voor het gebruik van 
mtDNA studies in prenatale diagnostiek zijn er nog slechts zeer beperkte mogelijkheden. 
Tot slot wordt in hoofdstuk VIII aangegeven welke wegen kunnen worden ingeslagen om 
de rol van mtDNA mutaties in de Pathogenese van mitochondriopathieën vast te leggen. 
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STELLINGEN 
behorend bij het proefschrift 
"Mitochondrial DNA mutations in neuromuscular disorders" 
1. Verschillen in fenotypen van matemale verwanten zijn toe te schrijven aan 
variaties in percentages van gemuteerd mitochondrieel-DNA in de matemale lijn 
Dit proefschrift 
2. Sommige patiënten welke aan het syndroom van Alpers lijden, zijn drager van de 
MELAS mutatie. 
Dit proefschrift 
3. Ontwikkeling en toepassing van een expressiesysteem voor het mitochondriële 
genoom zou een grote stap voorwaarts betekenen voor het moleculair biologische 
onderzoek aan mitochondrion. 
4. De door Poulton et al. als mitochondrieel DNA met grote inserties geïnter-
preteerde DNA moleculen, zouden beschouwd kunnen worden als gedeleteerde 
circulaire dimeren van mitochondrieel-DNA. 
Poulton J, Deadman M E, Gardiner R M, Lancet 1989; i: 236-240 
5. Voor de diagnostiek van mitochondriële cytopathieën is het van belang dat medici 
zich realiseren dat een matemale overerving alleen verklaard kan worden door een 
primair defect in het mitochondrieel-DNA. 
6. Onthullingen over het DNA-geheim van de Britse prins-gemaal in een weten-
schappelijk tijdschrift verlaagt het desbetreffende tijdschrift tot het niveau van 
roddelpers. 
7. Het is verwonderlijk dat niet-gepromoveerde medici in internationale brief-
wisselingen zonder moeite gepromoveerd lijken. 
8. Waar Caesar zegt "veni, vidi, vici", geldt voor de moderne promovendus "veni, 
vidi, vasi". 
9. The hand that can destroy is the hand that can help. 
World Wildlife Foundation 
10. Om voor twee afdelingen te werken dient de promovendus over de nodige hoeveel-
heid diplomatie te beschikken. 
Nijmegen, 9 november 1994 Danielle de Vries 



